

#### Clinical Audit / Service Evaluation Action Plan

Ref no: NS 342 BIOC/155

Clinical Audit Title	CSF samples for xanthochromia pre- analytical requirements audit 2019		
Date audit	08/10/2020	Date action plan	08/10/2020
complete		completed	
Auditor		Name of policy / guideline	Revised national guidelines for analysis of
			cerebrospinal fluid for bilirubin in suspected
			subarachnoid haemorrhage
Division	The Neuroscience Laboratories,	Source of policy /	Ann Clin Biochem 2008; 45: 238-244
	Neurosurgery Division	guideline	

### **Summary of Findings:**

- Data from 36 requests were included during the 6 month period of data collection 18/11/19 to 11/05/20.
- All the requests that were included were referred from external Trusts (AUH, RLUH, South Manchester, Salford, Bolton and Wigan). There were no internal requests from WCFT patients.
- A spreadsheet of all the results is included below for completeness. In summary:

	<u>Yes</u>		<u>No</u>		Not known	
Was the time between onset of symptoms and the LP recorded on the request form?	23	(63.8%)	13	(36.1%)	0	(0.0%)
Was the last fraction of CSF taken selected for xanthochromia analysis?	1	(2.8%)	0	(0.0%)	35	(97.2%)
Was the specimen centrifuged and transferred to a secondary container?	18	(50.0%)	0	(0.0%)	18	(50.0%)
Was the specimen kept at 4°C and in the dark?	7	(19.4%)	1	(2.8%)	28	(77.8%)
Were simultaneous serum biochemistry results available on the request form?	14	(38.9%)	22	(61.1%)	0	(0.0%)



• All referring Trusts performed similarly. There were no referring Trusts that were consistently not meeting the requirements. However, some Trusts referred a lot more samples than others.

## Key success:

• Referring Trusts seem to be very good at centrifuging the specimen and transferring it to a secondary container. There was 100% compliance with this when the information was available.

Version: 2019

#### **Key concerns:**

- There was low compliance with 2 questions:
- (a) Were simultaneous serum biochemistry results available on the request form? We do not feel that this is a big concern. The proportion of requests where the serum biochemistry results are actually required is very low. Should the serum biochemistry results be required when they are not available on the form, they can usually be obtained by phoning the referring lab.
- (b) Was the time between onset of symptoms and the LP recorded on the request form? Although this information is useful to have for full interpretation, we already have a procedure in place to follow when the information is not given the results are interpreted as if the LP was timed appropriately and a coded text comment is added to the result "Interpretation assumes the sample was appropriately times >12 hours and <14 days post event. Samples taken outside of these times may cause false negative results". This comment serves as a reminder to the referring Trust that the timing information is very useful for thorough interpretation.

#### Recommendations discussed:

• No internal requests were received from WCFT patients during the period of data collection, all requests were referred to us from external Trusts. This meant that we were unable to answer a number of the audit questions as the information was not available to us. For example, in the majority of cases we were unable to ascertain whether the last fraction of CSF collected was referred for xanthochromia analysis as this would all have been handled by the referring lab. If this audit were to be repeated at a later date, we would recommend that the questions be altered to just focus on the areas where we would definitely be able to answer the questions eg. was the sample received protected from light?

#### **Presentation / Dissemination of Project**

Date findings were presented / disseminated: Report emailed to all relevant members of Neurobiochemistry staff 08/10/20 Department where discussed or presented: Neurobiochemistry, The Neuroscience Laboratories

Actions agreed following recommendations discussed:-

Issue	Action required	Named lead for action	Timescale	Evidence	Reportable to (group/meeting)	
If the audit were to be repeated, the questions need to be altered slightly to just focus on the areas we would definitely be able to answer.	No action is currently required. Should a repeat audit be scheduled at any stage, the results of this current audit would be checked and this recommendation would be identified then.	N/A	N/A	N/A	N/A	
Re-audit date If no re-audit planned please give reasons why? No further useful information to be gained in the short term						
Will this be an on-going audit? Yes ☐ No ⊠						
Are there any potential barriers / problems to prevent the implementation of the above actions? Yes \( \subseteq \) No \( \subseteq \)						
If yes to the above please state who	the issues have been referred to:					

Version: 2019

Name	Designation	Date referred				
Signature:	Date:					
Have any issues been logged on the ris	sk register? Yes 🗌 No 🛛	N/A 🗌				
Please provide details of issue(s) logged on the risk register:						

Version: 2019

### Audit title: Preanalytical handling of samples for CSF xanthochromia

If the project is mandatory please specify what priority level:-

Category A – Full support

Category B – Moderate support

Category C – Minimal support

Level 1, 2 & 3

Level 4

Level 5

The below table provides a system for prioritising locally conceived projects and what level of clinical audit team resource should be offered / provided.

Level 1 – External 'must do' Level 2 'Internal 'must do'							
Criteria	Criteria						
High cost			(x3)				
High volume			(x2)				
High risk			(x3)				
Known quality issue			(x3)				
Wide variation in practice		Υ					
NICE / NCEPOD related audit			(x3)				
Defined measurable standards available		Υ					
Re-audit / repeat service evaluation			(x2)				
Topic is a key clinical interest for the department /	division		(x2)				
Multidisciplinary project							
National / regional or multicentre project			(x2)				
Total		2	Level 5 Cat C				
Priority levels and audit team support							
Priority level Priority s		score					
Level 1 – External 'must do'	Category	Α					
Level 2 – Internal 'must do' Category		Α					
Level 3 – High local priority	> 10						
Level 4 – Medium local priority	4 – 9						
Level 5 – Low local priority	< 4						
Priority level Audit team resource							

Full practical assistance offered

Level of practical assistance will be negotiated and agreed with project lead

Advice, registration and monitoring

### **CLINICAL AUDIT / SERVICE EVALUATION PROJECT REGISTRATION FORM**

Ref No: -	Project Type: - Clinical Audit ⊠ Service Evaluation □
Audit / Service Eval	uation Title: Preanalytical handling of samples for CSF xanthochromia
<b>Division:</b> Neurology <b>Neurobiochemistry</b>	$\square$ Neurosurgery $\ oxtimes$ Please specify department <b>The Neuroscience Laboratories</b> -
Project Lead:	
Contact No: Ble	eep No: Click here to enter text.
Email address:	
Audit / service evalu	uation supervisor:
	involved / project team members details es and roles within the project eg data collection, analysis etc.)
Background / Ration	nal <u>e</u>
at WCFT. There are Na should be handled prio suspected subarachnoi are followed to mainta	nemistry laboratories refer requests for CSF xanthochromia to The Neuroscience Laboratories tional Guidelines available that recommend how CSF samples for xanthochromia analysis r to analysis (Revised national guidelines for analysis of cerebrospinal fluid for bilirubin in d haemorrhage. Ann Clin Biochem 2008; 45: 238-244). It is important that these guidelines in the integrity of the sample and ensure that the most accurate result is obtained and that impretation can be provided.
<u>Methodology</u>	
•	requests for xanthochromia analysis are received in the department, a table will be whether the correct pre-analytical requirements have been met. See attached data neet for full details.
Aims / Objectives	
The aim is to establis recommended by the	h if CSF samples received in The Neuroscience Laboratories have been handled as National Guidelines.
Standards / Criteria	Details (service evaluation N/A)
Ann Clin Biochem 2008 recorded (2) The last freeceipt, the sample sho	ines for analysis of cerebrospinal fluid for bilirubin in suspected subarachnoid haemorrhage. ; 45: 238-244. Recommendations: (1) Time between onset of symptoms and LP should be action of CSF taken should be selected for xanthochromia analysis (3) Within 1 hour of ould be centrifuged and transferred into a secondary container before being referred (4) otected from light and stored at 4oC prior to analysis (5) Simultaneous serum biochemistry able

If yes, please attach a copy or provide web link to the most current version: <a href="https://journals.sagepub.com/doi/full/10.1258/acb.2008.007257">https://journals.sagepub.com/doi/full/10.1258/acb.2008.007257</a>

Guideline / Standards available: Yes ⊠ No

Name of Standard / guideline:
Revised national guidelines for the analysis of cerebrospinal fluid for bilirubin in suspected subarachnoid haemorrhage. Ann Clin Biochem 2008; 45: 238-244
Source of Standard / guideline: NSF □ NICE □ Royal College □ Trust □ Other ⊠ State other: Annals of Clinical Biochemistry
Review/assessment of guideline/standard undertaken to ensure it is appropriate & can be measured Yes $\boxtimes$ No $\square$
Is the audit / service evaluation issue:   High volume Yes □ No ☒   High risk Yes □ No ☒   High cost Yes □ No ☒   Known quality issue Yes □ No ☒   Wide variation in practice Yes ☒ No □
Sample No: >50 Procedure codes to identify sample: N/A
http://www.raosoft.com/samplesize.html - link to tool that may be used to calculate sample size
Are you planning to publish your audit/service evaluation findings nationally
(e.g. Medical journal)? Yes □ No ⊠
Is this a re-audit or if service evaluation, has service been reviewed previously? Yes □ No ☒
Is this project part of an agreed departmental rolling programme?  Yes □ No ☒
Rolling programme duration (number of years): N/A
<b>Rolling programme frequency:</b> Monthly □ Quarterly □ Biannually □ Annually □
Multidisciplinary: □ Single disciplinary: ⊠
ongic disopinary.
Is Clinical Audit Team support required? Yes □ No ☑  If yes, please specify type of assistance required:  ◆ Population Identification □  ◆ Design of data collection tool □  (If not required please, attach a copy of the tool to be used)  ◆ Database design □  ◆ Data entry □  ◆ Analysis □  ◆ Presentation □  Collection of case notes □ Total number / per week
Patient Contact / Involvement - (If project involves patient contact that is <u>not</u> part of the patients usual treatment or care please explain how in this section)  Will the audit involve direct patient contact?  Yes □ No ⊠

How will the patient be involved?						
Patient Questionnaire $\Box$ At clinic appointment $\Box$						
Other (please give details) Click here to enter text.						
Has approval been sought from the Patient Information Panel?	Yes [		No [	□ N	′A ⊠	
Anticipated start date: 18/11/2020						
Anticipated project completion date: 31/10/2020						
Anticipated Action Plan Submission date: 31/10/20						
PLEASE ATTACH A COPY OF YOUR DATA COLLECTION TOOL / PATIENT QUI	ESTIONN	NAIRE				
<ul> <li>FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATIONS PLEASE ATTACH A EVALUATION REPORT.</li> </ul>	COPY O	F THE	PREVI	IOUS AL	JDIT OR	SERVICE
<ul> <li>PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVISIONAL AUDIT LEAD BE AUDIT TEAM.</li> </ul>	BEFORE	SUBN	/IISSIOI	N TO TH	IE CLINI	CAL
Departmental Clinical Audit Lead (Signature)	Da	ite: 1	7/11/2	2020		
Comments Click here to enter text.						
Divisional Clinical Audit Lead (Signature)	Da	ite: C	lick he	ere to e	nter te	xt.
Is this topic a key clinical interest for the department / division?	Yes			No		

#### **Audit title: ERBS Protocol Service Evaluation Audit**

If the project is mandatory please specify what priority level:-

Category B – Moderate support

Category C – Minimal support

Level 1 – External 'must do'

Level 4

Level 5

The below table provides a system for prioritising locally conceived projects and what level of clinical audit team resource should be offered / provided.

Level 2 'Internal 'must do'

Criteria			Tick all that apply	Score			
High cost	High cost		Y	(x3)			
High volume			Y	(x2)			
High risk				(x3)			
Known quality iss	ue			(x3)			
Wide variation in	practice						
NICE / NCEPOD re	lated audit			(x3)			
Defined measurable standards available							
Re-audit / repeat service evaluation			(x2)				
Topic is a key clinical interest for the department / division		า	(x2)				
Multidisciplinary project		Y					
National / regiona	l or multicentre project			(x2)			
Total			6	Level 4 Cat B			
Priority levels an	d audit team support						
<b>Priority level</b>		Prior	ity score				
Level 1 – External 'must do'			Category A				
Level 2 – Internal 'must do'			gory A				
Level 3 – High local priority > 10							
Level 4 – Medium local priority 4 – 9							
Level 5 – Low lo	cal priority	< 4					
Priority level	Audit team resource						
Level 1, 2 & 3	Category A – Full support		Full practical assistance offe	ull practical assistance offered			

Version 2019 Review date: 2021

Level of practical assistance will be negotiated and agreed with project lead

Advice, registration and monitoring

### **CLINICAL AUDIT / SERVICE EVALUATION PROJECT REGISTRATION FORM**

Ref No: - Project Type: - Clinical Audit □ Service Evaluation ⊠
Audit / Service Evaluation Title: ERBS Protocol Service Evaluation Audit
Division: Pain Management and Neurosurgery
Project Lead:
Contact No: Bleep No: N/A
Email address:
Audit / service evaluation supervisor:
Other professionals involved / project team members details (Please provide names and roles within the project eg data collection, analysis etc.) Adam Doyle - data administrator
Background / Rationale  Acute sciatica is a common problem affecting over 3% of UK population at any time and is often caused by a prolapsed intervertebral disc. The Expedited Root Block Service is a joint service between the neurosurgical team and the chronic pain team and treats patients with acute sciatica from prolapsed intervertebral discs (PID). Follow the ERBS pathway, patients are either referred for dorsal root ganglion block, diagnostic root block or direct for neurosurgical intervention. At the consent clinic with the pain team the patient may be rejected as no longer needing root block, rejected as needing surgical intervention or consented for root block. At the neurosurgical consent clinic, patient may request root block rather than surgery.
Methodology
The case notes of all patients will be accessed and audited
Aims / Objectives
We aim to assess the ERBS pathway for service and clinical outcomes and make appropriate improvements to the service.  *How long patients wait from GP/A & E referral to Root block? *How long patients wait from Neurosurgery refer to Root block? *How long patients wait from consent clinic to Root block? *How many patients go on to need surgery (after root block and without root block)? *How many appointments do patients get with each clinical temprior to discharge? *Outcome after root block. (Pain relief/ Complications/discharge) *Number of post-laminectomy patients and reason for referral. *Outcomes in Post laminectomy patients (Pain relief, repeat surger conservative, discharge) *Number of patients who had spontaneous recovery *Duration from symptom onset at which spontaneous recovery noted. *How many patients who had injection conversion then needed surgery?  *Standards / Criteria Details (service evaluation N/A)*  *Click here to enter text.
Guideline / Standards available: Yes □ No □

If yes, please attach a copy or provide web link to the most current version: Click here to enter text.

Name of Standard / guideline:  ${\sf Click}\ {\sf here}\ {\sf to}\ {\sf enter}\ {\sf text}.$ 

Trust	Other $\square$	State other: 0	NICI lick here to en		Royai	College	
Review/assessment Yes □ No □	of guideline/s	tandard unde	ertaken to en	sure it is ap	propriate &	≩ can be r	neasured
Is the audit / service High volume High risk High cost Known quality issue Wide variation in prac	Yes ⊠ Yes ⊡ Yes ⊡ Yes □						
Sample No: Click here	e to enter text. I	Procedure co	des to identi	fy sample:	Click here to	enter text.	
http://www.raosoft.com	m/samplesize.h	ntml - link to to	ol that may be	e used to cal	lculate samp	ole size	
Are you planning to	publish your	audit/service	evaluation fi	ndings nati	onally		
(e.g. Medical journal)?	? Yes ⊠	No □					
Is this a re-audit or i	f service evalu	uation, has se	ervice been r	eviewed pre	eviously?	Yes □	No ⊠
Is this project part o	f an agreed de	epartmental r	olling progra	mme?	Yes	□ No 🛛	
Rolling programme	duration (num	ber of years)	: Click here to	enter text.			
Rolling programme	frequency: M	onthly 🗆 Qu	uarterly 🗆	Biannually [	□ Annuall	у 🗆	
Multidisciplinary:	$\boxtimes$	Single	disciplinary:				
Is Clinical Audit Teal If yes, please specify  ◆ Population Identifi  ◆ Design of data col (If not required please  ◆ Database design  ◆ Data entry  ◆ Analysis  ◆ Presentation Collection of case not	type of assistal cation lection tool e, attach a copy	nce required:		Nember/			
Patient Contact / Invorcare please explain h Will the audit involve	ow in this sectio	n)	s patient conta Yes	ct that is <u>not</u> ∫	•	ntients usua	al treatment
How will the patient	be involved?						
Patient Questionnaire	□ At clir	nic appointme	nt 🗆				
Other (please give deta	nils) Click here to	enter text.					
Has approval been s	ought from th	e Patient Info	ormation Pan	el? Yes	□ No □	□ N/A □	$\boxtimes$

Anticipated start date: ASAP

Anticipated project completion date: December 2020

Anticipated Action Plan Submission date:

- PLEASE ATTACH A COPY OF YOUR DATA COLLECTION TOOL / PATIENT QUESTIONNAIRE.
- FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATIONS PLEASE ATTACH A COPY OF THE PREVIOUS AUDIT OR SERVICE EVALUATION REPORT.
- PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVISIONAL AUDIT LEAD BEFORE SUBMISSION TO THE CLINICAL AUDIT TEAM.

Departmental Clinical Audit Lead (Signature)	Date: Click	here to enter text.	
Comments Click here to enter text.			
Divisional Clinical Audit Lead (Signature)	Date: Click	here to enter text.	
Is this topic a key clinical interest for the department / division?	Yes □	No □	

### Audit title: One to two level TLIF 2 yrs f/up

**Priority level** 

Level 1, 2 & 3

Level 4

Level 5

Audit team resource

Category A – Full support

Category B – Moderate support

Category C – Minimal support

If the project is mandatory please specify what priority level:-

The below table provides a system for prioritising locally conceived projects and what level of clinical audit team resource should be offered / provided.

Level 1 – External 'must do' Level 2 'Internal 'must do'				
Criteria	Tick all th	at apply Score		
High cost	Y	(x3)		
High volume	Y	(x2)		
High risk	Y	(x3)		
Known quality issue		(x3)		
Wide variation in practice	Y			
NICE / NCEPOD related audit		(x3)		
Defined measurable standards available				
Re-audit / repeat service evaluation		(x2)		
Topic is a key clinical interest for the department / o	pic is a key clinical interest for the department / division (x2			
Multidisciplinary project				
National / regional or multicentre project		(x2)		
Total	9	Level 4 Cat B		
Priority levels and audit team support				
Priority level	Priority score	core		
Level 1 – External 'must do' Category A				
Level 2 – Internal 'must do'	Category A	A		
Level 3 – High local priority	> 10			
Level 4 – Medium local priority	4-9			
Level 5 – Low local priority	< 4			

Version 2019 Review date: 2021

Full practical assistance offered

Level of practical assistance will be

Advice, registration and monitoring

negotiated and agreed with project lead

### **CLINICAL AUDIT / SERVICE EVALUATION PROJECT REGISTRATION FORM**

Ref No: -	Project Type: - Clinical Audit ⊠ Service Evaluation □
Audit / Service E	valuation Title: One to two level TLIF 2 yrs f/up
Division: Neurolo	gy $\boxtimes$ Neurosurgery $\square$ Please specify department $Click$ here to enter text.
Project Lead:	
Contact No:	Bleep No: Click here to enter text.
Email address:	
Audit / service ev	valuation supervisor:
(Please provide na	nals involved / project team members details ames and roles within the project eg data collection, analysis etc.) I. Vupputuri for data collection and measurements
with regards to spin long X rays to predice vidence at the time reducing the rate of	tionale L4/5 and/or L5/S1 transforaminal lumbar interbody fusion (TLIF) has been traditionally lacking hal balance. Since inception in 2016, MT team has calculated spinal radiographic parameters on ct the amount of sagittal correction required with instrumentation. There was moderate that restoring spinal balance where it is most crucial, i.e. at the lowermost levels, could help f mechanical complications in the middle and long terms as well as improving patient reported (PROMs.) routinely collected by the Trust for all spinal operations.
Methodology	
•	control analysis of prospectively collected data on a cohort of patients submitted to L4/5 and/or operative radiographic planning (group 1) versus none (group 2), age, sex and level matched.
Aims / Objectives	<u>s</u>
To highlight any diff between groups	ferences in mechanical complications, neurological complications, revision rates and PROMs
Standards / Crite	ria Details (service evaluation N/A)
COMI, VAS and OD	I outcome measures and GAP scores
Guideline / Stand	dards available: Yes □ No ⊠
If yes, please attach	ch a copy or provide web link to the most current version: Click here to enter text.
Name of Standar	d / guideline: Click here to enter text.
Source of Standa Trust □	ard / guideline: NSF □ NICE □ Royal College □ Other □ State other: Click here to enter text.
Review/assessm Yes □ No ⊠	ent of guideline/standard undertaken to ensure it is appropriate & can be measured

Is the audit / service eval High volume	luation issue: Yes ⊠ No □
High risk	Yes ⊠ No □
High cost	Yes ⊠ No □
Known quality issue	Yes □ No ⊠
Wide variation in practice	Yes ⊠ No □
Sample No: 55 per group	Procedure codes to identify sample: V386, V386 and V397
http://www.raosoft.com/sai	mplesize.html - link to tool that may be used to calculate sample size
Are you planning to publ	ish your audit/service evaluation findings nationally
(e.g. Medical journal)?	Yes ⊠ No □
	vice evaluation, has service been reviewed previously? Yes □ No ☒
	agreed departmental rolling programme? Yes □ No ☒
	tion (number of years): Click here to enter text.
Rolling programme frequ	<b>lency:</b> Monthly □ Quarterly □ Biannually □ Annually □
Multidisciplinary:	Single disciplinary: ⊠
Is Clinical Audit Team sur If yes, please specify type  ◆ Population Identificatio  ◆ Design of data collection (If not required please, attain  ◆ Database design  ◆ Data entry  ◆ Analysis  ◆ Presentation Collection of case notes	of assistance required:  □
Patient Contact / Involve or care please explain how in Will the audit involve dire	,
How will the patient be in	ivolved?
Patient Questionnaire	At clinic appointment
Other (please give details)	lick here to enter text.
Has approval been sough	ht from the Patient Information Panel? Yes $\square$ No $\square$ N/A $\boxtimes$
Anticipated start date:De	cember 2020
Anticipated project comp	oletion date: March 2021
Anticipated Action Plan	Submission date:April 2021

- PLEASE ATTACH A COPY OF YOUR DATA COLLECTION TOOL / PATIENT QUESTIONNAIRE.
- FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATIONS PLEASE ATTACH A COPY OF THE PREVIOUS AUDIT OR SERVICE EVALUATION REPORT.
- PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVISIONAL AUDIT LEAD BEFORE SUBMISSION TO THE CLINICAL AUDIT TEAM.

Departmental Clinical Audit Lead (Signature)	Date: Click	here to enter text.
Comments Click here to enter text.		
Divisional Clinical Audit Lead (Signature)	Date: Click	here to enter text.
Is this topic a key clinical interest for the department / division?	Yes □	No □

Audit title: Accountable Items, swab, Instrument and Needle Count

If the project is mandatory please specify what priority level:-

Category A – Full support

Category B – Moderate support

Category C – Minimal support

Level 1 – External 'must do'

Level 1, 2 & 3

Level 4

Level 5

The below table provides a system for prioritising locally conceived projects and what level of clinical audit team resource should be offered / provided.

Level 2 'Internal 'must do'

Criteria		Tick all that apply	Score
High cost			(x3)
High volume			(x2)
High risk		Υ	(x3)
Known quality issue		Υ	(x3)
Wide variation in practice			
NICE / NCEPOD related audit			(x3)
Defined measurable standards available		Υ	
Re-audit / repeat service evaluation		Υ	(x2)
Topic is a key clinical interest for the department / division			(x2)
Multidisciplinary project		Υ	
National / regional or multicentre project			(x2)
Total		10	Level 3 Cat A
Priority levels and audit team support			
Priority level	Priority so	core	
Level 1 – External 'must do' Category A			
Level 2 – Internal 'must do' Category A		A	
Level 3 – High local priority > 10			
Level 4 – Medium local priority 4 – 9			
Level 5 – Low local priority < 4			
Priority level Audit team resource			

Version 2019 Review date: 2021

Full practical assistance offered
Level of practical assistance will be

negotiated and agreed with project lead

Advice, registration and monitoring

## **CLINICAL AUDIT / SERVICE EVALUATION PROJECT REGISTRATION FORM**

Ref No: - Project Typ	oe: - Clinical Audit □	Service Evaluation	
Audit / Service Evaluation Title	: The use and han	dling of surgical ins	truments in Theatre
<b>Division:</b> Neurology □ Neurosur	gery ⊠ Please specify	department <b>Theatr</b>	es
Project Lead			
Contact No: Bleep No: Click he	re to enter text.		
Email address:			
Audit / service evaluation supe	rvisor:		
Other professionals involved / (Please provide names and roles Leeja Varughese			sis etc.)
Background / Rationale Perioperative staff do not handle their use in general and specific s		y competent to do sc	and unless they understand
Aims / Objectives  Perioperative staff person	nel have the required k	nowledge and skills	related to the handling of
sterile items, educational	and training records ex	ist for this purpose.	nave received training in their
use and records exist to s	upport this.		_
<ul> <li>Loan instruments are app be provided.</li> </ul>	ropriately managed and	d staff ar clear on the	eir use and the support that wi
<ul><li>Instruments are used only</li><li>User manuals and teachir</li></ul>		•	ned .
<ul> <li>Methodology</li> </ul>			about use and handling
surgical instruments.	mi observe, check re	Joius and ask stair	about use and nandling
Standards / Criteria Details (se	rvice evaluation N/A)		
Previously sent	vice evaluation N/A/		
remously serie			
Guideline / Standards available	e: Yes ⊠ No		
If yes, please attach a copy or pro	ovide web link to the m	ost current version: (	Click here to enter text.
Name of Standard / guideline: <sup>-</sup>	Γhe use and Handling α	of surgical instrument	s in Theatre
Source of Standard / guideline	: NSF □	NICE □	Royal College
Trust ☐ Other Practitioners)	State oth	ier: AfPP (Ass	ociation of Perioperative

Review/assessment of guideline/standard undertaken to ensure it is appropriate & can be measured $$ $\!$				
Is the audit / service evaluation High volume High risk High cost Known quality issue Wide variation in practice	Yes □ No ⊠ Yes □ No □ Yes □ No □ Yes □ No □			
Sample No: 10 Procedure	e codes to identify sample: Click here to enter text.			
http://www.raosoft.com/sam	nplesize.html - link to tool that may be used to calculate sample size			
Are you planning to publi	sh your audit/service evaluation findings nationally			
(e.g. Medical journal)?	Yes □ No ⊠			
Is this a re-audit or if serv	ice evaluation, has service been reviewed previously? Yes   No			
Is this project part of an a	greed departmental rolling programme? Yes ⊠ No □			
Rolling programme durati	ion (number of years): ongoing until updated			
Rolling programme freque	ency: Monthly □ Quarterly □ Biannually □ Annually ⊠			
Multidisciplinary: ⊠	Single disciplinary: □			
Is Clinical Audit Team sup If yes, please specify type of  ◆ Population Identification  ◆ Design of data collection (If not required please, attack  ◆ Database design  ◆ Data entry  ◆ Analysis  ◆ Presentation Collection of case notes	of assistance required:			
or care please explain how in Will the audit involve dire	ct patient contact?  Yes □ No ⊠  volved?  □ At clinic appointment □			
,	t from the Patient Information Panel? Yes $\square$ No $\square$ N/A $\boxtimes$			
Anticipated start date:11t				
Anticipated project comp	·			

### Anticipated Action Plan Submission date:30th august 2021

- PLEASE ATTACH A COPY OF YOUR DATA COLLECTION TOOL / PATIENT QUESTIONNAIRE.
- FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATIONS PLEASE ATTACH A COPY OF THE PREVIOUS AUDIT OR SERVICE EVALUATION REPORT.
- PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVISIONAL AUDIT LEAD BEFORE SUBMISSION TO THE CLINICAL AUDIT TEAM.

Departmental Clinical Audit Lead (Signature) Date: 23/11/2020		
Comments Click here to enter text.		
Divisional Clinical Audit Lead (Signature)	Date: Click	here to enter text.
Is this topic a key clinical interest for the department / division?	Yes ⊠	No □



#### Clinical Audit / Service Evaluation Action Plan

Ref no: NS 349

Clinical Audit Title	Use of Handling of surgical instruments		
Date audit complete	15/06/2021	Date action plan completed	19/07/2021
Auditor		Name of policy / guideline	AfPP Standard/Guideline
Division	Surgery	Source of policy / guideline	Association of Perioperative Practitioners

#### **Summary of Findings:**

Please concisely state the main conclusions of the project using bullet points

• 100% of the theatre staff who participated (80 staff) in the audit were aware there is a system in place that ensures the safe use and handling of surgical instruments

#### Key success:

Please concisely state the key success identified by the project – if none identified please state N/A

All Theatre staff who participated in the Audit had completed the educational competencies and training.

#### **Key concerns:**

Please concisely state the key concerns identified by the project using bullet points—if none identified please state N/A

• Recruitment and retention of theatre staff is still a national issue. Staff recruited may not have any theatre experience.

#### Recommendations discussed:

Please concisely summarise the recommendations that were discussed following the completion of the project

• Staff recruitment is on the risk register.

## **Presentation / Dissemination of Project**

Date findings were presented / disseminated: Theatre User Group August 2021

Department where discussed or presented: Theatre Audit Meeting August 2021

Actions agreed following recommendations discussed:-

Version: 2019

\*Please ensure each action has a named lead, timescale and reportable group stated on the action plan below. Please list the evidence of the action implementation e.g SOP, protocol, standardised template, presentation or meeting minutes etc

Issue	Action required	Named lead for action	Timescale	Evidence	Reportable to (group/meeting)	
Recruitment of new Theatre staff.	To ensure all new staff have completed the educational packs and competencies		On going	Completion of competencie s.	Theatre User Group.	
Re-audit date September 2022	If no re-audit planned	please give reas	sons why?			
Re-audit date September 2022 If no re-audit planned please give reasons why?  Will this be an on-going audit? Yes 🗵 No 🗌						
Are there any potential barriers / pro	blems to prevent the implementation of t	he above action	s? Yes 🗌 N	lo 🛚		
If yes to the above please state who	the issues have been referred to:					
Name	Designation	Date referr	ed			
Signature:	Date:					
Have any issues been logged on the	risk register? Yes 🛛 No 🗌 N/A					
Please provide details of issue(s) lo	gged on the risk register: Risk 703					

Version: 2019

Audit title: Management of specimens in Theatre

The below table provides a system for prioritising locally conceived projects and what level of clinical audit team resource should be offered / provided.

If the project is mandatory please specify what priority level:-  Level 1 – External 'must do'   Level 2 'Internal 'must do'				
Criteria	Tick all that apply	Score		
High cost		(v3)		

Criteria	Tick all that apply	Score
High cost		(x3)
High volume		(x2)
High risk	Y	(x3)
Known quality issue	Y	(x3)
Wide variation in practice		
NICE / NCEPOD related audit		(x3)
Defined measurable standards available	Υ	
Re-audit / repeat service evaluation	Υ	(x2)
Topic is a key clinical interest for the department / division		(x2)
Multidisciplinary project	Y	
National / regional or multicentre project		(x2)
Total	10	Level 3 Cat A

### Priority levels and audit team support

Priority level	Priority score
Level 1 – External 'must do'	Category A
Level 2 – Internal 'must do'	Category A
Level 3 – High local priority	> 10
Level 4 – Medium local priority	4-9
Level 5 – Low local priority	< 4

<b>Priority level</b>	Audit team resource	
Level 1, 2 & 3	Category A – Full support	Full practical assistance offered
Level 4	Category B – Moderate support	Level of practical assistance will be negotiated and agreed with project lead
Level 5	Category C – Minimal support	Advice, registration and monitoring

## **CLINICAL AUDIT / SERVICE EVALUATION PROJECT REGISTRATION FORM**

Ref No: -	Project Type: - <b>(</b>	Clinical Audit 🗆 🧐	Service E	ivaluation □	]	
Audit / Service Evalu	ation Title:	Management of spo	ecimens i	n Theatre		
<b>Division:</b> Neurology	☐ Neurosurgery	⊠ Please specify of the specified of the specific of the specified of the spec	departme	nt Click her	re to enter text.	
Project Lead						
Contact No: Blee	ep No: Click here	e to enter text.				
Email address:						
Audit / service evalua	ation superviso	or:				
Other professionals in (Please provide name)	•			on, analysis e	etc.)	
<ul> <li>Every specimen in optimum cond</li> <li>Specimens are a</li> <li>Blood managem</li> <li>Aims / Objectives</li> <li>Perioperative sta</li> </ul>	nination of specime reaches the patholition. accurately labelled ent and administra	ens determines subso ology, microbiology, h I to the patient. ation is managed safe e procedures involved appropriate dispatch	istology consistency.  If the call in the	ytology depart	ment without undue	
<ul> <li>Specimen handli</li> </ul>	ing is assessed ar	nd planned before the products have received.	procedur		ing	
<u>Methodology</u>						
A Theatre Practitione management	er will observe,	check records, a	nd ask s	taff in regard	d to specimen	
Standards / Criteria [	Details (service	evaluation N/A)				
Previously sent						
Guideline / Standards	s available: Y	res ⊠ No				
If yes, please attach a	copy or provide	web link to the mos	st current	version: Click	k here to enter text	
Name of Standard / g	j <b>uideline:</b> Mana	gement of Specime	ns in The	eatre		
Source of Standard / Trust  Practitioners)	guideline: N Other	ISF □ ☑ State othe	NICE er:	□ AfPP (Associ	Royal College ation of Periopera	□ itive

Review/assessment of guideline/standard undertaken to ensure it is appropriate & can be measured $_{\rm Yes}~\square~$ No $~\square$				
Is the audit / service evaluation High volume High risk High cost Known quality issue Wide variation in practice	Yes □ No ⊠ Yes □ No □ Yes □ No □ Yes □ No □			
Sample No: 10 Procedure	e codes to identify sample: Click here to enter text.			
http://www.raosoft.com/sam	nplesize.html - link to tool that may be used to calculate sample size			
Are you planning to publi	sh your audit/service evaluation findings nationally			
(e.g. Medical journal)?	Yes □ No ⊠			
Is this a re-audit or if serv	ice evaluation, has service been reviewed previously? Yes   No			
Is this project part of an a	greed departmental rolling programme? Yes ⊠ No □			
Rolling programme durati	ion (number of years): ongoing until updated			
Rolling programme freque	ency: Monthly □ Quarterly □ Biannually □ Annually ⊠			
Multidisciplinary: ⊠	Single disciplinary: □			
Is Clinical Audit Team sup If yes, please specify type of  ◆ Population Identification  ◆ Design of data collection (If not required please, attack  ◆ Database design  ◆ Data entry  ◆ Analysis  ◆ Presentation Collection of case notes	of assistance required:			
or care please explain how in Will the audit involve dire	ct patient contact?  Yes □ No ⊠  volved?  □ At clinic appointment □			
,	t from the Patient Information Panel? Yes $\square$ No $\square$ N/A $\boxtimes$			
Anticipated start date:11t				
·	Anticipated project completion date: 5th July 2021			

### Anticipated Action Plan Submission date:30th august 2021

- PLEASE ATTACH A COPY OF YOUR DATA COLLECTION TOOL / PATIENT QUESTIONNAIRE.
- FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATIONS PLEASE ATTACH A COPY OF THE PREVIOUS AUDIT OR SERVICE EVALUATION REPORT.
- PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVISIONAL AUDIT LEAD BEFORE SUBMISSION TO THE CLINICAL AUDIT TEAM.

Departmental Clinical Audit Lead (Signature) Date: 23/11/2020		
Comments Click here to enter text.		
Divisional Clinical Audit Lead (Signature)	Date: Click	here to enter text.
Is this topic a key clinical interest for the department / division?	Yes ⊠	No □



#### Clinical Audit / Service Evaluation Action Plan

Ref no: NS 350

Clinical Audit Title	Specimen Management		
Date audit complete	July 2021	Date action plan completed	September 2021
Auditor		Name of policy / guideline	AfPP Standard /Guideline
Division	Surgery	Source of policy / guideline	Association of Perioperative Practitioners

## **Summary of Findings**

Staff are aware about the management of specimens ie;

- Identifying the proper transport medium in which the specimens are transported
- Importance of safety
- Record keeping and how to dispatch properly

#### Issues identified

2% of staff had been observed not confirming patient details are attached to pot before placing specimen in container.

#### **Recommendations discussed**

- Staff education on ensuring patient details are checked prior to placing of specimen in container
- Ensuring Identification stickers are affixed securely to specimen containers prior to placing specimen in.

**Findings presented / disseminated** (please state date findings presented / disseminated and what Group / Department presented / disseminated to)
Report to be discussed at Theatre Audit, Theatre User Group

Version: 2016 Review: 2017

# Actions agreed following recommendations discussed:-

Issue	Action required	Named lead for action	Timescale	Reportable to (group/meeting)	
Staff not confirming patient details prior to placing specimen in container.	For all Theatre Staff to be aware of importance confirming patient details are correct on specimen container		October 2021 Been discussed At Staff meeting	Theatre User Group and Theatre Audit.	
2) Identification labels not being attached to specimen container prior to specimen placement in container.	The Labels should be affixed properly before placing specimen in container.		October 2021 Discussed at staff meeting	Theatre User Group and Theatre Audit	
Re-audit date April 2022 Will this be an on-going audit? Yes X No \[ \begin{align*} \text{Are there any potential barriers / problems to prevent the implementation of the above actions? Yes \[ \begin{align*} \text{No } X \\ \text{If yes to the above please state who the issues have been referred to:} \end{align*}					
Name Designation Date referred					
Signature: Date: September 2021					
Have any issues been logged on the risk register? Yes No X N/A Please provide details of issue(s) logged on the risk register:					

Version: 2016 Review: 2017

#### Audit title: Post Anaesthesia care in Theatres

If the project is mandatory please specify what priority level:-

The below table provides a system for prioritising locally conceived projects and what level of clinical audit team resource should be offered / provided.

Level 1 – External 'must do' Level 2 'Internal 'must do'		
Criteria	Tick all that apply	Score
High cost		(x3)
High volume		(x2)
High risk	Y	(x3)
Known quality issue	Υ	(x3)
Wide variation in practice		
NICE / NCEPOD related audit		(x3)
Defined measurable standards available	Υ	
Re-audit / repeat service evaluation	Υ	(x2)
Topic is a key clinical interest for the department / division		(x2)
Multidisciplinary project	Υ	
National / regional or multicentre project		(x2)

#### Priority levels and audit team support

**Total** 

Dulanter laval	Duiavitus accus
Priority level	Priority score
Level 1 – External 'must do'	Category A
Level 2 – Internal 'must do'	Category A
Level 3 – High local priority	> 10
Level 4 – Medium local priority	4 – 9
Level 5 – Low local priority	< 4

10

<b>Priority level</b>	Audit team resource	
Level 1, 2 & 3	Category A – Full support	Full practical assistance offered
Level 4	Category B – Moderate support	Level of practical assistance will be negotiated and agreed with project lead
Level 5	Category C – Minimal support	Advice, registration and monitoring

Version 2019 Review date: 2021

Level 3 Cat A

#### CLINICAL AUDIT / SERVICE EVALUATION PROJECT REGISTRATION FORM

Ref No: -	Project Type: - Clinical Audit ☐ Service Evaluation ☐	
Audit / Service Evalu	uation Title: Post Anaesthesia care in Theatres	
<b>Division:</b> Neurology [	$\square$ Neurosurgery $\boxtimes$ Please specify department $Click$ here to enter text.	
Project Lead		
Contact No: Ble	eep No: Click here to enter text.	
Email address:		
Audit / service evalu	nation supervisor:	
Other professionals involved / project team members details (Please provide names and roles within the project eg data collection, analysis etc.)		

### **Background / Rationale**

- To provide a safe environment for patient care.
- To provide patients with orientation into an environment in which they are emerging from anaesthesia, together with high levels of reassurance.
- To provide patients with skilled and competent individuals to care for them

#### Aims / Objectives

- The care is supervised by an appropriately trained perioperative practitioner (RGN/RODP) with a recognised qualification.
- Post anaesthetic care practitioners are competent to administer one to one patient care until the patient is fully conscious and able to maintain own airway.
- Staff act within the limits of their designated authority.
- The staffing skill mix reflects the nature of the dependency of the patients' expected in this
  area.
- Staff within the area have appropriate skills and experience to be able to fulfil any defined clinical roles for recovering patients.
- Patient monitoring equipment is available for every patient in this area throughout the duration of their stay.
- The environment provides privacy and dignity, with the consideration of single sex areas if applicable.
- There is adequate equipment available for patients within the environment and a training and management policy for it.
- Patient documentation is accurately and legibly completed to allow for safer transfer and continuity of care.
- There is a process for rapid access to treatment in the event of an emergency.
- Facilities exist to enable carers/parents to be present with a patient at a defined stage
  whereit has been agreed that attendance in POCU/Recovery area would be beneficial for
  the patient.
- Specific tools are available to assist in the assessment of a patients pain level, nausea and pressure areas

#### Standards / Criteria Details (service evaluation N/A)

Previously sent Methodology A recovery Practitioner will follow a patient in the transfer from the intraoperative phase to the immediate postoperative care phase and observe until discharge from POCU. Guideline / Standards available: Yes  $\boxtimes$ Nο If yes, please attach a copy or provide web link to the most current version: Click here to enter text. Name of Standard / guideline: Anaesthesia in Theatres **NSF Source of Standard / guideline:** NICE Royal College **⊠** State other: Other Trust □ AfPP (Association of Perioperative Practitioners) Review/assessment of guideline/standard undertaken to ensure it is appropriate & can be measured Yes □ No □ Is the audit / service evaluation issue: High volume Yes □ No ⊠ Yes ⊠ No □ High risk Yes □ No ⊠ High cost Yes ⊠ No □ Known quality issue Wide variation in practice Yes □ No ⊠ Sample No: 10 Procedure codes to identify sample: Click here to enter text. http://www.raosoft.com/samplesize.html - link to tool that may be used to calculate sample size Are you planning to publish your audit/service evaluation findings nationally (e.g. Medical journal)? Yes □ No ⊠ Is this a re-audit or if service evaluation, has service been reviewed previously? Yes □ No ☒ Is this project part of an agreed departmental rolling programme? Yes ⊠ No □ Rolling programme duration (number of years): ongoing until updated **Rolling programme frequency:** Monthly  $\square$  Quarterly  $\square$  Biannually  $\square$  Annually  $\boxtimes$ Multidisciplinary:  $\boxtimes$ Single disciplinary: Is Clinical Audit Team support required? Yes No X If yes, please specify type of assistance required: Population Identification Design of data collection tool (If not required please, attach a copy of the tool to be used)

Database design	
◆ Data entry	
♦ Analysis	
Presentation	
Collection of case notes	☐ Total number / per week
Patient Contact / Involvement – (If project involvement please explain how in this section) Will the audit involve direct patient contact	volves patient contact that is <u>not</u> part of the patients usual treatment $oldsymbol{?}$
How will the patient be involved?	
Patient Questionnaire	tment
Other (please give details) Click here to enter text	
Has approval been sought from the Patient	Information Panel? Yes □ No □ N/A ⊠
Anticipated start date:11th January 2021	
Anticipated project completion date: 5th Ju	ıly 2021
Anticipated Action Plan Submission date:3	0th august 2021
PLEASE ATTACH A COPY OF YOUR DATA COLL	ECTION TOOL / PATIENT QUESTIONNAIRE.
• FOR ALL RE-AUDITS OR REPEAT SERVICE EVAL EVALUATION REPORT.	UATIONS PLEASE ATTACH A COPY OF THE PREVIOUS AUDIT OR SERVICE
<ul> <li>PLEASE ENSURE THIS FORM IS SIGNED BY YOU AUDIT TEAM.</li> </ul>	JR DIVISIONAL AUDIT LEAD BEFORE SUBMISSION TO THE CLINICAL
Departmental Clinical Audit Lead (Signature	) Date: 23/11/2020
Comments Click here to enter text.	
Divisional Clinical Audit Lead (Signature)	Date: Click here to enter text.
Is this topic a key clinical interest for the de	epartment / division? Yes ⊠ No □



#### **Clinical Audit / Service Evaluation Action Plan**

Ref no: NS 351

Clinical Audit Title	Clinical Management: Perioperative patient care			
	Post-anaesthetic Care			
Date audit complete	August 2021	Date action plan completed	September 2021	
Auditor		Name of policy / guideline	AfPP Standard/Guideline	
Division		Source of policy / guideline	Association of Perioperative Practitioners	

### **Summary of Findings:**

- The Environmental Temperature can vary at times in Recovery.
- Trolleys or beds must tilt two ways and padded cot-sides are available.

#### **Key success:**

- Funding has been secured and there are now more ALS trained staff in recovery.
- Handover information is fully documented on new Perioperative patient pathway.

### **Key concerns:**

- The Environmental temperature of Recovery is not always between 19-22 degrees for adequate ventilation
- No padded cot sides available in Recovery due to different beds within the trust.

#### Recommendations discussed:

- Temperature difference has improved after upgrade works by Estates and heaters available if needed.
- Blankets used to pad cotsides.

Presentation / Dissemination of Project
Date findings were presented / disseminated:
Theatre User Group in October 2021.

Version: 2019

Theatre Audit in November 2021.	_				
	mendations discussed:- named lead, timescale and reportable group standardised template, presentation or meet		on plan below.	Please list the e	vidence of the action
Issue	Action required	Named lead for action	Timescale	Evidence	Reportable to (group/meeting)
1) Recovery Temp	Estates and heating system upgrade completed and additional heaters provided if needed.		Completed	Minutes from Theatre User Group/ Theatre Audit	Theatre User Group/Theatre Audit Day
2) No universal Padded cot sides available.	Blankets used to pad out cotsides.		Completed	Minutes from Theatre User Group/ Theatre Audit	Theatre User Group/Theatre Audit Day
3)					
4)					
Re-audit dateApril 2022	If no re-audit planned please give re	easons why?			
Will this be an on-going audit?	′es ⊠ No □				
Are there any potential barriers / pro	oblems to prevent the implementation of t	he above action	s? Yes □ N	o 🗵	
If yes to the above please state who	the issues have been referred to:				
Name Designation					
Signature:					
Have any issues been logged on the risk register? Yes 🗌 No 🛛 N/A 🗍					

Version: 2019

Please provide details of issue(s) logged on the risk register:	

Version: 2019

Audit title: Managing Perioperative Normothermia

The below table provides a system for prioritising locally conceived projects and what level of clinical audit team resource should be offered / provided.

If the project is mandatory please specify what priority level Level 1 – External 'must do' Level 2 'Internal'	rnal 'must do'	
Criteria	Tick all that apply	Score
High cost		(x3)
High volume		(x2)
High risk	Y	(x3)
Known quality issue	Y	(x3)
Wide variation in practice		
NICE / NCEPOD related audit		(x3)
Defined measurable standards available	Y	
Re-audit / repeat service evaluation	Y	(x2)
Topic is a key clinical interest for the department / division		(x2)
Multidisciplinary project	Y	
National / regional or multicentre project		(x2)
Total	10	Level 3 Cat A
Priority levels and audit team support		1

Priority level	Priority score
Level 1 – External 'must do'	Category A
Level 2 – Internal 'must do'	Category A
Level 3 – High local priority	> 10
Level 4 – Medium local priority	4 – 9
Level 5 – Low local priority	< 4

Priority level	Audit team resource	
Level 1, 2 & 3	Category A – Full support	Full practical assistance offered
Level 4	Category B – Moderate support	Level of practical assistance will be
		negotiated and agreed with project lead
Level 5	Category C – Minimal support	Advice, registration and monitoring

CLINICAL AU	DIT / SERVICE EVALUATION	PROJECT REGISTRATION FORM
Ref No: - Proje	ct Type: - Clinical Audit 🗆 S	ervice Evaluation □
Audit / Service Evaluation	Title: Managing Periope	rative Normothermia
<b>Division:</b> Neurology □ Neu	ırosurgery ⊠ Please specify d	department Click here to enter text.
Project Lead		
Contact No: Bleep No	Click here to enter text.	
Email address:		
Audit / service evaluation	supervisor:	
	ved / project team members of roles within the project eg data	
<ul> <li>problem for patient</li> <li>Perioperative hypo</li> <li>Hypothermia can be medical or surgical activity. (The reduce</li> <li>The young and the</li> </ul>	s undergoing surgery (NICE othermia can have a wide ran be deliberate or inadvertent. I reasons such as neurosurg	nge of detrimental effects to the patient. Deliberate hypothermia may be induced for gery when it is beneficial to reduce metabolic organ damage despite reduced perfusion)
Aims / Objectives		

- Patients at higher risk are identified during the pre-assessment procedure.
- Preventative warming measures are identified if appropriate
- Patient temperatures are measured throughout the procedure.
- There are sufficient warming devices
- <u>Methodology</u>
- A ODP will observe patients management of Perioperative Normothermia, also the checking of records and asking staff.

### Standards / Criteria Details (service evaluation N/A)

Previously sent							
Guideline / Standards available:	Yes	$\boxtimes$	No				
If yes, please attach a copy or provide web link to the most current version: Click here to enter text.							
Name of Standard / guideline: Managing perioperative Normothermia							
Source of Standard / guideline:	NSF			NICE		Royal College	

Trust ☐ Practitioners)	Other	⊠ State other:	AfPP (Association of Perioperative
Review/assessment	of guideline/	standard undertaken to e	ensure it is appropriate & can be measure
Is the audit / service High volume High risk High cost Known quality issue Wide variation in prac	Yes   Yes   Yes   Yes	□ No ⊠ ⊠ No □	
Sample No: 10 Prod	edure codes	to identify sample: Click h	here to enter text.
http://www.raosoft.co	m/samplesize	.html - link to tool that may	be used to calculate sample size
Are you planning to	publish your	· audit/service evaluation	ı findings nationally
(e.g. Medical journal)	? Yes □	□ No ⊠	
Is this a re-audit or i	f service eva	luation, has service been	n reviewed previously? Yes  No
Is this project part of	of an agreed o	lepartmental rolling prog	ıramme? Yes ⊠ No □
Rolling programme	duration (nur	nber of years): ongoing ເ	until updated
Rolling programme	frequency: N	// Monthly □ Quarterly □	Biannually □ Annually ⊠
Multidisciplinary:	$\boxtimes$	Single disciplinary	y: 🗆
Is Clinical Audit Tea  If yes, please specify  ◆ Population Identif  ◆ Design of data co  (If not required please  ◆ Database design  ◆ Data entry  ◆ Analysis  ◆ Presentation  Collection of case not	type of assistatication Ilection tool e, attach a cop	ance required:  □ □ □ oy of the tool to be used) □ □ □ □ □ □ □ □	No ⊠ number / per week
Patient Contact / Invorcare please explain h	now in this secti	ion)	ntact that is $not$ part of the patients usual treatme
How will the patient	be involved?	•	
Patient Questionnaire	e □ At cl	inic appointment □	
Other (please give deta	ails) Click here t	o enter text.	

las approval been sought from the Patient Information Panel? Yes   No   N/A								
Anticipated start date:11th January 2021								
Anticipated project completion date: 5th July 2021								
nticipated Action Plan Submission date:30th august 2021								
PLEASE ATTACH A COPY OF YOUR DATA COLLECTION TOOL / PATIENT QU	ESTION	NAIR	E.					
• FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATIONS PLEASE ATTACH A EVALUATION REPORT.	COPY (	OF TH	E PRE	VIOU	S AUDI	T OR SERVICE		
<ul> <li>PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVISIONAL AUDIT LEAD AUDIT TEAM.</li> </ul>	BEFORE	SUBI	MISSIG	ON TO	) THE C	CLINICAL		
Departmental Clinical Audit Lead (Signature) Date: 23/11/2020								
Comments Click here to enter text.								
Divisional Clinical Audit Lead (Signature)	Da	ate: (	Click h	nere 1	to ente	er text.		
Is this topic a key clinical interest for the department / division?	Yes			Ν	1o 🗆			



#### **Clinical Audit / Service Evaluation Action Plan**

Ref no: NS 352

Clinical Audit Title	Managing Perioperative Normothermia			
Date audit complete	19/7/2021	Date action plan completed	March 2021	
Auditor		Name of policy / guideline SOP Managing Perioperative Normothermia		
Division	Neurosurgery	Source of policy / guideline	Association of Perioperative Practice	

### **Summary of Findings:**

- All intravenous fluids/bloods are warmed in either a fluid warming cabinet or fluid warmer.
- All patients have their temperature monitored and recorded throughout the perioperative phase.

### **Key success:**

- All patients having a procedure lasting > 20 minutes have their temperature monitored and forced air warmer applied.
- There have been no reported incidents of perioperative hypothermia during the past 12 months.

## **Key concerns:**

- Fluid warming cabinets are sometimes set at the wrong temperature.
- Against manufacturer guidance; the department cuts forced air warming blankets to allow for surgical access.

#### Recommendations discussed:

- Audit temperature of fluid warming cabinets.
- Discussion to be had with procurement regarding obtaining surgical access blankets therefore preventing the need for them to be cut.

Presentation / Dissemination of Project Date findings were presented / disseminated:	-
Department where discussed or presented:	

Actions agreed following recommendations discussed:-

Version: 2019

\*Please ensure each action has a named lead, timescale and reportable group stated on the action plan below. Please list the evidence of the action implementation e.g SOP, protocol, standardised template, presentation or meeting minutes etc

Issue	Action required	Named lead for action	Timescale	Evidence	Reportable to (group/meeting)	
Fluid warming cabinet     temperatures are occasionally     set higher than the     recommended temperature	<ul> <li>Audit fluid cabinet temperatures</li> <li>Discuss at theatre audit meeting</li> <li>Ensure posters are positioned on fluid cabinet to remind staff of the recommended temperature.</li> </ul>		2 months	Audit results, meeting minutes	Theatre User Group	
<ol> <li>Staff are cutting the forced air warming blankets to allow for surgical access</li> </ol>	<ul> <li>Discussion with procurement and theatre management. Waiting pre-cut blanket orders lead time 4 weeks.</li> </ul>		2 months	Email from Procurement	Theatre User Group	
3)						
4)						
Re-audit dateApril 2022	If no re-audit planned please give re	asons why?			_	
Will this be an on-going audit? Ye	s ⊠ No □					
Are there any potential barriers / prol	plems to prevent the implementation of the	ne above actions	? Yes 🗌 N	o 🛚		
If yes to the above please state who t						
Name	Designation	_ Date referre	d			
Signature:	Date:					
Have any issues been logged on the	risk register? Yes 🗌 No 🛛 N/A					
Please provide details of issue(s) logged on the risk register:						

Version: 2019

Version: 2019

# **Project Prioritisation Assessment Tool**

## Audit title: The use of Electrosurgery in Theatre

If the project is mandatory please specify what priority level:-

**Priority level** 

Level 1, 2 & 3

Level 4

Level 5

**Audit team resource** 

Category A – Full support

Category B – Moderate support

Category C – Minimal support

The below table provides a system for prioritising locally conceived projects and what level of clinical audit team resource should be offered / provided.

Level 1 – External 'must do' Level 2 'Internal 'must do'					
Criteria		Tick all that apply	Score		
High cost			(x3)		
High volume			(x2)		
High risk		Υ	(x3)		
Known quality issue		Υ	(x3)		
Wide variation in practice					
NICE / NCEPOD related audit			(x3)		
Defined measurable standards available		Υ			
Re-audit / repeat service evaluation		Υ	(x2)		
Topic is a key clinical interest for the department / division			(x2)		
Multidisciplinary project		Υ			
National / regional or multicentre project			(x2)		
Total		10	Level 3 Cat A		
Priority levels and audit team support					
Priority level Priorit		Priority score			
Level 1 – External 'must do' Category		ry A			
Level 2 – Internal 'must do' Category		ory A			
Level 3 – High local priority > 10					
Level 4 – Medium local priority	4 – 9				
Level 5 – Low local priority	< 4				

Version 2019 Review date: 2021

Full practical assistance offered

Level of practical assistance will be negotiated and agreed with project lead

Advice, registration and monitoring

## **CLINICAL AUDIT / SERVICE EVALUATION PROJECT REGISTRATION FORM**

Ref No: - Project Type: - Clinical Audit
<b>Division:</b> Neurology □ Neurosurgery ⊠ Please specify department Click here to enter text.
Project Lead
Contact No: Bleep No: Click here to enter text.
Email address:
Audit / service evaluation supervisor:
Other professionals involved / project team members details (Please provide names and roles within the project eg data collection, analysis etc.) Jenny Fitzpatrick
<ul> <li>Background / Rationale</li> <li>Risks associated with electrosurgery are identified and minimised to reduce the potential to harm patients and staff.</li> <li>All members of the perioperative team have sufficient knowledge and experience of the principles and techniques of electrosurgery.</li> <li>Risks associated with inhalation of the surgical plume are minimised</li> </ul>
Aims / Objectives
<ul> <li>There is sufficient diathermy equipment available for use in use in the department</li> <li>There are training sessions for diathermy use and the attendance records are maintained.</li> <li>There is action on the diathermy incidents that have been reported.</li> <li>Staff observe safe diathermy practice.</li> <li>There is a surgical plume extraction system in place where appropriate</li> </ul>
Methodology A theatre Practitioner will observe, check records and ask staff with regard to Electrosurgery Standards / Criteria Details (service evaluation N/A)
Previously sent
Guideline / Standards available: Yes ⊠ No □
If yes, please attach a copy or provide web link to the most current version: Click here to enter text.
Name of Standard / guideline: The use of Electrosurgery in Theatres
Source of Standard / guideline: NSF

Practitioners)

Review/assessment of gurves $\square$ No $\square$	ideline/standard undertaken to ensure it is appropriate & can be measured
Is the audit / service evaluation High volume High risk High cost Known quality issue Wide variation in practice	Yes □ No ⊠ Yes □ No □ Yes □ No □ Yes □ No □
Sample No: 10 Procedure	e codes to identify sample: Click here to enter text.
http://www.raosoft.com/sam	nplesize.html - link to tool that may be used to calculate sample size
Are you planning to publi	sh your audit/service evaluation findings nationally
(e.g. Medical journal)?	Yes □ No ⊠
Is this a re-audit or if serv	ice evaluation, has service been reviewed previously? Yes   No
Is this project part of an a	greed departmental rolling programme? Yes ⊠ No □
Rolling programme durati	ion (number of years): ongoing until updated
Rolling programme freque	ency: Monthly □ Quarterly □ Biannually □ Annually ⊠
Multidisciplinary: ⊠	Single disciplinary: □
Is Clinical Audit Team sup If yes, please specify type of  ◆ Population Identification  ◆ Design of data collection (If not required please, attack  ◆ Database design  ◆ Data entry  ◆ Analysis  ◆ Presentation Collection of case notes	of assistance required:
or care please explain how in Will the audit involve dire	ct patient contact?  Yes □ No ⊠  volved?  □ At clinic appointment □
,	t from the Patient Information Panel? Yes □ No □ N/A ⊠
Anticipated start date:11t	
Anticipated project comp	·

## Anticipated Action Plan Submission date:30th august 2021

- PLEASE ATTACH A COPY OF YOUR DATA COLLECTION TOOL / PATIENT QUESTIONNAIRE.
- FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATIONS PLEASE ATTACH A COPY OF THE PREVIOUS AUDIT OR SERVICE EVALUATION REPORT.
- PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVISIONAL AUDIT LEAD BEFORE SUBMISSION TO THE CLINICAL AUDIT TEAM.

Departmental Clinical Audit Lead (Signature) Date: 23/11/2020		
Comments Click here to enter text.		
Divisional Clinical Audit Lead (Signature)	Date: Click	here to enter text.
Is this topic a key clinical interest for the department / division?	Yes ⊠	No □



#### **Clinical Audit / Service Evaluation Action Plan**

Ref no: NS 353

Clinical Audit Title	The Use of Electrosurgery		
Date audit complete	18/4/2020	Date action plan completed	16/7/2020
Auditor		Name of policy / guideline	AfPP Standard/Guideline
Division	Surgery	Source of policy / guideline	Association of Perioperative Practitioners

## **Summary of Findings:**

- Aim that risks associated with electrosurgery are identified and minimised to reduce the potential to harm patients and staff
- Sample size of 10 patients
- Method of evidence gathered was through observation, checking medical records and asking staff their awareness of electrosurgery.
- Approved smoke evacuator not available trials stopped during COVID pandemic.

## **Key success:**

• Staff are aware of the safe use of all electrosurgical equipment within the perioperative setting

## **Key concerns:**

No Smoke evacuators in Trust at present trials have now started back up.

#### **Recommendations discussed:**

• Smoke Evaluator trial commenced within the Theatre department.

## Presentation / Dissemination of Project

Date findings were presented / disseminated:

Report to be discussed at Theatre User Group in August 2021.

Version: 2019

Department where discussed or presented	
Theatre Audit August 2021.	

## Actions agreed following recommendations discussed:-

\*Please ensure each action has a named lead, timescale and reportable group stated on the action plan below. Please list the evidence of the action implementation e.g SOP, protocol, standardised template, presentation or meeting minutes etc

Issue	Action required	Named lead for action	Timescale	Evidence	Reportable to (group/meeting)
Presently no smoke     evacuators in Theatre when     using monopolar diathermy	Trial was on hold due to COVID. Trial restarted.		6 months	Theatre User Group minutes	Theatre User Group
	Update - theatres have acquired filters that project the suction equipment. Conventional suction still used to clear smoke, ideally the device is attached to the diathermy – options being trialled at the moment, surgeons are finding "bulky" – on-going				
2)	on genig				
3)					
4)					
Re-audit date April_2022	If no re-audit planned please give re	asons why?		1	_
Will this be an on-going audit?	es 🛛 No 🗌				
Are there any potential barriers / pro	oblems to prevent the implementation of t	he above action	ns? Yes □ N	o 🛚	

Version: 2019

If yes to the above please state who the	f yes to the above please state who the issues have been referred to:					
Name	Designation	Date referred				
Signature:	Date:					
Have any issues been logged on the ris	sk register? Yes 🗌 No 🛛 N/A 🗌					
Please provide details of issue(s) logge	ed on the risk register:					

Version: 2019

# **Project Prioritisation Assessment Tool**

## Audit title: : Anaesthesia

Level 1 – External 'must do'

**Priority level** 

Level 1, 2 & 3

Level 4

Level 5

**Audit team resource** 

Category A – Full support

Category B – Moderate support

Category C – Minimal support

If the project is mandatory please specify what priority level:-

The below table provides a system for prioritising locally conceived projects and what level of clinical audit team resource should be offered / provided.

Level 2 'Internal 'must do'

Criteria		Tick all that apply	Score		
High cost			(x3)		
			( - )		
High volume			(x2)		
High risk		Υ	(x3)		
THE THE		•	(,,5)		
Known quality issue		Υ	(x3)		
Wide variation in practice					
NICE / NCEPOD related audit			(x3)		
Defined measurable standards available		Υ			
Defined fileasurable standards available		1			
Re-audit / repeat service evaluation		Υ	(x2)		
			, ,		
Topic is a key clinical interest for the departmen	nt / division		(x2)		
Multidisciplinary project		Υ			
National / regional or multicentre project			(x2)		
Total		10	Level 3 Cat A		
Priority levels and audit team support		<u> </u>	.		
Priority level	Priority s	core			
Level 1 – External 'must do'	/ A				
Level 2 – Internal 'must do' Category		A			
Level 3 – High local priority	> 10				
Level 4 – Medium local priority	4-9				
Level 5 – Low local priority	< 4				

Version 2019 Review date: 2021

Full practical assistance offered
Level of practical assistance will be

negotiated and agreed with project lead

Advice, registration and monitoring

#### CLINICAL AUDIT / SERVICE EVALUATION PROJECT REGISTRATION FORM

Ref No: -	Project Type: - Clinical Audit ☐ Service Evaluation ☐
Audit / Service Evalu	uation Title: Anasethesia
Division: Neurology	□ Neurosurgery ⊠ Please specify department Click here to enter text.
Project Lead:	
Contact No: Ble	eep No: Click here to enter text.
Email address: Audit / service evalu	ation supervisor:
<u> </u>	involved / project team members details es and roles within the project eg data collection, analysis etc.)
Background / Ration  • A safe enviro	nale nment is maintained where anaesthesia is delivered

- Equipment is maintained and checked before use within a governance framework
- There is a holistic approach to safe practice
- Patients are protected from known clinical lists of anaesthesia
- Patients receive care from appropriately trained persons

Click here to enter text.

## **Aims / Objectives**

- Qualified anaesthetic practitioners are educated to support the anaesthetist in all aspects of anaesthetic care and safety
- The anaesthetist is responsible for the drugs which he/she administers
- Drawing up, double checking and administration of anaesthetic drugs is guided by comprehensive local protocols. Equipment is decontaminated to national standards
- Anaesthetic equipment is checked before use and a record maintained
- Emergency equipment is maintained and available at all times
- The five steps to safer surgery are performed by suitably qualified practitioners in a designated area
- Staff are educated to support in emergency situations in anaesthesia
- Emergency protocols and routine guidance are readily available to all staff
- Communication with patients by anaesthetic staff is appropriate to the situation

Methodology An ODP will Follow patients through start of Anaesthetic journey to Recovery and observe.

## Standards / Criteria Details (service evaluation N/A)

Previously sent					
Guideline / Standards available:	Yes	$\boxtimes$	No		
If yes, please attach a copy or provi	de web	link to	the mos	st current version: Click here to enter text.	

Name of Standard / guideling	<b>ne:</b> Anaesthesi	ia in Thea	itres				
Source of Standard / guidel  Trust  Other  Practitioners)		□ State	NICE <b>other:</b>		•	l College Perioperati	□ ive
Review/assessment of guid	eline/standar	d undert	aken to ens	ure it is ap	propriate	& can be m	neasured
' '	tion issue: Yes  No  Yes						
Sample No: 10 Procedure	codes to iden	tify samp	ole: Click here	e to enter te	ĸt.		
http://www.raosoft.com/samp	<u>lesize.html</u> - lir	nk to tool	that may be	used to cal	culate sam	ple size	
Are you planning to publish	n vour audit/s	ervice ev	aluation fin	dinas natio	onally		
	res □	No ⊠		3			
Is this a re-audit or if service	e evaluation,	has serv	ice been re	viewed pre	viously?	Yes □	No ⊠
Is this project part of an ag				-	·	⊠ No □	
Rolling programme duratio	-						
Rolling programme frequer	cy: Monthly	☐ Qua	rterly □ B	iannually [	☐ Annua	lly ⊠	
Multidisciplinary:		Single d	isciplinary:				
Is Clinical Audit Team supp If yes, please specify type of  ◆ Population Identification  ◆ Design of data collection  (If not required please, attach  ◆ Database design  ◆ Data entry  ◆ Analysis  ◆ Presentation  Collection of case notes	assistance req	nuired: [ [	] ] ]	No			
Patient Contact / Involvement or care please explain how in the Will the audit involve direct How will the patient be involved.	is section) patient conta	act?	Yes	t that is <u>not</u> p		atients usuai	

Other (please give details) Click here to enter text.						
Has approval been sought from the Patient Information Panel?	Yes		No		N/A	$\boxtimes$
Anticipated start date:11th January 2021						
Anticipated project completion date: 5th July 2021						
Anticipated Action Plan Submission date:30th august 2021						
<ul> <li>PLEASE ATTACH A COPY OF YOUR DATA COLLECTION TOOL / PATIENT QUID</li> <li>FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATIONS PLEASE ATTACH A EVALUATION REPORT.</li> <li>PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVISIONAL AUDIT LEAD IN AUDIT TEAM.</li> </ul>	COPY	OF TH	IE PRE			
Departmental Clinical Audit Lead (Signature) Date: 23/11/2020						
Comments Click here to enter text.						
Divisional Clinical Audit Lead (Signature)		ate:	Click h	nere t	to ente	er text.
Is this tonic a key clinical interest for the department / division?	٧a	e 🕅		N	ام ا	

# **Project Prioritisation Assessment Tool**

## Audit title: The use and handling of surgical instruments in Theatre

If the project is mandatory please specify what priority level:-

Category A – Full support

Category B – Moderate support

Category C – Minimal support

Level 1 – External 'must do'

Level 1, 2 & 3

Level 4

Level 5

The below table provides a system for prioritising locally conceived projects and what level of clinical audit team resource should be offered / provided.

Level 2 'Internal 'must do'

Criteria		Tick all that apply	Score
High cost			(x3)
High volume			(x2)
High risk	Y		(x3)
Known quality issue	Y		(x3)
Wide variation in practice			
NICE / NCEPOD related audit			(x3)
Defined measurable standards available	Υ		
Re-audit / repeat service evaluation	Υ		(x2)
Topic is a key clinical interest for the department / o	division		(x2)
Multidisciplinary project	Υ		
National / regional or multicentre project			(x2)
Total	10	0	Level 3 Cat A
Priority levels and audit team support			
Priority level	Priority scor	·e	
Level 1 – External 'must do'	Category A		
Level 2 – Internal 'must do' Category			
Level 3 – High local priority	> 10		
Level 4 – Medium local priority	4 – 9		
Level 5 – Low local priority	< 4		
Priority level Audit team resource			

Version 2019 Review date: 2021

Full practical assistance offered
Level of practical assistance will be

negotiated and agreed with project lead Advice, registration and monitoring

## **CLINICAL AUDIT / SERVICE EVALUATION PROJECT REGISTRATION FORM**

Ref No: -	Project Type:	- Clini	cal Au	dit ⊠	Service E	valuatio	on 🗆	
Audit / Service Eval	uation Title:	Acco	ountab	le Items	, swab, Ins	strument	and Needle Count	
Division: Neurology	□ Neurosurge	ry ⊠ F	Please	specify	departme	nt <b>Theat</b>	res	
Project Lead								
Contact No: Blo	eep No: Click h	ere to e	nter te	xt.				
Email address:								
Audit / service evalu	uation supervi	sor:						
Other professionals (Please provide name						on, analy	/sis etc.)	
(DH 2012)	ects are conside		-				efined in the 'never events' lis	st
patient. • Systemised a unintended re Aims / Objectives	nd careful cour tention of surgi	nting ar cal iter	nd doc	·			s subsequent injury to the	
<ul><li>Observed inte</li><li>Review of cou</li><li>Theatre envire</li><li>Discussion wi</li></ul>		atient a docun ooard). e teams	nentati s on th	on. e purpo			ropriate.  ocation of relevant policies.	
	ction programm cords for staff tr				e items an	d updat	es where required.	
<u>Methodology</u>								
The suggested me asking staff.	thod of gather	ring ev	ridenc	e will be	e by obse	rvation,	checking records, and	
Standards / Criteria	Details (servi	ce eva	luation	<u>1 N/A)</u>				
Previously sent								
Guideline / Standard	ds available:	Yes	$\boxtimes$	No				
If yes, please attach a	a copy or provi	de web	link to	the mo	st current	version:	Click here to enter text.	
Name of Standard /	guideline: The	use a	nd Har	ndling of	surgical i	nstrume	nts in Theatre	
Source of Standard	/ guideline:	NSF			NICE		Royal College	

<b>Trust</b>	Other	⊠ State other	AfPP (Association	on of Perioperative
<b>Review/assessmer</b> Yes ⊠ No □	nt of guideline/s	standard undertaken t	o ensure it is appropr	iate & can be measured
Is the audit / service High volume High risk High cost Known quality issue Wide variation in pra	Yes [	□ No ⊠ ☑ No □ □ No ⊠ ☑ No □	rk hara to anter toyt	
-		html - link to tool that ma		sample size
Are you planning t	o publish your	audit/service evaluation	on findings nationally	,
(e.g. Medical journa	I)? Yes □	No ⊠		
ls this a re-audit o	r if service eval	uation, has service be	en reviewed previous	ly? Yes □ No 🛛
Is this project part	of an agreed de	epartmental rolling pro	ogramme?	∕es ⊠ No □
Rolling programme	e duration (num	nber of years): ongoin	g until updated	
Rolling programme	e frequency: M	lonthly   Quarterly	□ Biannually □ Ar	nnually 🗵
Multidisciplinary:	$\boxtimes$	Single disciplin	ary: □	
Is Clinical Audit Te If yes, please specif  ◆ Population Ident  ◆ Design of data of (If not required please)  ◆ Database design  ◆ Data entry  ◆ Analysis  ◆ Presentation  Collection of case n	fy type of assista ification collection tool se, attach a copy	y of the tool to be used)		≅ eek
Patient Contact / In or care please explain Will the audit invol	how in this section	on)		the patients usual treatment
How will the patier	nt be involved?			
Patient Questionnai	re □ At cli	nic appointment $\ \Box$		
Other <i>(please give de</i>	etails) Click here to	o enter text.		
Has approval been	sought from th	he Patient Information	Panel? Yes □ ↑	No □ N/A ⊠

Anticipated start date:11th January 2021

Anticipated project completion date: 5th July 2021

Anticipated Action Plan Submission date:30th august 2021

- PLEASE ATTACH A COPY OF YOUR DATA COLLECTION TOOL / PATIENT QUESTIONNAIRE.
- FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATIONS PLEASE ATTACH A COPY OF THE PREVIOUS AUDIT OR SERVICE EVALUATION REPORT.
- PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVISIONAL AUDIT LEAD BEFORE SUBMISSION TO THE CLINICAL AUDIT TEAM.

Departmental Clinical Audit Lead (Signature) Date: 23/11/2020		
Comments Click here to enter text.		
Divisional Clinical Audit Lead (Signature)	Date: Click	here to enter text.
Is this topic a key clinical interest for the department / division?	Yes ⊠	No □



#### Clinical Audit / Service Evaluation Action Plan

Ref no: NS 355

Clinical Audit Title	Accountable Items, Swabs Instruments and needle count					
Date audit complete	July 2021	Date action plan completed	September 2021			
Auditor		Name of policy / guideline	AfPP Standard/Guideline			
Division	Surgery	Source of policy / guideline	Association of perioperative Practitioners			

## **Summary of Findings:**

- 10 staff (across HCA, ODP and nurses) observed
- When counts are being performed there isn't always reduced noise/distractions which reduce the acknowledgement by the team.
- The Surgeon is not audibly informed that the count is correct which occur before closure of a cavity.

### **Key success:**

• Staff are aware about a system which ensures that all swabs, needles and instruments used in clinical interventions or invasive procedures are accounted for at all times, wherever the intervention takes place;

#### **Key concerns:**

- 10% of the Theatre Team not engaging when counts are being performed. Staff member had not currently worked long in the department; staff member is currently working through competencies with support to improve engagement.
- 10% of the Scrub Staff not informing the Surgeon that count is correct before closure of a cavity.

#### Recommendations discussed:

- Discuss with Staff the importance of the Theatre Team engaging when counts are being performed.
- Discuss with Scrub Staff the importance of informing the Surgeon that count is correct before closure of a cavity
- To note, swab count compliance is documented on the local risk register and highlighted as part of WHO checklist

## **Presentation / Dissemination of Project**

Date findings were presented / disseminated: Theatre User Group October 2021

Department where discussed or presented: Theatre Audit November 2021

Version: 2019

## Actions agreed following recommendations discussed:-

\*Please ensure each action has a named lead, timescale and reportable group stated on the action plan below. Please list the evidence of the action implementation e.g SOP, protocol, standardised template, presentation or meeting minutes etc

Issue	Action required	Named lead for action	Timescale	Evidence	Reportable to (group/meeting)
When counts are being performed there is not always a reduced noise and distractions and acknowledgement by the team.	Discuss with Staff the importance of the Theatre Team engaging when counts are being performed.		November 2021	Minutes from Theatre Audit meeting	Theatre User Group/ Theatre Audit
2) The Surgeon was not audibly informed that the count is correct which occur before closure of a cavity.	Discuss with Scrub Staff the importance of informing the Surgeon that count is correct before closure of a cavity		November 2021	Minutes from Theatre Audit meeting	Theatre User Group/ Theatre Audit
Will this be an on-going audit? Ye	udit planned please give reasons why? _es   No		_	_	
If yes to the above please state who	the issues have been referred to:				
Name Designation	Date referred				
Signature:	Date:				
Have any issues been logged on the	risk register? Yes 🛛 (already on risk r	egister) No 🗌	N/A		
Please provide details of issue(s) log	ged on the risk register:				

Version: 2019

Version: 2019



#### Clinical Audit / Service Evaluation Action Plan

Ref no: NS 356

Clinical Audit Title	Patient Safety Audit		
Date audit complete	December 21	Date action plan completed	Yes
Auditor		Name of policy / guideline	ARHQ (Attached)
Division	Surgery	Source of policy / guideline	https://www.ahrq.gov/patient-
			safety/settings/esrd/resource/checklist.html & AQUA

Δı	tibı	Rati	ona	l۵.

The Audit used was the ARHQ audit tool which is designed to look at the Safety culture within a department.

30 staff across all disciplines replied to the audit (See attached Results Paper)

	Ì
 ulto	- -

Results.pdf

## **Summary of Findings:**

Please concisely state the main conclusions of the project using bullet points

- Overall the results showed a "Very Good" safety culture within the department
- The vast majority of questions asked were answered positively across all staff groups (See attached Results Paper)

## **Key success:**

Please concisely state the key success identified by the project – if none identified please state N/A

- "Very Good" safety Culture in department
- A strong reporting culture exists within the department
- The teams work well with one another
- The staff surveyed felt the department was a pleasant place to work (Section F)
- Cooperation between departments was positive (Section F)
- The connection between shop floor and management was strong (Section B)
- The staff surveyed felt that department actively looked to constantly improve patient safety

## **Key concerns:**

Please concisely state the key concerns identified by the project using bullet points—if none identified please state N/A

- Section C showed an issue with staff "speaking Up"
- A small number of staff (4) felt the Safety Culture was "acceptable"
- Staff were unaware of the Number of NE in the department, however due this only being 1 NE this is understandable

#### Recommendations discussed:

Please concisely summarise the recommendations that were discussed following the completion of the project

- Development of MDT teaching plan utilising audit days. The teaching will involve MDT simulation and session designed to develop staff resilience and a Just and Open Culture.
- Continue to utilise Trust Human Factors training and bring in-house on Audit days. Increase level of simulation teaching outside of Audit days

### **Presentation / Dissemination of Project**

Date findings were presented / disseminated: 11/1/22 (Attached: 2021 Audit Plan)

Department where discussed or presented: Theatre User Group

## Actions agreed following recommendations discussed:-

\*Please ensure each action has a named lead, timescale and reportable group stated on the action plan below. Please list the evidence of the action implementation e.g SOP, protocol, standardised template, presentation or meeting minutes etc

Issue	Action required	Named lead for action	Timescale	Evidence	Reportable to (group/meeting)
1)Speaking up	Utilise Audit days to build staff resilience		Complete	Attached Yearly teaching Plan	TUG, CAG
2)Increase use of simulation to maintain/ improve on "Very good" safety culture	Create MDT training on Audit days		Complete	As Above	TUG, CAG
3)Increase Risk and Governance reporting to staff via Audit days and Staff R&G board	Utilise Staff meetings and re-vamp R&G board		Complete	Audit Minutes, Audit Plan	TUG, CAG

Re-audit dateJan 2023	If no re-audit planned pl	ease give reasons why	/?		
Will this be an on-going audit?	es ⊠ No □				
Are there any potential barriers / pro	oblems to prevent the impleme	entation of the above a	ctions? Yes	] No x	
If yes to the above please state who the issues have been referred to:					
Name	Designation	Date	8/3/22 referred		
Signature:	Date:				
Have any issues been logged on the risk register? Yes  No x N/A Please provide details of issue(s) logged on the risk register:					

## **Project Prioritisation Assessment Tool**

## **Audit title: Safety Culture Audit (FOCUS Project)**

**Priority level** 

Level 1, 2 & 3

Level 4

Level 5

Audit team resource

Category A – Full support

Category B – Moderate support

Category C – Minimal support

If the project is mandatory please specify what priority level:-

The below table provides a system for prioritising locally conceived projects and what level of clinical audit team resource should be offered / provided.

Level 1 – External 'must do' Level 2 'Internal 'must do'					
Criteria	Tick all that apply	Score			
High cost		(x3)			
High volume	Y	(x2)			
High risk		(x3)			
Known quality issue	Υ	(x3)			
Wide variation in practice					
NICE / NCEPOD related audit		(x3)			
Defined measurable standards available	Y				
Re-audit / repeat service evaluation		(x2)			
Topic is a key clinical interest for the department / (	division Y	(x2)			
Multidisciplinary project	Y				
National / regional or multicentre project		(x2)			
Total	Level 4 – Category B	9			
Priority levels and audit team support					
Priority level	Priority score				
Level 1 – External 'must do' Category A					
Level 2 – Internal 'must do'	Category A				
Level 3 – High local priority	> 10				
Level 4 – Medium local priority	4-9				
Level 5 – Low local priority	< 4				

Version 2019 Review date: 2021

Full practical assistance offered

Level of practical assistance will be

Advice, registration and monitoring

negotiated and agreed with project lead

## CLINICAL AUDIT / SERVICE EVALUATION PROJECT REGISTRATION FORM

Ref No: -	Project Type: - Clinical Audit ⊠ Service Evaluation ⊠
Audit / Service E	valuation Title: Safety Culture Audit (FOCUS Project)
Division: Neurolo	gy $\square$ Neurosurgery $\boxtimes$ Please specify department Click here to enter text.
Project Lead:	
Contact No:	Bleep No: Click here to enter text.
Email address:	
Audit / service ev	valuation supervisor:
(Please provide na	als involved / project team members details ames and roles within the project eg data collection, analysis etc.) onals from ITU & Theatre
to the Patient Safet	tionale  uired as part of the upcoming FOCUS project, this will allow us to identify shortfalls with regards y Culture within the department. From this data we can then FOCUS on the systems and patient at may require improvement.
<u>Methodology</u>	
and thus allow the	I will be used to gather data (AHRQ Hospital Survey). This data will then be correlated FOCUS team to identify areas for improvement within the department. Once these areas ed the FOCUS team will engage the staff and via this engagement improve the areas idit.
Aims / Objectives	<u> </u>
	view of the safety culture within Theatre and allow the FOCUS team alongside staff prove/ re-design any areas that have been identified. This process is designed to further nt safety culture.
Standards / Crite	ria Details (service evaluation N/A)
Click here to enter t	ext.
Guideline / Stand	lards available: Yes ⊠ No □
https://www.ahrq.g	ch a copy or provide web link to the most current version: gov/sites/default/files/wysiwyg/sops/surveys/hospital/hospitalsurvey2-form.pdf gov/sops/surveys/hospital/index.html
Name of Standar	d / guideline: Agency for Healthcare and Research Qulaity
Source of Standa Trust □	ard / guideline: NSF □ NICE □ Royal College □ Other ☑ State other: See Above

Review/assessment of guid Yes $\boxtimes$ No $\square$	eline/standard undertaken to ensure it is appropriate & can be measured
High risk High cost	Yes ⊠ No □ Yes □ No ⊠ Yes □ No ⊠ Yes ☑ No □
Sample No: Click here to enter	r text. Procedure codes to identify sample: Click here to enter text.
http://www.raosoft.com/sample	esize.html - link to tool that may be used to calculate sample size
Are you planning to publish	your audit/service evaluation findings nationally
(e.g. Medical journal)?	∕es ⊠ No ⊠
Is this a re-audit or if servic	e evaluation, has service been reviewed previously? Yes $\square$ No $\boxtimes$
Is this project part of an agr	reed departmental rolling programme? Yes ⊠ No □
Rolling programme duration	n (number of years):On-Going
Rolling programme frequen	cy: Monthly □ Quarterly □ Biannually □ Annually ⊠
Multidisciplinary: ⊠	Single disciplinary: □
Is Clinical Audit Team supp If yes, please specify type of a  ◆ Population Identification  ◆ Design of data collection t (If not required please, attach  ◆ Database design  ◆ Data entry  ◆ Analysis  ◆ Presentation Collection of case notes	assistance required:
or care please explain how in thi Will the audit involve direct How will the patient be invo	patient contact? Yes □ No ☒  Ived?  At clinic appointment □
Has approval been sought t	from the Patient Information Panel? Yes □ No □ N/A □
Anticipated start date:Jan 2	021
Anticipated project complet	ion date: On-Going

## Anticipated Action Plan Submission date: March 2021 if not earlier

- PLEASE ATTACH A COPY OF YOUR DATA COLLECTION TOOL / PATIENT QUESTIONNAIRE.
- FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATIONS PLEASE ATTACH A COPY OF THE PREVIOUS AUDIT OR SERVICE EVALUATION REPORT.
- PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVISIONAL AUDIT LEAD BEFORE SUBMISSION TO THE CLINICAL AUDIT TEAM.

Departmental Clinical Audit Lead (Signature)	Date: 18/12/20		
Comments Click here to enter text.			
Divisional Clinical Audit Lead (Signature)		Date: Click	here to enter text.
Is this topic a key clinical interest for the depart	rtment / division?	Yes ⊠	No □



#### Clinical Audit / Service Evaluation Action Plan

Ref no: NS 357

Clinical Audit Title	Assessment the role of CT CAP in newly detected brain lesions		
Date audit complete	20/12/2021	Date action plan completed	22/03/2022
Auditor		Name of policy / guideline	
Division	Neurosurgery	Source of policy / guideline	

#### Audit Rationale:

The audit was undertaken to see if we can reduce the number of CT CAPs advised by the on call service for newly detected brain lesions.

## **Summary of Findings:**

- Screening CTCAP is indicated for multiple or infratentorial lesions and in patients with a history of treated cancer.
- CTCAP should be used judiciously in patients with a single lesion >4cm in size or with >5mm midline shift.
- Further data is required to assess the possible utility of CT Chest alone in newly presenting brain lesions.

#### **Key success:**

• We identified clinical and radiological criteria which can reduce the number of negative CT CAPS by nearly 45% without missing patients with positive CT CAPs

#### **Key concerns:**

• CT CAP is requested inadvertently many times, resulting in unnecessary costs and treatment delays.

#### Recommendations discussed:

• Recommendations need to be discussed with the consultant group and to be seen if this can be applied for the on call.

## **Presentation / Dissemination of Project**

Date findings were presented / disseminated: Presented at SBNS- Dundee- Sept 2021

**BASO** meeting

BTNW, Preston- March 2 <sup>nd</sup> 2022	
Department where discussed or presented: Neurooncology MDT- May 2021. No Recommendations were discussed.	

## Actions agreed following recommendations discussed:-

\*Please ensure each action has a named lead, timescale and reportable group stated on the action plan below. Please list the evidence of the action implementation e.g SOP, protocol, standardised template, presentation or meeting minutes etc

Issue	Action required	Named lead for action	Timescale	Evidence	Reportable to (group/meeting)
1)					,5
2)					
3)					
Re-audit date If I	no re-audit planned please give reasons v	vhy?			
Will this be an on-going audit? Ye	es 🗌 No 🛛				
Are there any potential barriers / pro	blems to prevent the implementation of the	ne above actions	? Yes 🗌 N	o 🛚	
If yes to the above please state who	the issues have been referred to:				
Name Designation Date referred					
Signature: Date: 22/03/20	022				
Have any issues been logged on the risk register? Yes ☐ No ☑ N/A ☐ Please provide details of issue(s) logged on the risk register:					



#### Clinical Audit / Service Evaluation Action Plan

Ref no: NS 359

Clinical Audit Title	Compliance with Trust guidelines for use of antimicrobial prophylaxis for elective neurosurgery – Re-audit		
Date audit complete	March 2022	Date action plan completed	March 2022
Auditor		Name of policy / guideline	
Division	Neurosurgery	Source of policy / guideline	

#### **Audit Rationale:**

Please summarize the rationale of the audit for the members of the Clinical Audit Group (please limit to one or two sentences)

- Re-audit the Compliance with Trust guidelines for use of antimicrobial prophylaxis for elective neurosurgery
- To audit that all antibiotics administered as prophylaxis are documented
- To audit that allergy status of the patient is documented

### **Summary of Findings:**

Please concisely state the main conclusions of the project using bullet points

- We audited the elective cases performed between 29/03/21 and 15/04/21.
- 62 patients' antibiotics audited
- 2 operations were cancelled
- 2 patients were not given antibiotics as there was no indication (Trigeminal neuralgia balloon compression)
- 1 patient received antibiotics without a clear indication (Trigeminal neuralgia balloon compression)
- Antibiotics given to 52 patients
- Antibiotics were not given in 6 cases where they are indicated.
- In 4 patients, the documented antibiotic administration time was after the documented incision time.
- There was documentation of the antibiotic used, time of administration and the dose in the anaesthetic sheet for all patients audited.
- 47 patients (including two with IV Cefuroxime and IV metronidazole)
- 5 patients had documents penicillin allergy (rash in 3 cases LL tingling in 1 case No details in 1 case)

## True penicillin allergy in 5/12 patients

(IV Teicoplanin (1.2 g) +/- Gentamycin (160 mg): 4 patients)

1st: cefalexin (anaphylaxis). Penicillin (rash)

2nd: details not available 3rd: Penicillin (anaphylaxis) 4th: Penicillin (Lumps)

5th: Penicillin (angioedema)

#### **Key success:**

Please concisely state the key success identified by the project – if none identified please state N/A

- There was documentation of the antibiotic used, time of administration and the dose in the anaesthetic sheet for all patients audited.
- The compliance for prophylactic antibiotics was 82% for all patients audited from 29/03/21 to 15/04/21.
- Allergy documentation 91.6%

#### **Key concerns:**

Please concisely state the key concerns identified by the project using bullet points—if none identified please state N/A

- In 4 patients, the documented antibiotic administration time was after the documented incision time.
- There were time delays of giving prophylactic antibiotics at the appropriate time it is crucial they are given prior to knife to skin
- 11/52 of patients who received antibiotics were not compliant with Trust guidelines for the choice and dose of antibiotics.

#### Recommendations discussed:

Please concisely summarise the recommendations that were discussed following the completion of the project

- To remind all anaesthetists of the current guidelines for prophylaxis
- To educate the anaethestists about time of antibiotic delivery being 30 mintues before knife to skin –
- To improve the compliance with antibiotics before knife to skin, consider adding this to the WHO checklist -
- Re-audit in 1 year

## **Presentation / Dissemination of Project**

Date findings were presented / disseminated: Antimicrobial Stewardship Group Sept 2021

Department where discussed or presented: Antimicrobial Stewardship Group Sept 2021 and Critical Care Ops group Sept 2021

## Actions agreed following recommendations discussed:-

\*Please ensure each action has a named lead, timescale and reportable group stated on the action plan below. Please list the evidence of the action implementation e.g SOP, protocol, standardised template, presentation or meeting minutes etc

Issue	Action required	Named lead for action	Timescale	Evidence	Reportable to (group/meeting)
To remind all anaesthetists of the current guidelines for prophylaxis	To re-circulate the antbiotic guidelines to the anaesthetists and an email and verbal reminder at departmental meeting		Sept 21	Email to all consultants 3/7/21	Antimicrobial Stewardship Group
2) To educate the anaethestists about time of antibiotic delivery being 30 mintues before knife to skin	As above, email and verbal reminder at departmental meeting		Sept 21	Email to all consultants 3/7/21	Antimicrobial Stewardship Group
3) To improve the compliance with antibiotics before knife to skin,	To review the WHO checklist and discuss with theatres about adding it on		1 year	WHO checklist has	Antimicrobial Stewardship

consider adding this to the WHO checklist				been updated and will be rolled out once the old forms are used up	Group
4) Re-audit in 1 year	Re-Audit		Jan 23		
Re-audit dateJan 2023	If no re-audit planned please give re	easons why?			
Will this be an on-going audit? No  Are there any potential barriers / prol  If yes to the above please state who	blems to prevent the implementation of	the above actions	s? No 🗌		
Name	Designation	Date referre	ed		
Signature:	Date:				
Have any issues been logged on the Please provide details of issue(s) log					

# **Project Prioritisation Assessment Tool**

**Audit title:** Compliance with Trust guidelines for use of antimicrobial prophylaxis for elective neurosurgery – Reaudit

The below table provides a system for prioritising locally conceived projects and what level of clinical audit team resource should be offered / provided.

riteria Tick all that apply	Score
Level 1 – External 'must do' Level 2 'Internal 'must do'	
If the project is mandatory please specify what priority level:-	

Criteria	Tick all that apply	Score
High cost		(x3)
High volume		(x2)
High risk		(x3)
Known quality issue		(x3)
Wide variation in practice		
NICE / NCEPOD related audit		(x3)
Defined measurable standards available	Υ	
Re-audit / repeat service evaluation	Υ	(x2)
Topic is a key clinical interest for the department / division	Υ	(x2)
Multidisciplinary project		
National / regional or multicentre project		(x2)
Total	Level 4 – Medium local priority	5

## Priority levels and audit team support

Priority level	Priority score
Level 1 – External 'must do'	Category A
Level 2 – Internal 'must do'	Category A
Level 3 – High local priority	> 10
Level 4 – Medium local priority	4-9
Level 5 – Low local priority	< 4

Priority level	Audit team resource	
Level 1, 2 & 3	Category A – Full support	Full practical assistance offered
Level 4	Category B – Moderate support	Level of practical assistance will be negotiated and agreed with project lead
		negotiated and agreed with project lead
Level 5	Category C – Minimal support	Advice, registration and monitoring

# **CLINICAL AUDIT / SERVICE EVALUATION PROJECT REGISTRATION FORM**

Ref No: -	roject Type: - Clinical Audit ⊌Service Evaluation □	
Audit / Service Evalua elective neurosurgery –	<b>tion Title:</b> Compliance with Trust guidelines for use of antimicrobial prophylaxis for Re-audit	
<b>Division:</b> Neurology □ Neurosurgery ☑Please specify department Click here to enter text.		
Project Lead:		
Contact No: Click here t	o enter text. Bleep No: Click here to enter text.	
Email address:		
Audit / service evaluat	ion supervisor: Click here to enter text.	
•	volved / project team members' details and roles within the project eg data collection, analysis etc.)	
Background / Rational	<u>e</u>	
Re-auditing the complia doses for neurosurgical	nce with trust guidelines for the use of the appropriate prophylactic antibiotics and operations.	
Previous audit in 2019 s	showed 92% compliance ratio.	
Methodology		
elective neurosurgery for This will be a prospective	inimum of 60 patients in a period of minimum 2 weeks (all patients who underwent or the period of 2 weeks). The review and the information about antibiotic administered as prophylaxis will be notes and electronic patients' records.	
Aims / Objectives		
To audit that all antibioti	e with Trust guidelines for use of antimicrobial prophylaxis for elective neurosurgery cs administered as prophylaxis are documented tus of the patient is documented	
Standards / Criteria De	etails (service evaluation N/A)	
Based on best practice	and available guidance and Trust Antimicrobial guidelines	
Guideline / Standards	available: Yes ☑ No □	
• .	opy or provide web link to the most current version: algovernance/All%20Documents/Antimicrobial%20Formulary.pdf	
Name of Standard / gu	ideline: Antimicrobial Formulary	
Source of Standard / g Trust ☑ O	ther State other: Click here to enter text.	
Review/assessment of	guideline/standard undertaken to ensure it is appropriate & can be measured	

Yes ☑ No □

Is the audit / service evaluation issue:  High volume Yes □ No ☑  High risk Yes □ No ☑  High cost Yes □ No ☑  Known quality issue Yes □ No ☑  Wide variation in practice Yes □ No ☑  Sample No: 60 patients. Procedure codes to identify sample: Click here to enter text.
http://www.raosoft.com/samplesize.html - link to tool that may be used to calculate sample size
Are you planning to publish your audit/service evaluation findings nationally
(e.g. Medical journal)? Yes □ No ☑
Is this a re-audit or if service evaluation, has service been reviewed previously? Yes ☑No □
Is this project part of an agreed departmental rolling programme? Yes □ No ☑
Rolling programme duration (number of years): Click here to enter text.
Rolling programme frequency: Monthly $\square$ Quarterly $\square$ Biannually $\square$ Annually $\square$
Multidisciplinary: □ Single disciplinary: □
Rolling programme duration (number of years): Click here to enter text.
Is Clinical Audit Team support required? Yes ☑ No ☐  If yes, please specify type of assistance required:  ◆ Population Identification ☑  ◆ Design of data collection tool ☑  (If not required please, attach a copy of the tool to be used)  ◆ Database design ☑  ◆ Data entry ☑  ◆ Analysis ☑  ◆ Presentation ☑  Collection of case notes ☑ Total number _60_ / per week
Patient Contact / Involvement – (If project involves patient contact that is <u>not</u> part of the patients usual treatment or care please explain how in this section) Will the audit involve direct patient contact?  Yes □ No ☑
How will the patient be involved?
Patient Questionnaire ☐ At clinic appointment ☐
Other (please give details) Click here to enter text.
Has approval been sought from the Patient Information Panel? Yes □ No □ N/A ☑
Anticipated start date: 03/03/2021
Anticipated project completion date: 03/04/2021.
Anticipated Action Plan Submission date: May 2021.

- PLEASE ATTACH A COPY OF YOUR DATA COLLECTION TOOL / PATIENT QUESTIONNAIRE.
- FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATIONS PLEASE ATTACH A COPY OF THE PREVIOUS AUDIT OR SERVICE EVALUATION REPORT.
- PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVISIONAL AUDIT LEAD BEFORE SUBMISSION TO THE CLINICAL AUDIT TEAM.

Departmental Clinical Audit Lead (Signature)	Date: Click here to enter text.		
Comments Click here to enter text.			
Divisional Clinical Audit Lead (Signature)	Date: Click	here to enter text.	
Is this topic a key clinical interest for the department / division?	Yes □	No □	



#### Clinical Audit / Service Evaluation Action Plan

Ref no: NS 360

Clinical Audit Title	Outcome of patients with lung cancer and brain mets		
Date audit complete	Write up ongoing	Date action plan completed	
Auditor		Name of policy / guideline	
Division	NS	Source of policy / guideline	

#### Audit Rationale:

Please summarize the rationale of the audit for the members of the Clinical Audit Group (please limit to one or two sentences)

Brain mets in patients with lung cancer often do poorly. When patients present with a new synchronous lung cancer and brain mets as their first diagnosis, there is an impression that they end up bouncing between the lung and brain mdt's and delaying treatment. The brain MDT is conscious of chemo options, whilst the lung MDT seems to take a long time to get a tissue diagnosis. The aim of this audit was to examine the outcome and treatment for this group of patients, a dn to see if a better pathway could be produced.

#### **Summary of Findings:**

Please concisely state the main conclusions of the project using bullet points

- 100 patients with brain mets from lung presented in 2020 and had identifiable records. 51 asynchornopus, 49 synchronous.
- Main delays came with SRS treatment in the synchronous group (46 days on average from MDT to treatment)
- 7 patients who were deemed suitable for SRS did not have this treatment (4 possibly preventable)
- Median survival best with surgery / srs (207 and 360 days respectively)
- Only 8 patients in both groups ended up having systemic chemo
- Synchronous median survivals were better than non-synchronous (139 vs 102 days) but was not significant

# Key success:

Please concisely state the key success identified by the project – if none identified please state N/A

- Successfully reviewed the outcomes for this group of paitents
- Survivals are poor, but better with treatment
- The pathway needs to be better

\_

# **Key concerns:**

Please concisely state the key concerns identified by the project using bullet points—if none identified please state N/A

- Some patients miss out on treatment, and the implication is because of delays in the system
- Very few people end up having chemo, despite delaying everyone's treatment in case they can.

Recommendations discussed:
----------------------------

Please concisely summarise the recommendations that were discussed following the completion of the project

- Audit discussed at CCC audit meeting
- · Audit is being presented at Lung SRG
- Audit is being presented at WCFT oncology MDT
- Need to consider a better pathway of urgent brain treatment and then consideration of chemo afterwards if appropriate.

Presentation / Dissemination of Project	
Date findings were presented / disseminated:	
Department where discussed or presented:	

# Actions agreed following recommendations discussed:-

\*Please ensure each action has a named lead, timescale and reportable group stated on the action plan below. Please list the evidence of the action implementation e.g SOP, protocol, standardised template, presentation or meeting minutes etc

Issue	Action required	Named lead for action	Timescale	Evidence	Reportable to (group/meeting)
1)Tell people about the problem	Presentations CCC complete, also WCFT, and CCC SRG, and BNOS proposed as well as a publication		6 months		Cancer services
2)Consider new pathway	New pathway agreement which can go through the CQG.		12 months		Cancer services
3)Assessment of complience	Reaudit after pathway running for > 1 yr				Cancer services
Re-audit date2024	If no re-audit planned please give reasons	why?			
Will this be an on-going audit?	Yes No No				
Are there any potential barriers / ¡	problems to prevent the implementation of t	he above action	s? Yes 🗌 N	lo 🗌	

If yes to the above please state who the issues have been referred to:		
Name	Designation	Date referred
Signature:	_Date:	
Have any issues been logged on the risl Please provide details of issue(s) logged		

# **Project Prioritisation Assessment Tool**

Audit title: Review of halo complications

Level 4 – Medium local priority

Level 5 – Low local priority

If the project is mandatory please specify what priority level:-

The below table provides a system for prioritising locally conceived projects and what level of clinical audit team resource should be offered / provided.

Level 1 – External 'must do' Level 2 'Internal 'must do'				
Criteria		Tick all that apply	Score	
High cost			(x3)	
High volume			(x2)	
High risk			(x3)	
rigii risk			(x3)	
Known quality issue			(x3)	
' ' '			, ,	
Wide variation in practice				
NICE / NCEPOD related audit			(x3)	
26.				
Defined measurable standards available				
Re-audit / repeat service evaluation			(x2)	
			(//=/	
Topic is a key clinical interest for the department / division		Υ	(x2)	
Multidisciplinary project				
National / regional or multicentre project			(x2)	
Total		Level 5 – low local	2	
Total		priority		
Priority levels and audit team support		. ,	1	
Priority level	Priority so	core		
Level 1 – External 'must do'	Category			
Level 2 – Internal 'must do'  Category  Category				
Level 3 – High local priority > 10				

Priority level	Audit team resource	
Level 1, 2 & 3	Category A – Full support	Full practical assistance offered
Level 4	Category B – Moderate support	Level of practical assistance will be
		negotiated and agreed with project lead
Level 5	Category C – Minimal support	Advice, registration and monitoring

4 - 9

< 4

# **CLINICAL AUDIT / SERVICE EVALUATION PROJECT REGISTRATION FORM**

Ref No: -	Project Type: - Clinical Audit □ Service Evaluation ⊠
Audit / Service E	Evaluation Title: Review of halo complications
Division: Neurolo	ogy □ Neurosurgery ⊠ Please specify department <b>Neurosurgery</b>
Project Lead:	
Contact No:	Bleep No:
Email address:	
Audit / service e	valuation supervisor:
-	nals involved / project team members details names and roles within the project eg data collection, analysis etc.) text.
	sed to manage cervical spine problems, the aim is to compare the delivery of care and resulting /alton Centre against the evidence available, to ensure best practice
<u>Methodology</u>	
Retrospective dat morbidities	ta collection examining the complications recorded, length of time in halo, age co
Aims / Objective	<u>s</u>
	he effectiveness or care, and complication rate experienced by patients treated at Walton rison to those documented in the evidence in order to inform practice
Standards / Crite	eria Details (service evaluation N/A)
Click here to enter	text.
Guideline / Stand	dards available: Yes □ No ⊠  ach a copy or provide web link to the most current version: Click here to enter text.
Name of Standa	rd / guideline: Click here to enter text.
Source of Stand Trust □	ard / guideline: NSF □ NICE □ Royal College □ Other □ State other: Click here to enter text.
Review/assessm Yes □ No □	nent of guideline/standard undertaken to ensure it is appropriate & can be measured
<b>Is the audit / ser</b> High volume High risk	vice evaluation issue:  Yes □ No ⊠  Yes □ No ⊠

Known quality issue Wide variation in practice	Yes □ No ⊠ Yes □ No ⊠ Yes □ No ⊠
Sample No: 151 Procede	ure codes to identify sample: Click here to enter text.
http://www.raosoft.com/sa	mplesize.html - link to tool that may be used to calculate sample size
Are you planning to pub	lish your audit/service evaluation findings nationally
(e.g. Medical journal)?	Yes ⊠ No □
Is this a re-audit or if ser	vice evaluation, has service been reviewed previously? Yes 🗆 No 🛭
Is this project part of an	agreed departmental rolling programme? Yes □ No ☒
Rolling programme dura	tion (number of years): Click here to enter text.
Rolling programme frequ	uency: Monthly □ Quarterly □ Biannually □ Annually □
Multidisciplinary:	Single disciplinary: □
<ul> <li>Design of data collection (If not required please, attained please)</li> <li>Database design</li> <li>Data entry</li> <li>Analysis</li> <li>Presentation</li> <li>Collection of case notes</li> </ul>	ach a copy of the tool to be used)  □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ Total number 151 / per week
Patient Contact / Involve or care please explain how in Will the audit involve dir	,
How will the patient be in	nvolved?
Patient Questionnaire	□ At clinic appointment □
Other (please give details)	lick here to enter text.
Has approval been soug	ht from the Patient Information Panel? Yes □ No □ N/A □
Anticipated start date:Cli	ck here to enter text.
Anticipated project com	pletion date: Click here to enter text.
Anticipated Action Plan	Submission date: Click here to enter text.

• PLEASE ATTACH A COPY OF YOUR DATA COLLECTION TOOL / PATIENT QUESTIONNAIRE.

- FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATIONS PLEASE ATTACH A COPY OF THE PREVIOUS AUDIT OR SERVICE EVALUATION REPORT.
- PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVISIONAL AUDIT LEAD BEFORE SUBMISSION TO THE CLINICAL AUDIT TEAM.

			_
Departmental Clinical Audit Lead (Signature)	Date: Click	here to enter text.	
Comments Click here to enter text.			
Divisional Clinical Audit Lead (Signature)	Date: Click	here to enter text.	
Is this topic a key clinical interest for the department / division?	Yes □	No □	



#### Clinical Audit / Service Evaluation Action Plan

Ref no: NS 362

Clinical Audit Title	Assessing if CAM-ICU is being used according to trust guidelines to screen for delirium patients admitted on Horsley ITU and if RASS targets are being achieved for each patients being sedated.		
	TO and it NASS targets are being achieved for each patients being sedated.		
Date audit complete	13 <sup>th</sup> April 2021	Date action plan completed	13.04.21
Auditor		Name of policy / guideline	
Division	Horsley ITU	Source of policy / guideline	

### **Summary of Findings:**

- Compliance with CAM-ICU use to screen for delirium was poor (11.8%)
- Compliance with documenting RASS targets for each patient was poor (13.9%)

### **Key success:**

- Nursing staffs compliance of assessing and recording sedated patients' RASS score was 93.6%
- •

# **Key concerns:**

- Compliance with CAM-ICU recordings was only 11.8%. Mixed delirium is the commonest type of delirium whilst hyperactive delirium is less common. With a poor compliance with CAM-ICU recordings, patients with mixed and hypoactive delirium can be easily missed and therefore, no properly and timely managed, therefore increasing their length of stay in hospital.
- Compliance with documenting RASS target for each patient was only 13.9%. For RASS targets documented, it was only achieved in 16.1% of
  cases. If RASS targets are not reviewed each day and documented clearly on ward round sheets, patients can be inappropriately sedated. For
  example, inadequate sedation can lead to patient self-extubating themselves, removing vascular catheters or poor patient-ventilator synchrony
  and aggressive behaviour by patients against staff. Whilst excessive and prolonged sedation can lead to patient having increasing risk of
  agitation and delirium or failed extubation.

#### Recommendations discussed:

- As part of our implementation plan, we shall send a gentle reminder email to all clinicians working on Horsley ITU to remind them to document the target the RASS score for every patients requiring sedation
- We shall also send a reminder email to all nursing staff for a gentle reminder to use the ICU CAM for all patients with a RASS target of -3 and above, according to trust guidelines.

Version: 2019

Date findings were presented / disseminated: 13.04.21
Department where discussed or presented: Horsley ITU audit meeting

# Actions agreed following recommendations discussed:-

Issue	Action required	Named lead for action	Timescale	Evidence	Reportable to (group/meeting)
Compliance with use of CAM-ICU	Reminder email to all nursing staff for a gentle reminder to use the ICU CAM for all patients with a RASS target of -3 and above, according to trust guidelines, will be sent out		By 15.05.21	NS 362 evidence CAM-ICU compliance audit.pdf	
2) Compliance with recording RASS target score	Reminder email to all clinicians working on Horsley ITU to remind them to document the target the RASS score for every patients requiring sedation, will be sent out		By 15.05.21	NS 362 evidence CAM-ICU compliance audit.pdf	
Re-audit date01.04.2022	If no re-audit planned please	give reasons wh	y?		
Will this be an on-going audit?	es x No				
Are there any potential barriers / pro	blems to prevent the implementation of the	ne above actions	? Yes 🗌 No	о 🗆х	
If yes to the above please state who	the issues have been referred to:				
Name De	Name Designation Date referred				
Signature:Date:					
Have any issues been logged on the	Have any issues been logged on the risk register? Yes No N/A				
Please provide details of issue(s) log	ged on the risk register:				

Version: 2019



#### Clinical Audit / Service Evaluation Action Plan

Ref no: NS 363

Clinical Audit Title	The British Orthopaedic Oncology Management (BOOM) Audit		
Date audit complete	March 2022	Date action plan completed	March 2022
Auditor		Name of policy / guideline	Metastatic Bone Disease: A guide to Good Practice
Division	Neurosurgery	Source of policy / guideline	British Orthopaedic Oncology Society & British
			Orthopaedic Association

#### **Audit Rationale:**

Please summarize the rationale of the audit for the members of the Clinical Audit Group (please limit to one or two sentences)

Bone is a frequent site of metastasis and can represent significant morbidity to patients. The guidance created by British Orthopaedic Oncology Society & British Orthopaedic Association in 2015 [1] aimed to set a clear standard of provision of adequate levels of care for the management of metastatic bone disease.

However since the release of this guidance it is unclear whether the recommendations have been adopted into clinical practice. With the impending release of a British Orthopaedic Association Standard for Trauma (BOAST) relating to a metastatic bones disease management we hope to evaluate the current practice before this is released

# **Summary of Findings:**

Please concisely state the main conclusions of the project using bullet points

- Total number of patients included = 54
- Average age of patients = 69
- Male: Female = 37:17
- Data collection period: 01/04/2021 16/06/2021
- Sources of referral: Aintree (7), Countess of Chester (3), Isle of Mann (2), Whiston (5), Southport (1), Glan Clywd (6), Warrington (6), Arrowe Park (2), Clatterbridge (4), Royal Liverpool (6), Ysbyty Gwynedd (4), Wrexham (5), St. Helens (1) and Walton (outpatients) (1).

Compliance to Audit Standard – Diagnostic Imaging				
Standard	Yes	No	Percentage compliance	
X ray whole bone obtained?	4	50	7.4%	
MRI whole bone?	54	0	100%	
CT Chest Abdo Pelvis?	42	11	79.2%	

Bone scan obtained ?	2	52	3.9%
Compliance to Audit Standard – Inve	stigations		
Standard	Yes	No	Percentage compliance
Standard	res	NO	Percentage compliance
Full blood count	46	1	97.9%
UnE	46	1	97.9%
LFT	43	3	93.5
Bone profile	27	9	75.0%
Calcium	23	13	63.9%
ESR	10	27	27.0%
CRP	36	2	94.7
Myeloma screen	15	22	40.5%
Other tumour markers	15	22	40.5%

#### **Key success:**

Please concisely state the key success identified by the project – if none identified please state N/A

- Whole bone MRI 100% compliance
- Full blood count and UnE 97.9% compliance
- LFT 93.5% compliance

#### **Key concerns:**

Please concisely state the key concerns identified by the project using bullet points- if none identified please state N/A

- X ray whole bone obtained 7.4% compliance
- Bone scan obtained 3.9% compliance
- ESR 27% compliance
- Myeloma screen and other tumour markers 40.5% compliance

# **Recommendations discussed:**

Please concisely summarise the recommendations that were discussed following the completion of the project

• Our reflections for re-audit (in a year) would be to examine the bloods (ESR, myeloma screen)

# **Presentation / Dissemination of Project**

Date findings were presented / disseminated:	
Department where discussed or presented:	

Actions agreed following recommendations discussed:\*Please ensure each action has a named lead, timescale and reportable group stated on the action plan below. Please list the evidence of the action implementation e.g SOP, protocol, standardised template, presentation or meeting minutes etc

			I		
Issue	Action required	Named lead	Timescale	Evidence	Reportable to
		for action			(group/meeting)
Re-Audit to examine the bloods (ESR, Myeloma screen)	Re-Audit		1 year	Re-audit	(great provided in the control of th
Re-audit date March 2023	If no re-audit planned please	give reasons wh	v?		
		,	,		
Will this be an on-going audit? Ye	s □ No □				
5 5					
Are there any potential barriers / prob	plems to prevent the implementation of the	ne above actions	? Yes 🗌 No	o X□	
If yes to the above please state who the issues have been referred to:					
Name Designation Date referred					
Signature:Date:					
	Have any issues been logged on the risk register? Yes No No N/A				
Please provide details of issue(s) log	ged on the risk register:				

# **Project Prioritisation Assessment Tool**

# **Audit title: Antimicrobial Stewardship**

Level 5 – Low local priority

If the project is mandatory please specify what priority level:-

The below table provides a system for prioritising locally conceived projects and what level of clinical audit team resource should be offered / provided.

Level 1 – External 'must do' Level 2 'Internal 'must do'				
Criteria	Criteria		Score	
High cost			(x3)	
High volume			(x2)	
High risk			(x3)	
Known quality issue			(x3)	
Wide variation in practice				
NICE / NCEPOD related audit			(x3)	
Defined measurable standards available		Υ		
Re-audit / repeat service evaluation			(x2)	
Topic is a key clinical interest for the department / division			(x2)	
Multidisciplinary project				
National / regional or multicentre project			(x2)	
Total		Level 5 – low local priority	1	
Priority levels and audit team support				
Priority level Priority s		core		
Level 1 – External 'must do'	Category	ry A		
Level 2 – Internal 'must do'	Category	ory A		
Level 3 – High local priority > 10		)		
Level 4 – Medium local priority 4 – 9				

Priority level	Audit team resource	
Level 1, 2 & 3	Category A – Full support	Full practical assistance offered
Level 4	Category B – Moderate support	Level of practical assistance will be negotiated and agreed with project lead
Level 5	Category C – Minimal support	Advice, registration and monitoring

< 4

# CLINICAL AUDIT / SERVICE EVALUATION PROJECT REGISTRATION FORM

Ref No: -	Project Type: - Clinical Audit √ Service Evaluation □
Audit / Service Eva	luation Title: Antimicrobial Stewardship
Division: Neurology	√ □ Neurosurgery ⊠ Please specify department <b>ITU</b>
Project Lead:	
Contact No: B	leep No:
Email address:	
Audit / service eva	luation supervisor:
-	s involved / project team members details nes and roles within the project eg data collection, analysis etc.)
Background / Ratio	<u>onale</u>
	oriate prescribing practice of antimicrobial usage on Horsley ITU. Similar audit carried out 2 ariation of data to capture this time around, therefore to register as new audit.
Methodology	
Prospective data co	llection of 20 in-patients on Horsley ITU
Aims / Objectives	
To ensure appropria patient group.	ate and identify inappropriate antimicrobial prescribing practice within the critical care
Standards / Criteria	a Details (service evaluation N/A)
Public Health England	(2015) 'Start Smart – Then focus' Antimicrobial Stewardship Toolkit for English Hospitals.
Guideline / Standa	rds available: Yes ⊠ No □
If yes, please attach	a copy or provide web link to the most current version: Click here to enter text.
Name of Standard Stewardship Toolkit fo	<b>/ guideline:</b> Public Health England (2015) 'Start Smart – Then focus' Antimicrobial or English Hospitals
Source of Standard Trust □	d / guideline: NSF □ NICE □ Royal College □ Other □ State other: Public Health England
Review/assessmer	nt of guideline/standard undertaken to ensure it is appropriate & can be measured
Is the audit / service High volume	e evaluation issue: Yes □ No ⊠

High risk High cost Known quality issue	Yes □ No □ Yes □ No □ Yes □ No □	$\boxtimes$				
Wide variation in practice						
Sample No: 20 Proced	ure codes to iden	tify sample:	Click here to en	ter text.		
http://www.raosoft.com/s	<u>samplesize.html</u> - li	nk to tool that	may be used	to calculate	e sample siz	ze
Are you planning to pu	ıblish your audit/s	ervice evalua	ation findings	nationall	у	
(e.g. Medical journal)?	Yes □	No ⊠				
Is this a re-audit or if s	ervice evaluation,	has service	been reviewe	d previou	sly? Yes	□ No 🗵
Is this project part of a	n agreed departm	ental rolling	programme?		Yes □ No	o 🛚
Rolling programme du	ration (number of	years): Click	nere to enter te	ext.		
Rolling programme fre	quency: Monthly	☐ Quarterly	/ □ Biannu	ally 🗆 🛭 A	nnually 🗆	
Multidisciplinary:		Single discip	linary: □			
Is Clinical Audit Team of yes, please specify typ  ◆ Population Identificate  ◆ Design of data collection (If not required please, ate)  ◆ Database design  ◆ Data entry  ◆ Analysis  ◆ Presentation  Collection of case notes	ne of assistance red tion ction tool attach a copy of the	quired:  tool to be use	otal number _			
Patient Contact / Involve or care please explain how Will the audit involve d	in this section)	·	t contact that is	s <u>not</u> part o	f the patients ⊠	usual treatment
How will the patient be	involved?					
Patient Questionnaire	☐ At clinic app	ointment $\square$				
Other (please give details)	Click here to enter t	ext.				
Has approval been sou	ight from the Patio	ent Information	on Panel? Y	∕es □	No □ N	I/A ⊠
Anticipated start date:	15.03.21					
Anticipated project cor	mpletion date: 15.	05.21				
Anticipated Action Plan	n Submission date	e:15.06.21				

<sup>•</sup> PLEASE ATTACH A COPY OF YOUR DATA COLLECTION TOOL / PATIENT QUESTIONNAIRE.

- FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATIONS PLEASE ATTACH A COPY OF THE PREVIOUS AUDIT OR SERVICE EVALUATION REPORT.
- PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVISIONAL AUDIT LEAD BEFORE SUBMISSION TO THE CLINICAL AUDIT TEAM.

Departmental Clinical Audit Lead (Signature)	Date: Click	here to enter text.
<b>Comments</b> I support this Audit in principle. The data collection tool /sprequest the CAG to approve pending submission /providing more deta form/spread sheet etc-I am requesting CAG to approve-I am presuming prescription charts in ITU(NOT ELECTRONIC).	ils about the d	lata collection
Divisional Clinical Audit Lead (Signature)	Date: Click	here to enter text.
Is this topic a key clinical interest for the department / division?	Yes □	No □



#### **Clinical Audit / Service Evaluation Action Plan**

Ref no: 364

Clinical Audit Title	Antimicrobial Stewardship- ITU		
Date audit complete	June 2021	Date action plan completed	June 2021
Auditor		Name of policy / guideline	Antimicrobial stewardship guidance
Division	ITU / Microbiology	Source of policy / guideline	

#### **Audit Rationale:**

- To review prescriptions of patients admitted on Horsley ITU to determine alignment with antimicrobial stewardship principles.
- Provide insight to prescriptions and related blood culture sampling practice.

# **Summary of Findings:**

Please concisely state the main conclusions of the project using bullet points

- Majority of prescriptions made by ITU Reg / ITU Consultant
- Prescriptions evenly made between weekday / weekend!!
- Stop / duration / review dates omitted in 50% of prescriptions
- Indication documented in 89%, good but room to improve
- Top 4 most frequent indications; Relevant reported microbiology / Increased FiO2 requirements / Temp > 38.4 / Rising inflammatory markers
- Blood cultures taken prior to first dose in 39%
- 86% of blood cultures taken prior to first dose were within 4 hours / 43% within 2 hours / 29% within 1 hour
- Limited utilisation of Micro Tracker form to document
- 63% of documented indication for antimicrobial was on prescription kardex

Microbiology ward round altered 11% of prescriptions, none were discontinued

#### **Key success:**

Please concisely state the key success identified by the project – if none identified please state N/A

• Indication documented in 89%, good but opportunity to improve

# Key concerns:

Please concisely state the key concerns identified by the project using bullet points—if none identified please state N/A

• As documented in findings above

#### Recommendations discussed:

Please concisely summarise the recommendations that were discussed following the completion of the project

Increase documentation of stop / duration / review dates

Greater documentation of indication - aim 100%

First dose blood cultures timescale under review

Utilise Micro Tracker form for use on all ITU patient records

# **Presentation / Dissemination of Project**

Date findings were presented / disseminated: Microbiology MDT meeting Department where discussed or presented: ITU seminar / MS Teams

### Actions agreed following recommendations discussed:-

\*Please ensure each action has a named lead, timescale and reportable group stated on the action plan below. Please list the evidence of the action implementation e.g SOP, protocol, standardised template, presentation or meeting minutes etc

Issue	Action required	Named lead	Timescale	Evidence	Reportable to
Andit manulta / findings/	Disseminate audit findings and	for action	By end of	Minutes of	(group/meeting)
Audit results / findings/ recommendations	recommendations to ITU / Microbiology		2021	Microbiology	
recommendations	MDT		2021	/ ITU MDT	
Stop / duration / review dates	Reminders to ITU prescribers to document a		By end of	Minutes of	
omitted in 50% of prescriptions.	duration / review / stop date /indication on		2021	Microbiology	
Indication documented in 89%,	prescription kardex.		2021	/ ITU MDT	
,				plus in	
				practice	
Limited utilisation of Micro	Encourage use of micro tracker form on ward		By end of	In practice	
Tracker form to document	round		2021	In practice	
Tracker form to document	Todila		202.		
	Set audit review date for 12 months with		By end of	Set as date	
	changes where relevant		2021	below	
Re-audit date June 2022 If no re-au	udit planned please give reasons why?				
Will this be an on-going audit? Ye	es √ No   □				
Are there any notential harriers / proj	blems to prevent the implementation of the	ne ahove actions	2 Yes □ N	0 1	
Are there any potential barriers / pro-	or an extension of a	ne above actions	7. 103 <u> </u>	0 1	
If yes to the above please state who	the issues have been referred to:				
Name	Designation	_ Date referre	ed		
Signature:	Date:				
Have any issues been logged on the	risk register? Yes □ No √ N/A □	<del></del>			
Please provide details of issue(s) log					

# **CLINICAL AUDIT / SERVICE EVALUATION PROJECT REGISTRATION FORM**

Ref No: -	Project Type: - Clinical Audit ☐ Service Evaluation ☐
Audit / Service I	Evaluation Title: Clinical Practice observing VIP Score
Division: Neuros	surgery ⊠ Please specify department <b>Horsley ITU</b>
Project Lead:	
Contact No:	Bleep No: Click here to enter text.
Email address:	
Audit / service e	evaluation supervisor:
Other professio	nals involved / project team members details
Background / R	ationalo
-	
our practice	ord of venflon insertion documentation, we are hoping that with this audit this will improve
<u>Methodology</u>	
Please see attac	hed questionnaire
Aims / Objective	<u>es</u>
To improve venfl	on insertion documentation
Standards / Crit	eria Details (service evaluation N/A)
Management of i	nvasive devices policy
Guideline / Stan	dards available: Yes ⊠
If yes, please atta	ach a copy or provide web link to the most current version: Click here to enter text.
Name of Standa	ard / guideline: Management of invasive devices policy
<b>Source of Stand</b> Trust ⊠	lard / guideline: NSF □ NICE □ Royal College □ Other □ State other: Click here to enter text.
<b>Review/assess</b> n Yes ⊠ No □	nent of guideline/standard undertaken to ensure it is appropriate & can be measured
Is the audit / ser High volume High risk High cost Known quality iss Wide variation in	

Sample No: 10-20 Procedure codes to identify sample: Click here to enter text.

http://www.raosoft.com/samplesize.html - link to tool that may be used to calculate sample size

Are you planning to publish your audit/service evaluation findings nationally
(e.g. Medical journal)? Yes □ No ⊠
Is this a re-audit or if service evaluation, has service been reviewed previously? Yes □ No ⊠
Is this project part of an agreed departmental rolling programme? Yes ⊠ No □
Rolling programme duration (number of years): Every 6 months
<b>Rolling programme frequency:</b> Monthly $oximes$ Quarterly $oximes$ Biannually $oximes$ Annually $oximes$
Multidisciplinary: □ Single disciplinary: ⊠
Is Clinical Audit Team support required? Yes □ No ☑  If yes, please specify type of assistance required:  ◆ Population Identification □  ◆ Design of data collection tool □  (If not required please, attach a copy of the tool to be used)  ◆ Database design □  ◆ Analysis □  ◆ Presentation □  Collection of case notes □ Total number / per week
Patient Contact / Involvement – (If project involves patient contact that is <u>not</u> part of the patients usual treatment or care please explain how in this section) Will the audit involve direct patient contact?  Yes □ No ☒
How will the patient be involved?
Patient Questionnaire $\Box$ At clinic appointment $\Box$
Other (please give details) Click here to enter text.
Has approval been sought from the Patient Information Panel? Yes □ No □ N/A ⊠
Anticipated start date: March 2021
Anticipated project completion date: October 2021
Anticipated Action Plan Submission date: October 2021
PLEASE ATTACH A COPY OF YOUR DATA COLLECTION TOOL / PATIENT QUESTIONNAIRE.
• FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATIONS PLEASE ATTACH A COPY OF THE PREVIOUS AUDIT OR SERVICE EVALUATION REPORT.
<ul> <li>PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVISIONAL AUDIT LEAD BEFORE SUBMISSION TO THE CLINICAL AUDIT TEAM.</li> </ul>

Departmental Clinical Audit Lead (Signature)	Date: Clic	k here to enter text.
Comments Click here to enter text.		
Divisional Clinical Audit Lead (Signature)	Date: Clic	k here to enter text.
Is this topic a key clinical interest for the department / division?	Yes □	No □

# **Project Prioritisation Assessment Tool**

## Audit title: Effectiveness of Anterior cervical discectomy and fusion (ACDF) in patients with radiculopathy

If the project is mandatory please specify what priority level:-

**Priority level** 

Level 1, 2 & 3

Level 4

Level 5

Audit team resource

Category A – Full support

Category B – Moderate support

Category C – Minimal support

The below table provides a system for prioritising locally conceived projects and what level of clinical audit team resource should be offered / provided.

Level 1 – External must do Level 2 Internal must do				
Criteria		Tick all that apply	Score	
High cost		Υ	(x3)	
18 de la constanta de la const			( 2)	
High volume		Y	(x2)	
High risk			(x3)	
Known quality issue			(x3)	
Wide variation in practice				
NICE / NCEPOD related audit		Y	(x3)	
Defined measurable standards available		Υ		
Re-audit / repeat service evaluation			(x2)	
Topic is a key clinical interest for the departmen	Υ	(x2)		
Multidisciplinary project	Υ			
National / regional or multicentre project			(x2)	
Total		12 – Level 3		
Priority levels and audit team support		1		
Priority level	score			
Level 1 – External 'must do' Category		A		
Level 2 – Internal 'must do' Category		A		
Level 3 – High local priority > 10				
Level 4 – Medium local priority 4 – 9				
Level 5 – Low local priority				

Version 2019 Review date: 2021

Full practical assistance offered

Level of practical assistance will be

Advice, registration and monitoring

negotiated and agreed with project lead

#### CLINICAL AUDIT / SERVICE EVALUATION PROJECT REGISTRATION FORM

Olivia at Assalit 🖂 . Osmala a Essalvantia a 🖂

Rei No: -	Project Type: - Clinical Audit & Service Evaluation
	uation Title: Effectiveness of Anterior cervical discectomy and fusion s with radiculopathy
Division: Neurology	☐ Neurosurgery ☒ Please specify department <b>Neurosurgery</b>
Project Lead:	
Contact No: Bleep N	lo:
Email address:	
Audit / service evalu	uation supervisor:
-	involved / project team members details es and roles within the project eg data collection, analysis etc.)

### Background / Rationale

Patients presenting with cervical radiculopathy undergo surgery to relieve them off their pain as the last resort. These patients experience severe shooting pain which is quite disabling and significantly disrupts their normal life. Most of these patients undergoing surgery have suffered from this pain for quite long and often a number of bouts of it. They often have neurological deficits as well. Most of these patients currently undergo anterior cervical discectomy to provide pain relief and to improve their functional status. According to NICE guidelines these patients need to try conservative management prior to being offered surgery including medical management for upto 12 weeks, interlaminar cervical epidural injections, transforaminal injections etc. Moreover with the advent of new procedures like endoscopic anterior cervical discectomy and resurgence of posterior cervical foraminotomy (Open and endoscopic), there is a need to audit our adherence to the NICE guidelines and to check if the outcomes with ACDF are good enough for us to continue offering the same procedure despite the latest trends. With evidence in Lumbar nerve compression that more than a year of nerve compression leads to worse outcomes in patients after surgery, there is a need to check if the same applies in the neck as well.

#### Methodology

- 1. All patients undergoing ACDF from 2012 onwards until December 2020 will be included with a minimum 6 month postoperative followup. (from spine tango)
  - 2. All patients relevant clinical / radiological and outcomes data will be collected.
  - 3. Patients with myelopathy/ significant cord compression on radiology will be excluded.
  - 4..Patients undergoing multilevel surgery will be analysed separately.
  - 5. Patients with conditions like Fibromyalgia and arthritis will be excluded.
  - 6. Effectiveness of use of plate in fusion will also be looked into.

# Aims / Objectives

- 1. To determine the effectiveness of ACDF in radiculopathy through Patient Reported Outcome Measures (PROMs)
- 2. To audit to the adherence to NICE guidelines in the management of Cervical Radiculopathy.

#### Standards / Criteria Details (service evaluation N/A)

- 1. Determine the PROM trend after surgery in patient undergoing ACDF for radiculopathy
- .2. Compare these with other studies reporting outcomes from Endoscopic ACDF/ Posterior foraminotomy
- .3. To audit the adherence to NICE guidelines in management.

surgery. 5. To assess the effectiveness of use of plate in cervical fusion
Guideline / Standards available: Yes ⊠ No □
If yes, please attach a copy or provide web link to the most current version: Click here to enter text. https://cks.nice.org.uk/topics/neck-pain-cervical-radiculopathy/management/management/
Name of Standard / guideline: Neck pain - cervical radiculopathy: Scenario: Management
Source of Standard / guideline: NSF □ NICE ☒ Royal College □  Trust □ Other □ State other: Click here to enter text.
Review/assessment of guideline/standard undertaken to ensure it is appropriate & can be measured Yes $\ oxed{\boxtimes}\ \ \ \ \ \ \Box$
Is the audit / service evaluation issue:   High volume Yes No   High risk Yes No   High cost Yes No   Known quality issue Yes No   Wide variation in practice Yes No
Sample No: Click here to enter text. Procedure codes to identify sample: Click here to enter text. <a href="http://www.raosoft.com/samplesize.html">http://www.raosoft.com/samplesize.html</a> - link to tool that may be used to calculate sample size
Are you planning to publish your audit/service evaluation findings nationally
(e.g. Medical journal)? Yes ⊠ No □
Is this a re-audit or if service evaluation, has service been reviewed previously? Yes □ No ☒
Is this project part of an agreed departmental rolling programme? Yes □ No ☒
Rolling programme duration (number of years): Click here to enter text.
Rolling programme frequency: Monthly $\square$ Quarterly $\square$ Biannually $\square$ Annually $\square$
Multidisciplinary: □ Single disciplinary: □
Is Clinical Audit Team support required? Yes ⋈ No ☐  If yes, please specify type of assistance required:  ◆ Population Identification Spine Tango ⋈  ◆ Design of data collection tool ☐  (If not required please, attach a copy of the tool to be used)  ◆ Database design ☐  ◆ Data entry ☐  ◆ Analysis ☐  ◆ Presentation ☐  Collection of case notes ☐ Total number / per week

To determine the relationship between length of nerve compression and patient outcomes after

Patient Contact / Involvement – (If project involves patient co	ntact th	at is <u>n</u>	o <u>t</u> part o	f the patients usual treatment
or care please explain how in this section) Will the audit involve direct patient contact?	es [		No	
How will the patient be involved?				
Patient Questionnaire				
Other (please give details) Click here to enter text.				
Has approval been sought from the Patient Information I	Panel?	Yes		No □ N/A ⊠
Anticipated start date:20/04/2021				
Anticipated project completion date: 30/06/2021				
Anticipated Action Plan Submission date:15/07/2021				
PLEASE ATTACH A COPY OF YOUR DATA COLLECTION TOOL / P	ATIENT (	QUESTI	ONNAIR	Ε.
<ul> <li>FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATIONS PLEASE EVALUATION REPORT.</li> </ul>	ATTAC	I A COF	Y OF TH	E PREVIOUS AUDIT OR SERVICE
<ul> <li>PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVISIONAL AT AUDIT TEAM.</li> </ul>	UDIT LE <i>F</i>	AD BEFO	ORE SUBI	MISSION TO THE CLINICAL
Departmental Clinical Audit Lead (Signature)		-	Date: (	Click here to enter text.
Comments Click here to enter text.				
Divisional Clinical Audit Lead (Signature)			Date: 0	Click here to enter text.
Is this topic a key clinical interest for the department / di	vision	? Y	es 🗆	No □



#### Clinical Audit / Service Evaluation Action Plan

Ref no: NS 368

Clinical Audit Title	LOCAL AUDIT OF CARE AT THE END OF LIFE (LACEL)		
Date audit complete		Date action plan completed	16/4/21
Auditor		Name of policy / guideline	
Division	Trustwide	Source of policy / guideline	

# **Summary of Findings:**

Overall, many of the findings from the Local Audit for Care at the End of Life were similar to that of the National Audit for 2019. This will form part of the action plan moving forward when auditing end of life care and providing education to the workforce.

Uptake of the Individualised end of life care plan – Significant improvement noted with this in 2020 71% versus 0% uptake in 2019. Some areas of the end of life care plan were incomplete and times not recorded. From the information available it would appear that the average time that the dying person was supported with an end of life care plan was 38hours

Regular holistic assessment – Due to lack of data available for the 2019 audit, it was not possible to make a comparison with the results seen in the 2020 audit

Page | 15

Spiritual/Religious/Cultural Assessment – The results shown in the 2020 audit showed improvement in the assessment of Spiritual needs although improvement still required

Nutrition and Hydration – Increase in discussion with the nominated person regarding Hydration in the 2020 audit (57% versus 14%) and Nutrition (29% versus 14%)

Anticipatory prescribing - Improvement noted for the prescribing of Anticipatory Medications (100% versus 0%) and Indication for use recorded for all (100% versus 79%).

Length of stay – For the sample of patients in the LACEL audit, Length of time from admission to death was shorter overall (57% versus 28% for the most common time frame of 1-10 days). Recognition of dying was identified earlier in the 2020 audit 152 hours prior to death versus 74 hours in 2019) Communication - Despite the fact that restrictions on visiting were in place during the Pandemic, discussions and documentation of conversations with the nominated person showed significant improvement. It is important to note that this may not have been the case with all deaths, but was evident in the random sample.

Referral to the Hospital Specialist Palliative Care Team – Increased referral rate in the 2020 audit 100% versus 14% in 2019

#### Key success:

- \*Family requested if mouth care could be provided with the patient's favourite drink this was made possible
- \*Good spiritual needs assessment for a specific culture that required certain practices to be in place
- \*Very clear communication and family support from all staff members for one family that were particularly struggling with the situation
- \* Offer of accommodation to NOK

Version: 2019

Key concerns:
•
Recommendations discussed:
□ Disseminate results to Specialist Palliative care team. ✓
□ Share results with EOL operational group – Walton Centre Foundation Trust ✓
□ Share results as required with General Staff members through education as appropriate
□ Share results with CQC if required during inspection
□ To participate in the National Audit for End of Life Care 2021.✓

Presentation / Dissemination of Project
Department where discussed or presented: Also presented to the EOL operational group 19/05/21 and EOL committee 21/06/21 (not a full attendance) via teams. Will be presented again at Walton EOL committee group 11/10/21.

# Actions agreed following recommendations discussed:-

Issue	Action required	Named lead for action	Timescal e	Evidence	Reportable to (group/meeting)
1) Limited information on previous National Audit of Care at the End of Life, therefore not able to make full direct comparisons to note improvement or areas for development with all aspects of end of life care.	Participate in the National Audit of End of Life Care 2021(Round 3)		Currently participati ng – results expected early 2022	National Benchmark results	EOL operational group/EOL committee
Re-audit dateN/A If no re-audit planned please give reasons why?This was a local audit in to garner some information regarding end of life care in place of the postponed national audit. The National audit is now reinstated, therefore a local audit is not required again  Will this be an on-going audit? Yes No _x					
Are there any potential barriers / problems to prevent the implementation of the above actions? Yes No × If yes to the above please state who the issues have been referred to:					

Version: 2019

Name	Designation	Date referred	
Signature:	Date:		
Signature			
Have any issues been logged on the ris	k register? Yes 🔲 No 🗌 N/A 🔲		
Please provide details of issue(s) logge	d on the risk register:		

Version: 2019

# **Project Prioritisation Assessment Tool**

### Audit title: Local Audit for Care at the End of Life

If the project is mandatory please specify what priority level:-

**Priority level** 

Level 1, 2 & 3

Level 4

Level 5

Audit team resource

Category A – Full support

Category B – Moderate support

Category C – Minimal support

The below table provides a system for prioritising locally conceived projects and what level of clinical audit team resource should be offered / provided.

Level 1 – External 'must do' Level 2 'Internal 'must do' Level 2 'Internal 'must do'			
Criteria		ck all that apply	Score
18th and			( 2)
High cost			(x3)
High volume			(x2)
High risk			(x3)
Known quality issue			(x3)
Wide variation in practice			
NICE / NCEPOD related audit			(x3)
Defined measurable standards available			
Re-audit / repeat service evaluation			(x2)
Topic is a key clinical interest for the department / division			(x2)
Multidisciplinary project			
National / regional or multicentre project			(x2)
Total		evel 4	
Priority levels and audit team support		·	
Priority level	Priority score		
Level 1 – External 'must do'	Category A		
Level 2 – Internal 'must do' Category A			
Level 3 – High local priority > 10			
Level 4 – Medium local priority	4 – 9		
Level 5 – Low local priority	< 4		

Version 2019 Review date: 2021

Full practical assistance offered

Level of practical assistance will be

Advice, registration and monitoring

negotiated and agreed with project lead

## **CLINICAL AUDIT / SERVICE EVALUATION PROJECT REGISTRATION FORM**

Ref No: -	Project Type: - Clinical Audit ☐ Service Evaluation ☒
Audit / Service Eval	uation Title: Local Audit for Care at the End of Life
• • • • • • • • • • • • • • • • • • • •	$\square$ Neurosurgery $\square$ Please specify department Palliative and End of Life Project Lead liative Care Team – Aintree site, LUFHT.
Project Lead:	
Contact No: Ble	eep No:
Email address:	
Audit / service evalu	ation supervisor:
-	involved / project team members details es and roles within the project eg data collection, analysis etc.)
Pandemic. It is helpful t	nale sen as the National Audit for End of Life Care for 2020 was cancelled due to the Coronavirus o gather such data to audit the quality and outcomes of care provided to the dying person them during the last admission to hospital.
<u>Methodology</u>	
using a number general JAC medication system those not identified to death was not recognis due to a life threatening hospital admission. The	fup to 10 case notes of inpatients that have died in the trust. The notes will be randomly tor and will be selected from the last 2 quarters of 2020; this will also include accessing the The inclusion criteria are those patients recognised to be dying. The data may also include be imminently dying but have been recognised to have a life limiting condition, so whilst led as imminent, staff were "not surprised" that the patient died. Exclusion criteria are deaths a gacute condition caused by a sudden catastrophic event and, deaths within 4 hours of data collection tool is the same as the National Audit for Care at the End of Life to allow for the number of reviews is less than would be expected for a national audit.
Aims / Objectives	
end of life in the acute	to learn and share from best practice as well as improve the quality of care for people at the setting where it has been recognised that optimal care may not have been achieved. The risks small study is being unable to identify areas for improvement particularly during a pandemic.
Standards / Criteria	Details (service evaluation N/A)
N/A	
Guideline / Standard	ls available: Yes ⊠ No □

• NICE guidance for end of life care/care of dying in the last days of life

If yes, please attach a copy or provide web link to the most current version:

Name of Standard / guideline:

https://www.nice.org.uk/guidance/QS13

# https://www.nice.org.uk/guidance/ng31

The current individ	FT End of Life Care Strateg ualised end of life care pla Care of the Dying as per th	n is measured by sta		•	•
incorporate this gu	idance when inspecting En	d of Life Care.	· ·	· ·	
Source of Standard / gu Trust ⊠ Ot		<b>NICE</b> Click here to enter t	⊠ ext.	Royal College	
Review/assessment of Yes ⊠ No □	guideline/standard und	dertaken to ensur	e it is appro	opriate & can be r	neasured
Is the audit / service ev High volume High risk High cost Known quality issue Wide variation in practice	Yes □ No ⊠ Yes □ No ⊠ Yes □ No ⊠ Yes □ No ⊠				
<b>Sample No:</b> Up to 10 <b>Pr</b> data	ocedure codes to ident	t <b>ify sample:</b> Rando	m selection	from NHS No from N	∕lortality
http://www.raosoft.com/s	amplesize.html - link to t	ool that may be us	ed to calcul	ate sample size	
Are you planning to pu	blish your audit/service	e evaluation findi	ngs nation	ally	
(e.g. Medical journal)?	Yes □ No □	$\boxtimes$			
ls this a re-audit or if se	ervice evaluation, has s	service been revie	wed previo	ously? Yes 🗆	No ⊠
ls this project part of a	n agreed departmental	rolling programm	ie?	Yes □ No 🛚	
Rolling programme du	ation (number of years	s): N/A			
Rolling programme free	quency: Monthly □ 0	Quarterly 🗆 Biar	nnually $\square$	Annually $\square$	
Multidisciplinary:	Sing	le disciplinary:			
Is Clinical Audit Team s If yes, please specify typ  ◆ Population Identificat  ◆ Design of data collect (If not required please, at  ◆ Database design  ◆ Data entry  ◆ Analysis  ◆ Presentation  Collection of case notes	e of assistance required. ion tion tool	⊠ □ □ □ □	No er 12 (to allo	□ ow for exclusion)	
Patient Contact / Involvor care please explain how Will the audit involve d	in this section)	es patient contact th	at is <u>not</u> part □ No	f of the patients usua	al treatmen

How will the patient be involved?	
Patient Questionnaire	
Other (please give details) Click here to enter text.	
Has approval been sought from the Patient Information Panel?	Yes □ No □ N/A ⊠
Anticipated start date: W/C 22/03/2021	
Anticipated project completion date: W/E 30/04/2021	
Anticipated Action Plan Submission date:30/06/2021	
<ul> <li>PLEASE ATTACH A COPY OF YOUR DATA COLLECTION TOOL / PATIENT QUID</li> <li>FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATIONS PLEASE ATTACH A EVALUATION REPORT.</li> <li>PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVISIONAL AUDIT LEAD I AUDIT TEAM.</li> </ul>	COPY OF THE PREVIOUS AUDIT OR SERVICE
Departmental Clinical Audit Lead (Signature)	Date: Click here to enter text.
Comments Click here to enter text.	
Divisional Clinical Audit Lead (Signature)	Date: Click here to enter text.
Is this tonic a key clinical interest for the department / division?	Ves □ No □



#### Clinical Audit / Service Evaluation Action Plan

#### Ref no:

Clinical Audit Title	Subarachnoid Haemorrha	ge Time to Treatment	
Date audit complete		Date action plan completed	
Auditor		Name of policy / guideline	National Clinical Guideline for Stroke 2016
Division	Neurosurgery	Source of policy / guideline	Royal College of Physicians

#### **Summary of Findings:**

Please concisely state the main conclusions of the project using bullet points

- The findings of this year's audit have been compared with last year's (2018-2019). However, last year's audit has been re-calculated using the methodology employed in the calculations of this year's (2019-2020) audit.
- Only patient's that were eligible for endovascular intervention were *included* in the calculations. Patient's that were delayed in their presentation to services, were transferred, or received neurosurgical intervention were *excluded*.

#### 2018-2019 Findings

- The preceding audit (2018-2019), had a total of 113 patients eligible for endovascular intervention.
- Of those 113 patients, 66 were treated within the 48 hour window, and 47 patients were not.
- Of the 47 patients treated *outside* of the 48 hour window, 20 were due to delayed presentation to services, were transferred, or received neurosurgical intervention. Therefore, *only* 27 patients (47-20 = 27) could have been treated within the 48 hour window. As such, the total population that *could* have been treated within 48 hours was 93 (66+27 = 93) the figure used as the denominator in the following percentage calculation:
- The percentage of patients that were treated within the 48 hour window in 2018-2019 was 71%.

#### 2019-2020 Findings

- Of the 151 subarachnoid haemorrhage patients, 98 were eligible for endovascular services.
- Of these 98 patients, 50 were treated within 48 hours, and 48 patients were delayed.

Version: 2019

- Of the 48 patients not treated within the 48 hour window, 46% (n=22) were delayed in their presentation to services. This means that of those 48 patients, only 26 could have been treated within the 48 hour window. Therefore, the total population that could have been treated within 48 hours was 76 (50+26 = 76) the figure used as the denominator in the following percentage calculation:
- The percentage of patients that were treated within the 48 hour window in 2019-2020 was 66% (50/76 = 66%).

#### Comparison

• This demonstrates a reduction of 5% (71-66 = 5) between 2018-2019 and 2019-2020.

#### **Key success:**

Please concisely state the key success identified by the project – if none identified please state N/A

•

#### **Key concerns:**

Please concisely state the key concerns identified by the project using bullet points—if none identified please state N/A

- Of the 48 patients that were treated after 48 hours of ictus, 46% (22/48 = 46%) were delayed in their presentation to services, and 25% (n=12) was due to weekend/holiday admission.
- In 2018-2019, the percentage of patients delayed as a result of a weekend/holiday admission was 19%, compared to 25% in 2019-2020.
- For the majority of cases there is a lack of *precise documentation* of the timing of ictus; however, it is acknowledged that precise documentation is *not always* possible.

#### Recommendations discussed:

Please concisely summarise the recommendations that were discussed following the completion of the project

- Precise documentation of the time of ictus in patient notes.
- Weekend service for endovascular intervention.

Presentation / Dissemination of Project
Date findings were presented / disseminated:
Department where discussed or presented:

Version: 2019

Actions agreed following recommendations discussed:\*Please ensure each action has a named lead, timescale and reportable group stated on the action plan below. Please list the evidence of the action implementation e.g SOP, protocol, standardised template, presentation or meeting minutes etc

Issue	Action required	Named lead for action	Timescale	Evidence	Reportable to (group/meeting)
Lack of precise documentation of the timing of ictus onset.	Staff documentation training	Tor detroit	On-going	e-Learning or Staff sign-off	(group/meeting)
2)					
3)					
4)					
Re-audit dateEnd of 2021	If no re-audit planned please	give reasons wh	y?		
Will this be an on-going audit? Ye	s 🗌 No 🔲				
Are there any potential barriers / prol	plems to prevent the implementation of the	ne above actions	? Yes 🗌 No	o 🗌	
If yes to the above please state who t	the issues have been referred to:				
Name	Designation	_ Date referre	ed		
Signature:	Date:				
Have any issues been logged on the	risk register? Yes 🔲 No 🗌 N/A				
Please provide details of issue(s) log	ged on the risk register:				

Version: 2019

# **Project Prioritisation Assessment Tool**

# Audit title: Subarachnoid Haemorrhage Time to Treatment

If the project is mandatory please specify what priority level:-

Level 1, 2 & 3

Level 4

Level 5

Category A – Full support

Category B – Moderate support

Category C – Minimal support

The below table provides a system for prioritising locally conceived projects and what level of clinical audit team resource should be offered / provided.

Level 1 – External 'must do' Level	vel 2 'Internal 'must do'		
Criteria	Tick all that apply	Score	
High cost		(x3)	
High volume		(x2)	
High risk		(x3)	
Known quality issue	Y	(x3)	
Wide variation in practice			
NICE / NCEPOD related audit		(x3)	
Defined measurable standards available			
Re-audit / repeat service evaluation	Y	(x2)	
Topic is a key clinical interest for the department / c	livision Y	(x2)	
Multidisciplinary project	Y		
National / regional or multicentre project		(x2)	
Total	8 – Level 4		
Priority levels and audit team support			
Priority level	Priority score		
Level 1 – External 'must do'	Category A		
Level 2 – Internal 'must do'	Category A		
Level 3 – High local priority	> 10		
Level 4 – Medium local priority	4 – 9		
Level 5 – Low local priority	< 4		
Priority level Audit team resource			

Version 2019 Review date: 2021

Full practical assistance offered

Level of practical assistance will be

Advice, registration and monitoring

negotiated and agreed with project lead

# **CLINICAL AUDIT / SERVICE EVALUATION PROJECT REGISTRATION FORM**

Ref No: -	Project Type: - Clinical Audit □ Service Evaluation ⊠
Audit / Service Ev	valuation Title: Subarachnoid Haemorrhage Time to Treatment
Division: Neurolog	gy ⊠ Neurosurgery □ Please specify department <b>Neuroradiology</b>
Project Lead:	
Contact No:	Bleep No: Click here to enter text.
Email address:	
Audit / service ev	aluation supervisor:
-	als involved / project team members details ames and roles within the project eg data collection, analysis etc.)
•	ionale g with a subarachnoid haemorrhage (SAH) should generally be treated within two days This evaluation aims to assess this sites performance.
Methodology	
identified and thei	y evaluating this sites performance 1/11/2019 – 31/10/2020. SAH patients will be r time of endovascular treatment will be identified using the CRIS system. The ictus will patient notes, Orion and eP2. Delays will be identified and their cause will be
Patient's that were	ntage calculation, only patients eligible for endovascular intervention will be <i>included</i> . e delayed in their presentation to services, were transferred, or received neurosurgical <i>excluded</i> from this final percentage calculation.
•	1/2018 - 31/10/2019 study was re-calculated using the above methodology to facilitates with this 2019-2020 study.
Aims / Objectives	
To determine the pwindow post SAH i	percentage of patients that underwent endovascular treatment within the 48 hour ctus.
Standards / Criter	ria Details (service evaluation N/A)
N/A	
Guideline / Stand	ards available: Yes □ No ⊠
If yes, please attac	ch a copy or provide web link to the most current version: Click here to enter text.

Name of Standard / guideline: Click here to enter text.

Trust	•	State other: C	NIC lick here to en		Royal	College	
Review/assessment of Yes No D	of guideline/s	tandard unde	ertaken to er	sure it is a	ppropriate 8	& can be r	measured
Is the audit / service High volume High risk High cost Known quality issue Wide variation in pract	Yes □ Yes □ Yes □	No					
Sample No: Click here	to enter text.	Procedure co	des to ident	ify sample:	Click here to	enter text.	
http://www.raosoft.com	<u>n/samplesize.h</u>	tml - link to to	ol that may b	e used to ca	alculate sam	ple size	
Are you planning to p	publish your a	audit/service	evaluation f	indings nat	tionally		
(e.g. Medical journal)?	Yes □	No ⊠					
Is this a re-audit or if	service evalu	ation, has se	rvice been r	eviewed pı	reviously?	Yes ⊠	No □
Is this project part of	<sup>:</sup> an agreed de	partmental re	olling progra	amme?	Yes	□ No ⊠	
Rolling programme d	luration (num	ber of years):	Click here to	enter text.			
Rolling programme for	requency: Mo	onthly 🗆 Qu	uarterly 🗆	Biannually	□ Annual	ly 🗵	
Multidisciplinary:		Single	disciplinary:				
Is Clinical Audit Team If yes, please specify t  ◆ Population Identific  ◆ Design of data coll (If not required please,  ◆ Database design  ◆ Data entry  ◆ Analysis  ◆ Presentation Collection of case note	type of assistar cation ection tool , attach a copy	nce required:			No □		
Patient Contact / Invo or care please explain ho Will the audit involve	ow in this section	n)	s patient conta Yes		t part of the pa	atients usua	il treatmen
How will the patient b	be involved?						
Patient Questionnaire	☐ At clin	ic appointmer	nt 🗆				
Other (please give detail	ils) Click here to	enter text.					
Has approval been so	ought from th	e Patient Info	rmation Par	nel? Yes	□ No [	□ N/A [	$\boxtimes$

Anticipated start date: Now

Anticipated project completion date: By April 2021

Anticipated Action Plan Submission date: Click here to enter text.

- PLEASE ATTACH A COPY OF YOUR DATA COLLECTION TOOL / PATIENT QUESTIONNAIRE.
- FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATIONS PLEASE ATTACH A COPY OF THE PREVIOUS AUDIT OR SERVICE EVALUATION REPORT.
- PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVISIONAL AUDIT LEAD BEFORE SUBMISSION TO THE CLINICAL AUDIT TEAM.

Departmental Clinical Audit Lead (Signature)	Date: Click	here to enter text.	
Comments Click here to enter text.			
Divisional Clinical Audit Lead (Signature)	Date: Click	here to enter text.	
Is this topic a key clinical interest for the department / division?	Yes □	No □	



#### Clinical Audit / Service Evaluation Action Plan

Ref no: NS 370

Clinical Audit Title	Imaging timing after surgery for glioblastoma- an evaluation of practice in Great Britain (INTERVAL-GB)- Liverpool pilot study		
Date audit complete	30/05/2021	Date action plan completed	30/06/2021
Auditor		Name of policy / guideline	NICE 2018- Management of primary brain tumours
Division	Neurosurgery	Source of policy / guideline	https://www.nice.org.uk/guidance/ng99/chapter/recommendations

#### **Summary of Findings:**

Please concisely state the main conclusions of the project using bullet points

- Only 40% of patients at the Walton Centre undergo an MRI scan within 72 hours of surgery for glioblastoma (recommendation is 100%)
- 65% of progression is detected using routine 'scheduled' imaging, with 35% being detected through clinical deterioration (no survival difference between groups)

#### **Key success:**

Please concisely state the key success identified by the project – if none identified please state N/A

- Survival for GB patients at the Walton Centre is in line with national levels (median 15 months)
- Highlighted that patients need an MRI within 72 hours of undergoing GB surgery (2 other centres in pilot had rates of 80% and 96% respectively)

# Key concerns:

Please concisely state the key concerns identified by the project using bullet points—if none identified please state N/A

• 40% adherence to NICE guidelines when target is 100%.

# Recommendations discussed:

Please concisely summarise the recommendations that were discussed following the completion of the project

- Increase awareness by presenting findings in audit meeting
- Re-audit in Summer 2022 after finding presentation to see if has had any impact on scanning rates.

# **Presentation / Dissemination of Project**

<u>Date findings were presented / disseminated:</u> 25th September 2021 (SBNS National meeting)

Department where discussed or presented: Next audit department meeting (planned-date TBC)

Version: 2019

# Actions agreed following recommendations discussed:-

\*Please ensure each action has a named lead, timescale and reportable group stated on the action plan below. Please list the evidence of the action implementation e.g SOP, protocol, standardised template, presentation or meeting minutes etc

Issue	Action required	Named lead for action	Timescale	Evidence	Reportable to (group/meeting)	
Low compliance to 72hr MRI scan after surgery	Inform surgeons of the low compliance and need to order imaging timely		Completed		Oncology services	
	To have dedicated MRI slots in Radiology on a Monday		Completed		Oncology services	
	Re-audit in 3-6 months		3-6 months	Re-audit	Oncology services	
Are there any potential barriers / pr	oblems to prevent the implementation of	the above action	s? Yes No	x		
Are there any potential barriers / pr	oblems to prevent the implementation of	the above action	s? Yes No	X		
If yes to the above please state who	n the issues have been referred to:					
If yes to the above please state who		Date refer	ed			
If yes to the above please state who Name	Designation	Date refer	red			
Name	Designation Date:	Date refer	red			

Version: 2019

# **Project Prioritisation Assessment Tool**

#### Audit title: Audit on MRI under sedation/GA

Level 5 – Low local priority

**Audit team resource** 

Category A – Full support

Category B – Moderate support

Category C – Minimal support

**Priority level** 

Level 1, 2 & 3

Level 4

Level 5

If the project is mandatory please specify what priority level:-

The below table provides a system for prioritising locally conceived projects and what level of clinical audit team resource should be offered / provided.

Level 1 – External 'must do' Level 2 'Internal 'must do'				
Criteria		Tick all that apply	Score	
High cost			(x3)	
High volume			(x2)	
High risk			(x3)	
Known quality issue			(x3)	
Wide variation in practice	,	Y		
NICE / NCEPOD related audit			(x3)	
Defined measurable standards available				
Re-audit / repeat service evaluation			(x2)	
Topic is a key clinical interest for the department / division			(x2)	
Multidisciplinary project				
National / regional or multicentre project			(x2)	
Total		1	5 C	
Priority levels and audit team support				
Priority level	Priority sco	ore		
Level 1 – External 'must do'	Category A	y A		
Level 2 – Internal 'must do'	Category A	egory A		
Level 3 – High local priority	> 10	10		
Level 4 – Medium local priority 4 – 9		9		

< 4

Full practical assistance offered

Level of practical assistance will be negotiated and agreed with project lead

Advice, registration and monitoring

# **CLINICAL AUDIT / SERVICE EVALUATION PROJECT REGISTRATION FORM**

Ref No: -	Project Type: - Clinical Audit ☐ Service Evaluation ⊠
Audit / Service Eva	aluation Title: Audit on MRI under sedation/GA
<b>Division:</b> Neurology	y $\square$ Neurosurgery $\boxtimes$ Please specify department $Click$ here to enter text.
Project Lead:	
Contact No: Ble	ep No: Click here to enter text.
Email address:	
Audit / service eva	lluation supervisor:
	Is involved / project team members details mes and roles within the project eg data collection, analysis etc
Background / Rati	<u>onale</u>
done under sedation earlier practice of M	dation was introduced at WCFT in 2020, we would like to look at the number of cases in and general anaesthesia cases since it was introduced and compare it against the IRI under General anaesthesia. We would like to assess the efficacy, feasibility and cost and GA techniques for patients undergoing MRI.
<u>Methodology</u>	
Retrospective data	collection from June 2019 to May 2021, Data collection sheet attached.
Aims / Objectives	
To evaluate the cur	rent practice compared to earlier practice solely based on General anaesthesia
Standards / Criteri	a Details (service evaluation N/A)
N/A	
Guideline / Standa	rds available: Yes □ No ⊠
If yes, please attach	a copy or provide web link to the most current version: Click here to enter text.
Name of Standard	/ guideline: Click here to enter text.
<b>Source of Standar</b> Trust □	d / guideline: NSF □ NICE □ Royal College □ Other □ State other: Click here to enter text.
Review/assessme	nt of guideline/standard undertaken to ensure it is appropriate & can be measured
Is the audit / servion High volume High risk High cost Known quality issue Wide variation in pr	

Sample No: 50 Procedure codes to identify sample: Click here to enter text.

http://www.raosoft.com/samplesize.html - link to tool that may be used to calculate sample size

Are you planning to publish your audit/service evaluation findings nationally
(e.g. Medical journal)? Yes ⊠ No □
Is this a re-audit or if service evaluation, has service been reviewed previously? Yes □ No ☒
Is this project part of an agreed departmental rolling programme? Yes □ No ☒
Rolling programme duration (number of years): Click here to enter text.
<b>Rolling programme frequency:</b> Monthly $\square$ Quarterly $\square$ Biannually $\square$ Annually $\square$
Multidisciplinary: □ Single disciplinary: □
Is Clinical Audit Team support required? Yes ⋈ No □   If yes, please specify type of assistance required: Population Identification □   ◆ Design of data collection tool □   (If not required please, attach a copy of the tool to be used)   ◆ Database design □   ◆ Data entry □   ◆ Analysis □   ◆ Presentation □   Collection of case notes ☒ Total number10_ / per week
Patient Contact / Involvement – (If project involves patient contact that is <u>not</u> part of the patients usual treatment or care please explain how in this section) Will the audit involve direct patient contact?  Yes □ No ☒
How will the patient be involved?
Patient Questionnaire
Other (please give details) Click here to enter text.
Has approval been sought from the Patient Information Panel? Yes □ No □ N/A □
Anticipated start date: June 2021
Anticipated project completion date: November 2021
Anticipated Action Plan Submission date: December 2021

- PLEASE ATTACH A COPY OF YOUR DATA COLLECTION TOOL / PATIENT QUESTIONNAIRE.
- FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATIONS PLEASE ATTACH A COPY OF THE PREVIOUS AUDIT OR SERVICE EVALUATION REPORT.
- PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVISIONAL AUDIT LEAD BEFORE SUBMISSION TO THE CLINICAL AUDIT TEAM.

Departmental Clinical Audit Lead (Signature)	Date: Click	k here to enter text.	
Comments Click here to enter text.			
Divisional Clinical Audit Lead (Signature)	Date: Click	here to enter text.	
Is this topic a key clinical interest for the department / division?	Yes □	No □	



#### Clinical Audit / Service Evaluation Action Plan

#### Ref no:

Clinical Audit Title	Clinical Value of immediate postoperative cranial CT in long standing oevert hydrocephalus and NPH patients after CSF				
	<u>diversion</u>				
Date audit complete	31/08/2021	Date action plan completed	31/08/2021		
Auditor		Name of policy / guideline			
Division	Neurosurgery,	Source of policy / guideline	ICRP Guidelines.		
	Neuroradiology				

#### **Summary of Findings:**

Please concisely state the main conclusions of the project using bullet points

- Immediate postoperative CTH after CSF diversion in patients with LOVA & NPH showed a low rate of rate of catheter malposition, postoperative complications, and anatomical changes.
- Re-surgery requirement in the analysed cohort is 0%
- Costs in terms of radiation and economical resources surpasses the benefits.

# **Key success:**

Please concisely state the key success identified by the project – if none identified please state N/A

- Identify objectively a very low incidence of proximal catheter malposition with image guided techniques.
- Gather enough information to support a change in professional custom / habits based on the results.
- Provide evidence to propose alternatives for outcome management.
- Provide awareness of the costs and propose to free these resources for other clear beneficial indications.
- Propose a reduction of congestion, work overload and delays in the radiology department and reduce the time of admission.

# Key concerns:

Please concisely state the key concerns identified by the project using bullet points—if none identified please state N/A

- Exposure to unnecessary radiation
- · Costs in economic terms and length of admission
- Low incidence of complications and catheter malposition

#### Recommendations discussed:

Please concisely summarise the recommendations that were discussed following the completion of the project

Version: 2019

- In asymptomatic patients after a reasonable time of observation in the postoperative period or an ETV, CTH can be avoided.
- In asymptomatic patients after a Shunt placement, guided by imaging and performed under the supervision of an experienced operator CTH can be avoided.
- In the case of high risk of catheter malposition (No image guidance or performed by and non-expert operator), CTH can be considered.
- In the case of patients with known risk of bleeding, previous uncontrolled risk factors (seizures, hypertension or coagulopathy) or any other former complications in similar procedures, CTH could be indicated.

Presentation / Dissemination of Project		
Date findings were presented / disseminated:	Audit day 29/09/2021	
Department where discussed or presented:	Neurosurgery/ Neuroradiology	

### Actions agreed following recommendations discussed:-?

\*Please ensure each action has a named lead, timescale and reportable group stated on the action plan below. Please list the evidence of the action implementation e.g SOP, protocol, standardised template, presentation or meeting minutes etc

Issue	Action required	Named lead for action	Timescale	Evidence	Reportable to (group/meeting)	
1)						
2)						
3)						
4)						
Re-audit date If	If no re-audit planned please give reasons why?					
Will this be an on-going audit? Ye	Yes No No					

Version: 2019

Are there any potential barriers / problems to prevent the implementation of the above actions? Yes 🗌 No 💮					
If yes to the above please state who the issues have been referred to:					
Name	Designation	Date referred			
Signature:	_ Date:				
Have any issues been logged on the risk register? Yes  No N/A					
Please provide details of issue(s) logged on the risk register:					

Version: 2019

# **Project Prioritisation Assessment Tool**

### Audit title: Telephone clinic service review for neuro trauma clinics

If the project is mandatory please specify what priority level:-

Level 1, 2 & 3

Level 4

Level 5

Category A – Full support

Category B – Moderate support

Category C – Minimal support

The below table provides a system for prioritising locally conceived projects and what level of clinical audit team resource should be offered / provided.

Level 1 – External 'must do' Level 2 'Internal 'must do'				
Criteria	Tick all th	at apply Score		
High cost		(x3)		
High volume		(x2)		
High risk		(x3)		
Known quality issue		(x3)		
Wide variation in practice				
NICE / NCEPOD related audit		(x3)		
Defined measurable standards available				
Re-audit / repeat service evaluation		(x2)		
Topic is a key clinical interest for the department / o	division Y	(x2)		
Multidisciplinary project				
National / regional or multicentre project		(x2)		
Total	2	5C		
Priority levels and audit team support				
Priority level	Priority score			
Level 1 – External 'must do'	Category A	ry A		
Level 2 – Internal 'must do'	Category A			
Level 3 – High local priority	> 10			
Level 4 – Medium local priority	4 – 9			
Level 5 – Low local priority	< 4			
Priority level Audit team resource				

Version 2019 Review date: 2021

Full practical assistance offered

Level of practical assistance will be

Advice, registration and monitoring

negotiated and agreed with project lead

# **CLINICAL AUDIT / SERVICE EVALUATION PROJECT REGISTRATION FORM**

Ref No: -	Project Type:	- Clinical A	Audit 🗆 🦇	Service E	valuation	$\boxtimes$	
Audit / Service Ev	valuation Title: T	elephone (	clinic serv	ice revie	w for neur	o trauma clinics	
Division: Neurolog	gy 🗆 Neurosurge	ery ⊠ Pleas	se specify	departme	nt <b>Neurotr</b>	auma	
Project Lead:							
Contact No:	Bleep No:						
Email address:							
Audit / service ev	aluation superv	isor:					
<b>Other profession</b> (Please provide na					on, analysi	s etc.)	
head injury patient's	eak the Neurotraum s needs, as these pa eting a telephone a	atients were	still being a	dmitted th	roughout.	service to remain mee HIAP took over triagin narged, referred on to	g all
<u>Methodology</u>							
appointment, in ordetc. 1. Did you red call at the right tim	der to gain their foceive a follow up to e after discharge you find the telep	eedback. The elephone c (If not whe ohone clinic	nis informa all from Hl en do you t useful? (If	tion will th AP?2. think woul not why r	nen be colla Did you fea Id have bea not?)4. Wo	d a telephone clinic ated in Excel to look el you received this t en the right time afte uld you prefer teleph	elephone er
Aims / Objectives	<u> </u>						
To gain important face to face clinic a			nade meet	the patie	nt's needs	as well as reducing	cost of
Standards / Crite	<u>ria Details (servi</u>	ce evaluati	ion N/A)				
N/A							
Guideline / Stand	ards available:	Yes ⊠	No				
lf yes, please attac	ch a copy or provi	de web link	to the mos	st current	version: T	rauma Pathway	
Name of Standar	<b>d / guideline:</b> TAF	RN					
<b>Source of Standa</b> Trust □	ard / guideline: Other □	NSF □ State other	er: TARN	NICE		Royal College	

Review/assessment of guideline/standard undertaken to ensure it is appropriate & can be measured

Yes ⊠ No □	
Is the audit / service evalu	ation issue:
High volume	Yes □ No ⊠
High risk	Yes □ No ⊠
High cost	Yes □ No ⊠
Known quality issue	Yes □ No ⊠
Wide variation in practice	
vvido variation in praotico	
Sample No: 40 Procedure	codes to identify sample: Clinic code
http://www.raosoft.com/sam	plesize.html - link to tool that may be used to calculate sample size
Are you planning to publis	sh your audit/service evaluation findings nationally
(e.g. Medical journal)?	Yes □ No ⊠
Is this a re-audit or if servi	ice evaluation, has service been reviewed previously? Yes □ No ⊠
Is this project part of an ag	greed departmental rolling programme? Yes □ No ☒
Rolling programme duration	on (number of years): Click here to enter text.
Rolling programme freque	ency: Monthly □ Quarterly □ Biannually □ Annually □
Multidisciplinary:	Single disciplinary: □
Is Clinical Audit Team sup If yes, please specify type o  ◆ Population Identification  ◆ Design of data collection (If not required please, attack  ◆ Database design  ◆ Data entry  ◆ Analysis  ◆ Presentation Collection of case notes	f assistance required: □
Patient Contact / Involvem or care please explain how in t Will the audit involve direct	,
How will the patient be inv	olved?
Patient Questionnaire	☐ At clinic appointment □
Other (please give details) Clic	ck here to enter text.
Has approval been sought	t from the Patient Information Panel? Yes □ No ⊠ N/A □
Anticipated start date:May	2021
Anticipated project compl	etion date: Sep 2021

Anticipated Action Plan Submission date:Dec 2021

- PLEASE ATTACH A COPY OF YOUR DATA COLLECTION TOOL / PATIENT QUESTIONNAIRE.
- FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATIONS PLEASE ATTACH A COPY OF THE PREVIOUS AUDIT OR SERVICE EVALUATION REPORT.
- PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVISIONAL AUDIT LEAD BEFORE SUBMISSION TO THE CLINICAL AUDIT TEAM.

Departmental Clinical Audit Lead (Signature)	Date: Click	k here to enter text.	
Comments Click here to enter text.			
Divisional Clinical Audit Lead (Signature)	Date: Click	k here to enter text.	
Is this topic a key clinical interest for the department / division?	Yes ⊠	No □	

# **Project Prioritisation Assessment Tool**

# Audit title: Acute pain review in thoraco-lumbar surgery patients.

If the project is mandatory please specify what priority level:-

**Priority level** 

Level 1, 2 & 3

Level 4

Level 5

Audit team resource

Category A – Full support

Category B – Moderate support

Category C – Minimal support

The below table provides a system for prioritising locally conceived projects and what level of clinical audit team resource should be offered / provided.

Level 1 – External 'must do' Level 2 'Internal 'must do'				
Criteria	Ti	ck all that apply	Score	
High cost	N		(x3)	
High volume	N		(x2)	
High risk	N		(x3)	
Known quality issue	N		(x3)	
Wide variation in practice	Y			
NICE / NCEPOD related audit	Υ		(x3)	
Defined measurable standards available	Υ			
Re-audit / repeat service evaluation			(x2)	
Topic is a key clinical interest for the department / division			(x2)	
Multidisciplinary project	Υ			
National / regional or multicentre project	N		(x2)	
Total	8		Lvl 4 – Cat. B	
Priority levels and audit team support				
Priority level	Priority score			
Level 1 – External 'must do' Category				
Level 2 – Internal 'must do'	Category A			
Level 3 – High local priority	> 10			
Level 4 – Medium local priority	4 – 9	9		
Level 5 – Low local priority < 4				

Full practical assistance offered

Level of practical assistance will be

Advice, registration and monitoring

negotiated and agreed with project lead

#### CLINICAL AUDIT / SERVICE EVALUATION PROJECT REGISTRATION FORM

Ref No: - Project Type: - Clinical Audit

Audit / Service Evaluation Title: Acute pain review in thoraco-lumbar surgery patients.

**Division:** Neurosurgery

Project Lead: Contact No: Email address:

Audit / service evaluation supervisor:

Other professionals involved / project team members' details:

\_\_\_\_\_

#### Background / Rationale.

In 2018 a patient satisfaction survey showed 30% of patients undergoing thoraco-lumbar surgery had moderate to severe pain in recovery- this was the one aspect of our anaesthetic services that was found underperforming at the ACSA review . An acute pain service was started with an acute pain consultant and an acute pain nurse. We are due an ACSA review soon and an audit and service evaluation is necessary to show that we have attained our goals

#### Methodology:

- Review of patient pre-operative medications via JAC.
- Review of patient reported pain scores in theatre recovery.
- Post-operative JAC prescription review.

#### Aims / Objectives:

 To assess effectiveness of post operative analgesia in patients having thoracolumbar spinal surgery following education and introduction of postop analgesic regimes

#### Standards / Criteria Details (service evaluation N/A)

Guideline / Standards available: Name of Standard / guideline:

NICE Guideline 180. August 2020.

Source of Standard / guideline: NICE

Review/assessment of guideline/standard undertaken to ensure it is appropriate & can be measured Yes

#### Is the audit / service evaluation issue:

High volume No
High risk No
High cost No
Known quality issue No
Wide variation in practice Yes

Sample No: 50 Procedure codes to identify sample: N/A- Prospective review of surgical schedule.

Are you planning to publish your audit/service evaluation findings nationally?

Yes

Is this a re-audit or if service evaluation, has service been reviewed previously?

Is this project part of an agreed departmental rolling programme	e? N
Multidisciplinary: X	
Is Clinical Audit Team support required?  No  If yes, please specify type of assistance required:  Population Identification  Design of data collection tool  (If not required please, attach a copy of the tool to be used)  Database design  Data entry  Analysis  Presentation  Collection of case notes	
Patient Contact / Involvement – (If project involves patient contact treatment or care please explain how in this section) Will the audit involve direct patient contact?  No x	tact that is <u>not</u> part of the patients usual
Has approval been sought from the Patient Information Panel?	N/A
Anticipated start date: August 2021	
Anticipated project completion date: September 2021	
Anticipated Action Plan Submission date: December 2021	
<ul> <li>PLEASE ATTACH A COPY OF YOUR DATA COLLECTION TOO</li> <li>FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATIONS PI AUDIT OR SERVICE EVALUATION REPORT.</li> <li>PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVISION THE CLINICAL AUDIT TEAM.</li> </ul>	LEASE ATTACH A COPY OF THE PREVIOUS
Departmental Clinical Audit Lead (Signature)	Date: Click here to enter text.
Comments Click here to enter text.	
Divisional Clinical Audit Lead (Signature)	Date: Click here to enter text.
Is this topic a key clinical interest for the department / division?	Yes □ No □



#### **Clinical Audit / Service Evaluation Action Plan**

Ref no: NS 376

Clinical Audit Title	Cappucinni Test				
Date audit complete	28/6/21	Date action plan completed	4/4/22		
Auditor		Name of policy / guideline			
Division	Neurosurgery	Source of policy / guideline			

#### **Audit Rationale:**

Please summarize the rationale of the audit for the members of the Clinical Audit Group (please limit to one or two sentences)

A test recommended by the Royal College of Anaesthetists to assess trainee supervision whilst working solo. Test being carried out region-wide

# **Summary of Findings:**

Please concisely state the main conclusions of the project using bullet points

- •
- •

# Key success:

# Question

- Who is supervising you? 100%
- Does the supervisor know what the trainee is doing? 100%
- How supported the trainee felt? 100%
- How often supervisors were contactable 100%
- How often the supervisor would be able to attend if required 92%

Version: 2021 Review: 2022

### **Key concerns:**

Please concisely state the key concerns identified by the project using bullet points—if none identified please state N/A

- Does the supervisor know they are supervising? 85%
- How often the supervisor would be able to attend if required 92%

#### Recommendations discussed:

Please concisely summarise the recommendations that were discussed following the completion of the project

- When assessing the results from this cycle 85% of supervisors knowing who they are supervising should be higher, things have changed subsequently and the weekly rota now places the trainee name next to the consultant.
- Alternative supervisor highlighted if unable to attend
- Maintain improvements from previous audit cycles

#### **Presentation / Dissemination of Project**

Date findings were presented / disseminated: 30/11/21

Department where discussed or presented: Departmental audit meeting

#### Actions agreed following recommendations discussed:-

\*Please ensure each action has a named lead, timescale and reportable group stated on the action plan below. Please list the evidence of the action implementation e.g SOP, protocol, standardised template, presentation or meeting minutes etc

Issue	Action required	Named lead for action	Timescale	Evidence	Reportable to (group/meeting)
Supervisor unaware they were supervising	Supervision highlighted on rota		Already actioned		

Version: 2021 Review: 2022

3)									
Re-audit date Regional audit. TBA If r	o re-audit planned please give reaso	ns why?							
Will this be an on-going audit? Ye	Will this be an on-going audit? Yes								
Are there any potential barriers / prob	plems to prevent the implementation	of the above actions	? No						
If yes to the above please state who t	he issues have been referred to:								
Name	Designation	Date referre	d						
Signature:	Date:								
Have any issues been logged on the risk register? Yes No N/A Please provide details of issue(s) logged on the risk register:									

Version: 2021 Review: 2022

# **Project Prioritisation Assessment Tool**

Audit title: Nasogastric Tube Management; Compliance with standards & guidelines in checking tube position.

The below table provides a system for prioritising locally conceived projects and what level of clinical audit team resource should be offered / provided.

Level 2 'Internal 'must do'

If the project is mandatory please specify what priority level:-

Level 1 – External 'must do'

Level 5 - Low local priority

Criteria	Tick all that apply	Score		
High cost	Park and			
nigri cost			(x3)	
High volume			(x2)	
			, ,	
High risk			(x3)	
Known quality issue			(x3)	
Wilder and the control of the contro				
Wide variation in practice				
NICE / NCEPOD related audit			(x3)	
. ,			( - /	
Defined measurable standards available		Υ		
Re-audit / repeat service evaluation		(x2)		
Topic is a key clinical interest for the department	/ division	Υ	(x2)	
Multidisciplinary project				
National / regional or multicentre project			(x2)	
			(//=/	
Total	3	Lvl 5 – Cat C		
Priority levels and audit team support			1	
Priority level	Priority s	core		
Level 1 – External 'must do'	Category	A		
Level 2 – Internal 'must do' Category		/ A		
Level 3 – High local priority	> 10			
Level 4 – Medium local priority				

Priority level	Audit team resource	
Level 1, 2 & 3	Category A – Full support	Full practical assistance offered
Level 4	Category B – Moderate support	Level of practical assistance will be
		negotiated and agreed with project lead
Level 5	Category C – Minimal support	Advice, registration and monitoring

< 4

# **CLINICAL AUDIT / SERVICE EVALUATION PROJECT REGISTRATION FORM**

Ref No: -	Project Type:	- Clinic	cal Au	dit ⊠ \$	Service E	valuati	on 🗆	
Audit / Service Eva			stric Tu	be Man	agement;	Compl	iance with standards &	
Division: Neurolog	y □ Neurosurç	jery ⊠	Pleas	e speci	fy depart	tment:	Horsley ITU	
Project Lead:								
Contact No: Bleep	No: N/A							
Email address:								
Audit / service eva	luation supervi	sor:						
Other professional (Please provide nar						on, ana	lysis etc.)	
N/A								
		-						
Background / Ratio	<u>onale</u>							
Care Practitioner. As preview of the literature	part of my acaden re to demonstrate	nic asses the jus	ssments tificatio	s I am red on for the	quired to de audit. I a	complete m seekir	University; Advancing the an audit in practice with a approval to carry out an e position of the nasogastr	a clear audit on
Methodology								
Monitor staff compli and policies. Please		_	_	c tube p	osition a	nd pH te	ests in accordance to gu	idelines
Aims / Objectives								
To monitor staffs co levels prior to use.	mpliance with do	ocumer	ntation	of naso	gastric tul	be posit	ion checks and aspirate	рН
<u> Standards / Criteri</u>	a Details (servi	ce eval	uation	N/A)				
Standards set in the t patients in critical car		_	_		_		My criteria would be a sam via nasogastric tube.	ple of 10
Guideline / Standa	rds available:	Yes	$\boxtimes$	No				
If yes, please attach	a copy or provi	de web	link to	the mos	st current	version	: Walton Centre intrane	t
Name of Standard in adults, children and	•	SA guide	lines; 'F	Reducing	harm cau	sed by n	nisplaced nasogastric feedi	ng tubes
Source of Standar	d / guideline:	NSF			NICE	$\boxtimes$	Royal College	

Other 

State other: NPSA Guideline

Trust ⊠

Review/assessment of guideline/standard undertaken to ensure it is appropriate & can be measured $$ Yes $\Box$ No $\boxtimes$
Is the audit / service evaluation issue:   High volume Yes □ No ⋈   High risk Yes □ No ⋈   High cost Yes □ No ⋈   Known quality issue Yes □ No ⋈   Wide variation in practice Yes □ No ⋈
Sample No: 10 Procedure codes to identify sample: Patients in critical care with nasogastric tube in place and in use.
http://www.raosoft.com/samplesize.html - link to tool that may be used to calculate sample size
Are you planning to publish your audit/service evaluation findings nationally
(e.g. Medical journal)? Yes □ No ⊠
Is this a re-audit or if service evaluation, has service been reviewed previously? Yes □ No ☒
Is this project part of an agreed departmental rolling programme? Yes □ No ☒
Rolling programme duration (number of years): Click here to enter text.
<b>Rolling programme frequency:</b> Monthly □ Quarterly □ Biannually □ Annually □
Multidisciplinary: □ Single disciplinary: □
Is Clinical Audit Team support required? Yes □ No ☑  If yes, please specify type of assistance required:  ◆ Population Identification □  ◆ Design of data collection tool □  (If not required please, attach a copy of the tool to be used)  ◆ Database design □  ◆ Data entry □  ◆ Analysis □  ◆ Presentation □  Collection of case notes □ Total number / per week
Patient Contact / Involvement – (If project involves patient contact that is not part of the patients usual treatment or care please explain how in this section) Will the audit involve direct patient contact?  Yes □ No ⊠
How will the patient be involved?
Patient Questionnaire    At clinic appointment
Other (please give details)

Has approval been sought from the Patient Information Panel? Yes $\Box$ No $oxtimes$ N/A $\Box$								
Anticipated start date:26/7/21								
Anticipated project completion date: 9/8/21								
Anticipated Action Plan Submission date: 6/9/21								
<ul> <li>PLEASE ATTACH A COPY OF YOUR DATA COLLECTION TOOL / PATIENT QUESTIONNAIRE.</li> <li>FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATIONS PLEASE ATTACH A COPY OF THE PREVIOUS AUDIT OR SERVICE EVALUATION REPORT.</li> <li>PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVISIONAL AUDIT LEAD BEFORE SUBMISSION TO THE CLINICAL AUDIT TEAM.</li> </ul>								
Departmental Clinical Audit Lead (Signature) _ Date: 05/0721								
Comments Click here to enter text.								
Divisional Clinical Audit Lead (Signature) Date: Click here to enter text.								
Is this topic a key clinical interest for the department / division? Yes ⊠ No □								

# **AUDIT TOOL**

# **Nasogastric Tube Management;**

# Compliance with standards & guidelines in checking tube position

Sample	LocSSIPs Form Completed	NGT Position at nose documented	Date of insertion & Nostril used	NGT Position checked prior to administration of medication	NGT Position checked prior to commencing Feed	NGT Position checked 4 hourly when feed on	NGT in same position as documented on insertion	NGT Aspirates Checked	Aspirates PH Checked	Comments
1										
2										
3										
4										
5										
6										
7										
8										
9										
10										

#### **Audit Proposal Title**

Nasogastric Tube Management; Compliance with standards & guidelines in checking tube position

#### **Rationale**

The vast majority of our patient's will have an NGT inserted on the unit or already in place on admission due to use of sedation, artificial airway, low GCS or impaired swallow.

This is vital for nutrition, fluids and administration of medication.

However there is high risk of incorrect position on insertion and/or being displaced overtime especially for the critical ill patient.

#### **Methodology**

Documentation for auditing;

We use a LocSSIPs (Local Safety Standards for Invasive Procedures) Form when an NGT is inserted which includes the date of insertion, nex measurement, measurement secured at nose and confirmation whether safe to use, determined either by aspirate or chest x-ray.

Further documentation is located on our daily observation charts which states whether an NGT is in place, which nostril was used for NGT, date of insertion along with the nurse checking the measurement at nose for correct positon and aspirates prior to administrating medication, commencing feed and on a minimum 4 hourly bases when enteral feeding is taking place.

Compliance against the standards set in the trust policy of nasogastric feeding and the NICE guidelines.

Propose the audit to take place over a 2 week period; suggest dates from the 26<sup>th</sup> July to the 9<sup>th</sup> August 2021.

On a sample size of 10 patients, who meet the criteria of a patient in the critical care setting who have a nasogastric tube in place and are being feed via nasogastric tube.

#### **Action Plan**

Following the audit process and presentation of audit results with relevant management, I propose the development of an action plan to improve practice on the standards of NGT management with the practice education team. With the aim to improve awareness of guidelines, staff training and nursing documentation. I would propose the use of information posters, worksheets and training sessions.

Action Plan to commence early September 2021, suggest date 6<sup>th</sup> September 2021 for a period of 3 months to ensure training of every member of staff. After completion of staff updates and training, plan to re-audit to monitor practice improvement.

# **Project Prioritisation Assessment Tool**

# Audit title: Retrospective review of colloid cysts for last 20 years & outcomes

The below table provides a system for prioritising locally conceived projects and what level of clinical audit team resource should be offered / provided.

If the project is mandatory please specify what priority level:-  Level 1 – External 'must do' Level 2 'Internal 'must do'						
Criteria	Criteria			Score		
High cost				(x3)		
High volume			Υ	(x2)		
High risk				(x3)		
Known quality issu	le			(x3)		
Wide variation in	practice					
NICE / NCEPOD re	NICE / NCEPOD related audit			(x3)		
Defined measurab	Defined measurable standards available					
Re-audit / repeat service evaluation				(x2)		
Topic is a key clini	cal interest for the department /	division		(x2)		
Multidisciplinary p	project					
National / regiona	l or multicentre project			(x2)		
Total			2	Lvl 5 – Cat. C		
Priority levels an	d audit team support					
Priority level Priority s			core			
Level 1 – External 'must do' Category						
Level 2 – Internal 'must do' Category		Α				
Level 3 – High local priority > 10						
Level 4 – Medium local priority 4 – 9						
Level 5 – Low local priority < 4						
Priority level	Audit team resource					

Level 1, 2 & 3

Level 4

Level 5

Category A – Full support

Category B – Moderate support

Category C – Minimal support

Version 2019 Review date: 2021

Full practical assistance offered

Level of practical assistance will be

Advice, registration and monitoring

negotiated and agreed with project lead

# **CLINICAL AUDIT / SERVICE EVALUATION PROJECT REGISTRATION FORM**

Ref No: -	Project Type: - Clinical Audit ☐ Service Evaluation ☒
Audit / Service Eval	uation Title: Retrospective review of colloid cysts for last 20 years & outcomes
Division: Neurology	$\square$ Neurosurgery $\boxtimes$ Please specify department $Click$ here to enter text.
Project Lead:	
Contact No: Bleep I	No:
Email address:	
Audit / service evalu	ation supervisor:
Other professionals	involved / project team members details
	cudy looking at outcomes in colloid cysts – service evaluation audit. Looking at anatomic different surgical intervention and outcomes including post op complications and the role of
<u>Methodology</u>	
Retrospective audit. and documented on a	Patient population from histology coding. Data collection from patient notes and EP2 in excel spreadsheet.
. ,	dit outcomes locally in colloid cyst patient treated with surgery c score in assessing patients
Standards / Criteria	Details (service evaluation N/A)
Guideline / Standard	ls available: Yes □ No ⊠
If yes, please attach a	a copy or provide web link to the most current version: Click here to enter text.
Name of Standard /	guideline: Click here to enter text.
Source of Standard Trust □	/ guideline: NSF □ NICE □ Royal College □ Other □ State other: Click here to enter text.
Review/assessment Yes □ No ⊠	of guideline/standard undertaken to ensure it is appropriate & can be measured
Is the audit / service High volume High risk High cost Known quality issue Wide variation in prac	Yes ⊠ No □ Yes □ No ⊠ Yes □ No ⊠ Yes □ No ⊠

Sample No: 107 Procedure codes to identify sample: Histology codes for colloid cyst

http://www.raosoft.com/samplesize.html - link to tool that may be used to calculate sample size

Are you planning to publish your audit/service evaluation finding	gs nationally
(e.g. Medical journal)? Yes ⊠ No □	
Is this a re-audit or if service evaluation, has service been review	ved previously? Yes □ No 🛛
Is this project part of an agreed departmental rolling programme	? Yes □ No ☒
Rolling programme duration (number of years): Click here to enter to	text.
Rolling programme frequency: Monthly $\ \square$ Quarterly $\ \square$ Biann	ually 🗆 Annually 🗆
Multidisciplinary: $\square$ Single disciplinary: $\square$	
Patient Contact / Involvement – (If project involves patient contact that or care please explain how in this section)	
Will the audit involve direct patient contact? Yes ☐ Anticipated start date: 01/06/2021	No ⊠
Anticipated start date: 01/00/2021  Anticipated project completion date: 30/06/2021	
Anticipated Action Plan Submission date: 10/07/2021	
PLEASE ATTACH A COPY OF YOUR DATA COLLECTION TOOL / PATIENT QU	JESTIONNAIRE.
• FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATIONS PLEASE ATTACH A EVALUATION REPORT.	A COPY OF THE PREVIOUS AUDIT OR SERVICE
<ul> <li>PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVISIONAL AUDIT LEAD AUDIT TEAM.</li> </ul>	BEFORE SUBMISSION TO THE CLINICAL
Departmental Clinical Audit Lead (Signature)	Date: Click here to enter text.
Comments Click here to enter text.	
Divisional Clinical Audit Lead (Signature)	Date: Click here to enter text.
Is this topic a key clinical interest for the department / division?	Yes □ No □



#### Clinical Audit / Service Evaluation Action Plan

Ref no: NS 379

Clinical Audit Title	Real World Experience with Minimally Invasive Wireless Percutaneous Neuromodulation in a Tertiary Care Centre						
Date audit complete	15-07-2021	Date action plan completed	15-08-2021				
Auditor		Name of policy / guideline	NA NA				
Division	Neuromodulation- Pain	Source of policy / guideline	NA				
	Medicine,						
	Neurosurgery and						
	Neuroradiology						

# **Summary of Findings:**

Please concisely state the main conclusions of the project using bullet points

- All patients showed >50% pain relief at 3months.
- EQ-5D and PGIC did not show any improvement in the subjects.
- Two of the patients managed to decrease their analgesics after implantation.
- Sustained benefits could not be demonstrated after one year of implant.

### **Key success:**

Please concisely state the key success identified by the project – if none identified please state N/A

• Wireless PNS can provide analgesia in appropriately selected cases.

### **Key concerns:**

Please concisely state the key concerns identified by the project using bullet points—if none identified please state N/A

- Naivety of the technique and procedure might cause some degree of uncertainty.
- Robust prospective controlled studies and RCTs in future might provide further insights on utility in other neuropathic pain diagnosis, long-term outcomes and acceptability of wireless PNS compared to conventional SCS.

#### Recommendations discussed:

Please concisely summarise the recommendations that were discussed following the completion of the project

- Wireless PNS can provide analgesia in appropriately selected cases
- Minimally invasive nature of the technique might be attractive and preferable for patients with complex medical issues, nickel allergy and poor general health who may otherwise be unsuitable for Spinal Cord Stimulation (SCS) with conventional hardware

Version: 2019

Presentation / Dissemination of Project  Date findings were presented / disseminated: This manuscript has been accepted for publication in the British Journal of Pain and is in the process of production.									
Department where discussed or presented: Dept. of Pain Medicine									
Actions agreed following recommendations discussed:- *Please ensure each action has a named lead, timescale and reportable group stated on the action plan below. Please list the evidence of the action implementation e.g SOP, protocol, standardised template, presentation or meeting minutes etc									
Issue	Action required	Named lead for action	Timescale	Evidence	Reportable to (group/meeting)				
1)									
2)									
3)									
4)									

4)								
Re-audit date NA be repeated. If no re-audit planned please give reasons why? the audit was to assess our initial experience but has a propensity to								
Will this be an on-going audit? Yes ☐ No ☒								
Are there any potential barriers / problems to prevent the implementation of the above actions? Yes \( \subseteq \) No \( \subseteq \)								
If yes to the above please state who the issues have been referred to:								
Name	Designation	_ Date referre	ed					

Version: 2019

Review: 2020

Signature: Manohar Lal Sharma	Date: 30/11/21
Have any issues been logged on the risk register? Yes	No 🗌 N/A 🖂
Please provide details of issue(s) logged on the risk register:	

Version: 2019

Review: 2020

# **Project Prioritisation Assessment Tool**

Audit title: Real World Experience with Minimally Invasive Wireless Percutaneous Neuromodulation in a Tertiary Care Centre

	provides a system for prioritising I be offered / provided.	ocally	conce	eived projects and what	level of clinical audit team
If the project is n Level 1 – Externa	nandatory please specify what pridule in the control of the contro	•		nal 'must do' 🗌	
Criteria			Tick all that apply	Score	
High cost					(x3)
High volume					(x2)
High risk					(x3)
Known quality iss	ue				(x3)
Wide variation in	practice		Y		
NICE / NCEPOD re	elated audit			(x3)	
Defined measural	ble standards available				
Re-audit / repeat	service evaluation			(x2)	
Topic is a key clin	ical interest for the department /	divisio	n	Υ	(x2)
Multidisciplinary	project				
National / regiona	al or multicentre project				(x2)
Total			3	Lvl 5 – Cat. C	
Priority levels an	d audit team support				
Priority level		rity sc	ore		
Level 1 – External 'must do' Category				4	
Level 2 – Internal 'must do' Category				4	
Level 3 – High local priority > 10					
Level 4 – Medium local priority 4 – 9					
Level 5 – Low lo	ocal priority	< 4			
Priority level	Audit team resource				
Level 1, 2 & 3	Category A – Full support	Full	Full practical assistance offered		

Level of practical assistance will be

Advice, registration and monitoring

negotiated and agreed with project lead

Category B – Moderate support

Category C – Minimal support

Level 4

Level 5

### **CLINICAL AUDIT / SERVICE EVALUATION PROJECT REGISTRATION FORM**

Ref No: - Project	t Type: - Clinio	cal Audit 🗆	Service E	Evaluation	ı ⊠	
Audit / Service Evaluation le Percutaneous Neuromodul		•		inimally l	nvasive Wireless	
Division: Neuromodulation	- Pain Medici	ne, Neurosı	rgery and	Neurorad	liology	
Project Lead:						
Contact No: Bleep No:	NA					
Email address:						
Audit / service evaluation s	upervisor:					
Other professionals involve (Please provide names and r				on, analys	sis etc.)	
Background / Rationale Wireless Percutaneous nerve neuromodulation paradigm for term pain relief obtained from PNS with implanted pulse ge similar benefit, without often u mood and functionality in app	or chronic neul n this cannot b nerator with fo unpleasant wid	ropathic pain e over emph ocal pleasant despread pa	The safety asized esp paraesthesp aesthespa	y and lowe ecially in t sia has als	er risks with a potentia he ongoing opioid par so been shown to prov	al of long ndemic. /ide
<u>Methodology</u>						
We retrospectively extracted specialised pain neuromodula demographics, pain history, a extracted at 6 months and 1 y Patients' Global Impression of	ation service s analgesic intak year post-impl	since initiation se and details ant including	n of wireles s on implan	s PNS dev t were ext	vice in August 2019. F racted. Follow-up data	Patient a were
Aims / Objectives						
To evaluate the effectiveness Walton centre NHS foundation	•			•		n at the
Standards / Criteria Details	(service eva	luation N/A)				
N/A						
Guideline / Standards avail	able: Yes	□ No	$\boxtimes$			
If yes, please attach a copy of	r provide web	link to the m	ost current	version: (	Click here to enter text.	
Name of Standard / guidelii	ne: NA					
Source of Standard / guide	line: NSF		NICE		Royal College	

Trust □ O	other   State other: Click here to enter text.
Review/assessment of	f guideline/standard undertaken to ensure it is appropriate & can be measured
Is the audit / service e High volume High risk High cost Known quality issue Wide variation in practic	Yes □ No ⊠ Yes □ No ⊠ Yes □ No ⊠ Yes □ No ⊠
Sample No: 5 Procedu	ure codes to identify sample: Click here to enter text.
http://www.raosoft.com/	samplesize.html - link to tool that may be used to calculate sample size
Are you planning to p	ublish your audit/service evaluation findings nationally
(e.g. Medical journal)?	Yes ⊠ No □
Is this a re-audit or if s	service evaluation, has service been reviewed previously? Yes D No 🗵
Is this project part of a	an agreed departmental rolling programme? Yes □ No ☒
Rolling programme du	ration (number of years): Click here to enter text.
Rolling programme fre	equency: Monthly   Quarterly  Biannually  Annually
Multidisciplinary:	Single disciplinary: □
<ul><li>Population Identifica</li><li>Design of data colle</li></ul>	pe of assistance required:  ation
or care please explain how	<b>vement –</b> (If project involves patient contact that is <u>not</u> part of the patients usual treatment $v$ in this section)  direct patient contact?  Yes $\square$ No $\boxtimes$
How will the patient be	
Patient Questionnaire	
Other (please give details	Click here to enter text.
Has approval been so	ught from the Patient Information Panel? Yes □ No □ N/A ⊠

Anticipated start date: Click here to enter text.								
Anticipated project completion date: 15-07-2021								
Anticipated Action Plan Submission date:15-08-2021								
PLEASE ATTACH A COPY OF YOUR DATA COLLECTION TOOL / PATIENT QU	ESTIONNAIRE.							
• FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATIONS PLEASE ATTACH A COPY OF THE PREVIOUS AUDIT OR SERVICE EVALUATION REPORT.								
PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVISIONAL AUDIT LEAD AUDIT TEAM.	BEFORE SUBMISS	ION TO THE CLINICAL						
Departmental Clinical Audit Lead (Signature)	Date: Click	here to enter text.						
Comments Click here to enter text.								
Divisional Clinical Audit Lead (Signature)	Date: Click	here to enter text.						
Is this topic a key clinical interest for the department / division?	Yes ⊠	No □						

### **OUTCOME FORMS / DATA COLLECTION TOOL**

## **PNS 4 WEEK QUESTIONNAIRE**

**Hospital Number:** 

Name:

On the scale below please rate your average <b>LEG/ARM</b> pain in the past week by circling a number.											
(No pain) 0	1	2	3	4	5	6	7	8	9	10 (	(Worst pain ever)

												g a number.
pain)	0	1	2	3	4	5	6	7	8	9	10	(Worst pain eve
PNS	6 Month	Follow L	Jn Na	ame					Walton	Numbe	r	

I feel tense or wound up Most of the time

A lot of the time
From time to time (occasionally)
Not at all

over your replies: your immediate is best.

I still enjoy the things I used to enjoy

Definitely as much Not quite as much Only a little Hardly at all

# I get a sort of frightening feeling as if something awful is about to happen

Very definitely and quite badly

Yes, but not too badly

A little, but it doesn't worry me

Not at all

#### I can laugh and see the funny side of things

As much as I always could Not quite so much now Definitely not so much now

Not at all

#### Worrying thoughts go through my mind

A great deal of the time

A lot of the time

Not too often

Very little

#### I feel cheerful

Never

Not often

Sometimes

Most of the time

#### I can sit at ease and feel relaxed

Definitely

Usually

Not often

Not at all

#### I feel as if I am slowed down

Nearly all the time

Very often

Sometimes

Not at all

# I get a sort of frightened feeling like butterflies in the stomach

Not at all

Occasionally

Quite often

Very often

#### I have lost interest in my appearance

Definitely

I don't take as much care as I should

I may not take quite as much care

I take just as much care as ever

#### I feel restless as if I have to be on the move

Very much indeed

Quite a lot

Not very much

Not at all

#### I look forward with enjoyment to things

As much as I ever did

Rather less than I used to

Definitely less than I used to

Hardly at all

#### I get a sudden feeling of panic

Very often indeed

Quite often

Not very often

Not at all

# I can enjoy a good book or radio or television programme

Often

Sometimes

Not often

Very Seldom

Please answer every section and tick in each section only the statement which applies to you. We realise you may consider that two of the statements in any one section relate to you. But please just tick the one which most closely describes your problem. **SECTION 1 PAIN INTENSITY** 

My pain is mild to moderate but I do not need pain killers The pain is bad but I manage without taking pain killers Pain killers give complete relief from pain Pain killers give moderate relief from pain Pain killers give very little relief from pain Pain killers have no effect on the pain
SECTION 2 PERSONAL CARE (WASHING, DRESSING, ETC)  I can look after myself normally without causing extra pain I can look after myself normally but it causes extra pain It is painful to look after myself and I am slow and careful I need some help but manage most of my personal care I need help every day in most aspects of self-care I do not get dressed, wash with difficulty, and stay in bed
SECTION 3 LIFTING  I can lift heavy weights without extra pain  I can lift heavy weights but it gives extra pain  Pain prevents me from lifting heavy weights off the floor, but I can manage if they are conveniently positioned.  Pain prevents me from lifting heavy weights but I can manage light weights if they are conveniently positioned.  I can lift only very light weights  I cannot lift or carry anything at all
SECTION 4 WALKING  I can walk as far as I wish  Pain prevents me walking more than 1 mile  Pain prevents me walking more than ½ mile  Pain prevents me walking more than ¼ mile  I can only walk using a stick or crutches  I am in bed or in a chair for most of everyday
SECTION 5 SITTING  I can sit in any chair as long as I like I can only sit in my favourite chair as long as I like Pain prevents me sitting more than 1 hour Pain prevents me from sitting more than ½ hour Pain prevents me from sitting more than 10 minutes Pain prevents me from sitting at all

Pain prevents me from sitting at all

	SECTION 6 STANDING
	I can stand as long as I want without extra pain
	I can stand as long as I want but it gives me extra pain
	Pain prevents me from standing more than 1 hour
	Pain prevents me from standing more than 30 minutes
	Pain prevents me from standing for more than 10 minutes
	Pain prevents me from standing at all
	SECTION 7 SLEEPING
	Pain does not prevent me from sleeping well
	I can sleep well only by using tablets
	Even when I take tablets I have less than 6 hours sleep
	Even when I take tablets I have less than 4 hours sleep
	Even when I take tablets I have less than 2 hours sleep
	Pain prevents me from sleeping at all
_	Tam prevents me nom siceping at an
	SECTION 8 SEX LIFE
	My sex life is normal and causes no extra pain
	My sex life is normal but causes some extra pain
	My sex life is nearly normal but is very painful
	My sex life is severely restricted by pain
	My sex life is nearly absent because of pain
	Pain prevents any sex life at all
	SECTION 9 SOCIAL LIFE
	My social life is normal and gives me no extra pain
	My social life is normal but increases the degree of pain
	Pain has no significant effect on my social-life apart from limiting my more energetic interests e.g. dancing.
	Pain has restricted my social life and I do not go out as often
	Pain has restricted my social life to my home
	I have no social life because of pain
	SECTION 10 TRAVELLING
	I can travel anywhere without extra pain
	I can travel anywhere but it gives me extra pain
	Pain is bad but I manage journeys over two hours
	Pain restricts me to journeys of less than 1 hour
	Pain restricts me to short necessary journeys under 30 minutes

MOBILITY	
I have no problems in walking about	
I have slight problems in walking about	
I have moderate problems in walking about	
I have severe problems in walking about	
I am unable to walk about	
SELF-CARE	
I have no problems washing or dressing myself	
I have slight problems washing or dressing myself	
I have moderate problems washing or dressing myself	
I have severe problems washing or dressing myself	
I am unable to wash or dress myself	
USUAL ACTIVITIES (e.g. work, study, housework, family	y or leisure activities)
I have no problems doing my usual activities	
I have slight problems doing my usual activities	
I have moderate problems doing my usual activities	
I have severe problems doing my usual activities	
I am unable to do my usual activities	
PAIN/DISCOMFORT	
I have no pain or discomfort	
I have slight pain or discomfort	
I have moderate pain or discomfort	
I have severe pain or discomfort	
I have extreme pain or discomfort	
ANXIETY/DEPRESSION	
I am not anxious or depressed	
I am slightly anxious or depressed	
I am moderately anxious or depressed	
I am severely anxious or depressed	
I am extremely anxious or depressed	

Under each heading, please tick the  ${\color{red} {\bf ONE}}$  box that best describes your health  ${\color{red} {\bf NOW}}$ 

Please rate, with a tick, how much betty you feel with this treatment	ter or worse	care	se rate, wi and atten omodulat	tion you	have re	ceived	you are with the from the
3 Very much improved		2	Very S	atisfied			
2 Much improved  1 Minimally improved		1	Satisfie	ed			
0 No change		0	Neithe	r Satisfie	ed nor D	issatisf	fied
on the scale below please rate your	average <b>LEG/A</b> I	<b>RM</b> pain	in the pa	st wee	k by cir	rcling	a number.
(No pain) 0 1 2 3	4 5	6	7	8	9	10	(Worst pain ever)
on the scale below please rate your	average BACK/	<b>NECK</b> pa	in in the	past w	eek by	circlin	ıg a number.
(No pain) 0 1 2 3	_	6	7	8	9		(Worst pain ever)
Please specify any other pain you may	have						
<b>Employed</b> □Full-time	Not employed	(not due t	o nain)				
☐Full-time (on sick leave)	□Unemployed ( □Unemployed (		-				
☐Part-time	□Retired		-				
□Part-time (on sick leave)	□On sickness be		-				
Student  □Full-time	☐Home maker	enemo (un	to pain)				
□Part-time	Other:						

You have now completed the questionnaire pack, thank you for your time and co-operation

## **Project Prioritisation Assessment Tool**

#### **Audit title: Visual Impairment Service Review**

Level 5 – Low local priority

The below table provides a system for prioritising locally conceived projects and what level of clinical audit team resource should be offered / provided.

If the project is mandatory please specify Level 1 – External 'must do'		level:- ernal 'must do'	
Criteria		Tick all that apply	Score
High cost			(x3)
High volume		Υ	(x2)
High risk			(x3)
Known quality issue			(x3)
Wide variation in practice			
NICE / NCEPOD related audit			(x3)
Defined measurable standards available			
Re-audit / repeat service evaluation			(x2)
Topic is a key clinical interest for the departition	rtment /		(x2)
Multidisciplinary project			
National / regional or multicentre project			(x2)
Total		2	Lvl 5 – Cat C
Priority levels and audit team support			
Priority level	Priority :		
Level 1 – External 'must do'	Category		
Level 2 – Internal 'must do'	Category	/ A	
Level 3 – High local priority	> 10		
Level 4 – Medium local priority	4 – 9		

Priority level	Audit team resource	
Level 1, 2 & 3	Category A – Full support	Full practical assistance offered
Level 4	Category B – Moderate support	Level of practical assistance will be
		negotiated and agreed with project lead
Level 5	Category C – Minimal support	Advice, registration and monitoring

#### CLINICAL AUDIT / SERVICE EVALUATION PROJECT REGISTRATION FORM

Ref No: -	Project Type: - Clinical Audit ☐ Se	rvice Evaluation ⊠
Audit / Service Evalu	uation Title: Visual Impairment S	Service Review
Division: Neurology	☐ Neurosurgery ☒ Please specify de	partment Click here to enter text.
Project Lead:		
Contact No: Bleep N	lo:	
Email address:		
Audit / service evalu	uation supervisor:	
	involved / project team members des and roles within the project eg data	

#### **Background / Rationale**

Each year increasing numbers of patients with visual impairment attend or are admitted to The Walton Centre. The severity of the visual impairment (sight impairment or severely sight impairment) is not always formally documented as an alert record within the medical notes. Not recognising visual impairment could result in individuals having greater difficulty accessing and negotiating services within The Walton Centre, as well as increased risk of falls resulting in potential harm to the patient.

Within outpatient department we have adopted an electronic systems to summon patients to clinic rooms, this is particularly challenging for any visually impaired individual, potentially reducing their independence. The early identification of visual impaired patients attending the hospital should be an important pre-requisite for good healthcare.

The service evaluation will provide evidence towards a sight loss project where we have been successful in gaining charitable funds to purchase alert signs for the patient bedside and offer basic training for ward and clinic staff. We hope to improve patient experience by improving staff confidence, skills to approach and escort patients, creating staff champions and the daily visual field and acuity clinic run by outpatient staff, so results are available for the consultation.

#### Methodology

We would like to retrospectively identify skull base patients with a visual impairment to see if they have a corresponding alert record on their medical records. Both the paper and electronic medical records will be accessed to gain the information.

#### Aims / Objectives

The aim of the study is to measure the number of skull base patients classified as having a visual impairment and record the number of corresponding 'alert' (VISN) documented within the medical records.

Objectives

Access both paper and electronic medical records on all skull base patients under the care of

Collect data on the number of patients classified as having a visual impairment. Visual impairment will be measured by visual acuity and mean deviation from visual field assessment in both eyes.

Collect data on the number of visual impairment (VISN) alerts recorded from the medical records (this will include paper patient alert records and PAS alerts).

As well as the data collection, I plan to devise a staff survey monkey questionnaire in relation to the identification and specific needs of a visually impaired patient, staff confidence with patient interaction and perceived training benefits.

Standards / Criteria Details (service evaluation N/A)

N/A									
Guideline / Standards av	ailable:	Yes		No	$\boxtimes$				
If yes, please attach a cop	y or provi	de web	link to	the mo	st current	version: Cli	ck here to e	nter text.	
Name of Standard / guid	<b>eline:</b> Clic	k here t	o enter	text.					
Source of Standard / gui Trust ☐ Oth		NSF State	□ other:		NICE		Royal (	College	
Review/assessment of g	uideline/s	standa	rd und	lertakeı	า to ensu	re it is app	ropriate &	can be n	neasured
Is the audit / service evaluable High volume High risk High cost Known quality issue Wide variation in practice	Yes [ Yes [ Yes [	sue: ⊠ No ∣ □ No ∣							
Sample No: Click here to e	nter text.	Proced	dure c	odes to	identify	sample: Cli	ck here to e	nter text.	
http://www.raosoft.com/sa	<u>mplesize.</u>	<u>html</u> - li	nk to to	ool that	may be u	sed to calcu	ılate sampl	e size	
Are you planning to pub	lish your	audit/s	service	e evalua	ation find	lings natior	nally		
(e.g. Medical journal)?	Yes ⊠		No [						
Is this a re-audit or if ser	vice eval	uation,	has s	ervice	been rev	iewed previ	iously?	Yes □	No ⊠
Is this project part of an	agreed d	epartm	ental	rolling	programi	me?	Yes 🗆	□ No 🏻	
Rolling programme dura	tion (nun	nber of	years	): Click h	nere to ent	ter text.			
Rolling programme frequency	u <b>ency</b> : M	onthly		Quarterly	/ □ Bia	annually 🗆	Annually		
Multidisciplinary:			Singl	e discip	linary:				
Rolling programme dura	tion (nun	nber of	years	): Click h	nere to ent	ter text.			

<ul> <li>Anticipated Action Plan Submission date: Dec 2</li> <li>PLEASE ATTACH A COPY OF YOUR DATA COLLECTION</li> <li>FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATION REPORT.</li> <li>PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVAUDIT TEAM.</li> <li>Departmental Clinical Audit Lead (Signature)</li> <li>Comments Click here to enter text.</li> <li>Divisional Clinical Audit Lead (Signature)</li> </ul>	ON TOOL ONS PLE	ASE ATTACH	A COPY	OF TH	E PREVI		NICAL  text.
<ul> <li>PLEASE ATTACH A COPY OF YOUR DATA COLLECTION</li> <li>FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATION REPORT.</li> <li>PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVAUDIT TEAM.</li> </ul> Departmental Clinical Audit Lead (Signature)	ON TOOL	ASE ATTACH	I A COPY	OF TH	E PREVI	N TO THE CLI	NICAL
<ul> <li>PLEASE ATTACH A COPY OF YOUR DATA COLLECTION</li> <li>FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATION REPORT.</li> <li>PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVAUDIT TEAM.</li> </ul>	ON TOOL	ASE ATTACH	I A COPY	OF TH	E PREVI	N TO THE CLI	NICAL
<ul> <li>PLEASE ATTACH A COPY OF YOUR DATA COLLECTION</li> <li>FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATION REPORT.</li> <li>PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVINING THE PROPERTY OF THE PROPERTY OF</li></ul>	ON TOOL	ASE ATTACH	I A COPY	OF TH	E PREVI		
<ul> <li>PLEASE ATTACH A COPY OF YOUR DATA COLLECTION</li> <li>FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATION REPORT.</li> </ul>	ON TOOL	ASE ATTACH	I A COPY	OF TH	E PREVI		
PLEASE ATTACH A COPY OF YOUR DATA COLLECTION	ON TOOL					OLIC ALIDIT (	OR SERVICE
Anticipated Action Plan Submission date: Dec 2	2021						
Anticipated Action Plan Submission date: Dec 2	2021						
Anticipated project completion date: Oct 2021							
Anticipated start date: June 2021							
las approval been sought from the Patient Info	rmatio	n Panel?	Yes		No [	⊠ N/A □	
Other (please give details) Click here to enter text.							
Patient Questionnaire	nt 🗆						
low will the patient be involved?							
or care please explain how in this section)  Will the audit involve direct patient contact?		Yes [	□ N	0	$\boxtimes$		
Patient Contact / Involvement – (If project involves	s patient	contact th	at is <u>not</u>	part o	f the pa	atients usua	I treatment
Soliection of case notes		tai numbe	;i <i>i</i>	per v	veek _		
<ul> <li>Presentation</li> <li>Collection of case notes</li> </ul>	⊠ □ To	tal numbe	ar /	ner	wook		
• Analysis	$\boxtimes$						
<ul><li>Database design</li><li>Data entry</li></ul>							
Databasa dasing		d)					
If not required please, attach a copy of the tool to							
Design of data collection tool	$\boxtimes$						
<b>G</b>							



#### Clinical Audit / Service Evaluation Action Plan

Ref no: NS 380

Clinical Audit Title	Visual Impairment Service	Review	
Date audit complete	March 2022	Date action plan completed	March 2022
Auditor		Name of policy / guideline	
Division	Neuro surgery	Source of policy / guideline	

#### Audit Rationale:

To assess the quality of documentation of patients with a visual impairment (VI) within a neurosurgery department to see if they have a corresponding vision alert (VISN) within the medical notes.

#### **Summary of Findings:**

Please concisely state the main conclusions of the project using bullet points

- Out of 256 surgical patients only 56 patients had a documented visual impairment
- Although VI was common in this study population, most patients had useful vision.
- Documentation to alert clinicians and carers about VI was poor and needs improvement.

#### Key success:

Please concisely state the key success identified by the project – if none identified please state N/A

- A significant number of patients had a preservation or recovery of central vision despite peripheral visual field loss
- The ranges of VFD were predominately graded minimal to subtle level of field loss.

#### **Key concerns:**

Please concisely state the key concerns identified by the project using bullet points—if none identified please state N/A

- 23.40% patients had a VISN alert on their medical records while 77% were not identified or not supported for their VI
- 3 patients certified sight impaired and severely sight impaired (75%) did not have an VISN alert.

#### Recommendations discussed:

Please concisely summarise the recommendations that were discussed following the completion of the project Second part to the audit:

• Patient questionnaire sent to 44 patients, return of 20 questionnaires. Results pending

Date f	ntation / Dissemination of Projudings were presented / dissemi	nated: Nil				
Бераг	tment where discussed or preser	ted: Article submitted to BJNN journal				
*Pl imp		amed lead, timescale and reportable gro standardised template, presentation or m	neeting minutes etc			
Issue		Action required	Named lead for action	Timescale	Evidence	Reportable to (group/meeting)
1)	20 patient questionnaires returned out of 44 sent.	Results need to be processed		3 months		
2)	Set up a working group to identify and improve healthcare access for patients	Working group set up key members identified and agreed		ongoing		
	with a disability visiting or	1st meeting 28 <sup>th</sup> April 2022				

<ol> <li>Set up a working group to identify and improve healthcare access for patients with a disability visiting or staying at The Walton Centre.</li> </ol>	Working group set up key members identified and agreed  1st meeting 28 <sup>th</sup> April 2022	ongoing	
<ul><li>3) Write best practice guidelines for visually impaired.</li><li>4) Staff awareness of this group of patients</li></ul>	Training for staff funded by charitable funds Care plan for inpatients with VI Magnetic alert signs for bed space	1 year	
Will this be an on-going audit?	no re-audit planned please give reasons we project will continue plems to prevent the implementation of the	•	

If yes to the above please state who the	e issues have been referred to:		
Name	Designation	Date referred	-
Signature:	Date:		
Have any issues been logged on the ris	<del>_</del>		

## **Project Prioritisation Assessment Tool**

Audit title: Evaluation of pharmacological management of (exclude the term delirium) agitation in patients with traumatic head injury in the immediate (intensive care )and intermediate (wards and neurorehab) time frame

The below table provides a system for prioritising	ng locally conceived projects and what level of clinical audit team
resource should be offered / provided.	
If the project is mandatory please specify what I	priority level:-
Level 1 – External 'must do'	Level 2 'Internal 'must do'

Criteria	Tick all that apply	Score
High cost	N	(x3)
High volume	N	(x2)
High risk	N	(x3)
Known quality issue	N	(x3)
Wide variation in practice	N	
NICE / NCEPOD related audit	N	(x3)
Defined measurable standards available	N	
Re-audit / repeat service evaluation	N	(x2)
Topic is a key clinical interest for the department / division		(x2)
Multidisciplinary project	N	
National / regional or multicentre project	N	(x2)
Total	N	

#### Priority levels and audit team support

Priority level	Priority score
Level 1 – External 'must do'	Category A
Level 2 – Internal 'must do'	Category A
Level 3 – High local priority	> 10
Level 4 – Medium local priority	4 – 9
Level 5 – Low local priority	< 4

Priority level	Audit team resource	
Level 1, 2 & 3	Category A – Full support	Full practical assistance offered
Level 4	Category B – Moderate support	Level of practical assistance will be
		negotiated and agreed with project lead
Level 5	Category C – Minimal support	Advice, registration and monitoring

#### CLINICAL AUDIT / SERVICE EVALUATION PROJECT REGISTRATION FORM

Ref No: -	Project Type: - Clinical Audit ☐ Service Evaluation ⊠
delirium) agitation	lluation Title: Evaluation of pharmacological management of (exclude the term in patients with traumatic head injury in the immediate (intensive care )and s and neurorehab ) time frame.
Division: Neurology neuropsychiatry a	v oxtimes Neurosurgery $oxtimes P$ lease specify department <b>Anaesthesia &amp; Intensive care and neurorehab</b>
Project Lead:	
Contact No: Bleep	No: Click here to enter text.
Email address:	
Audit / service eva	luation supervisor:
Other professional	s involved / project team members details

#### Background / Rationale We are the tertiary care centre for all neurotrauma in the region. There are a large group of patients that we treat here at the Walton Centre with traumatic brain injury.

Traumatic brain injury (TBI) is a major cause of mortality and morbidity. In England and Wales,  $\sim 1.4$  million patients per year attend hospital following head injury and it is the most common cause of death under the age of 40 years (Lawrence et al, BMJ Open 2016). The commonest mechanisms of injury were falls in the elderly and road traffic collisions in the young, many of whom are likely to present with cognitive and behavioural manifestation both in the acute and long term.

#### Agitation is a prominent problem as patients sedation is weaned off and as they continue to recover either as a consequence of the delirium or the core structural damage to the brain).

A constellation of behaviours has been associated with the term 'agitation' in TBI patients, including restlessness, confusion, physical-verbal aggression, impulsivity, perceptual disturbances and inattention creating a very heterogeneous group of patients to study(Williamson et.al 2019 BMJ Open). Ciurli et all 2011 found a wide range of neuropsychiatric symptoms in the population with severe TBI including irritability (37%), disinhibition (28%) and agitation (24%). Agitation has been reported in 20%-41% of patients during the early stage of recovery in acute care units and up to 70% of patients in rehabilitation unit (van der Naalt J et. al 2000).

For the purpose of investigation all the above terms would be utilised as behavioural and cognitive manifestation of TBI. The term post traumatic amnesia (PTA) incorporates the features of confusion and memory loss in any domain following a traumatic injury. Van der Naalt et al 2000 noted in their patient sample that PTA might still remain long after the acute agitation associated with confusion resolves. The treatment focus of agitation manifestation therefore need to encompasses all the above entities and investigation should also aim to evaluate how each of these domains change to different medication that are used in practice.

Bogner 2001 study on role of agitation in prediction of outcome highlighted that increase length of hospital stay and decreased achievement of rehabilitation goals. It was also found those individual presenting with agitation are discharged earlier to residential placement. A similar observation was made around cognitive function with lower levels of cognitive functioning associated with more agitation and conclusion around agitation at least partially

driving the cognitive decline. It is therefore essential to consider cognitive functions among other benefits in management of agitation.

In the intensive care we have done extensive work into the agitation management of our patients and have had remarkable results. This is a combination of non-pharmacological and pharmacological interventions. However patients once discharged to the wards do not get the same standard of non-pharmacological interventions and the neuropsychiatry team are often asked to review patients regarding the agitation that develops.

There is a pathway for TBI patients in intensive care whereby we wean the intravenous sedatives off, substituting them with oral drugs. Our primary attention is on restoration of sleep pattern ensuring the patients get adequate sleep at night and the diurnal rythmn is maintained as far as possible. Additional pharmacological assistance with melatonin 4-8 mg and Trazadone as the preferred night sedation agent especially for TBI patients is the normal practice. RASS scores and Delirium scores are done daily and if they manifest hyperactive delirium -Olanzapine is added . The incidence of agitation and delirium in Intensive care has decreased over the time frame we have introduced this protocol. We hope this would therefore have benefit on these patient long term outcomes.

A similar clinical approach guided by Neuropsychiatry is undertaken on the wards. Here patients are either transferred from the intensive care for further rehabilitation or moved from other sites for that purpose. In addition to the above pharmacotherapy and non pharmacotherapy we recognise the care and treatment of these patients might be different. Again PTA and its long-term presence might still be evident when patients are on these intermediate units. The range of drugs used in controlling agitation are wider and so are the non pharmacological management approaches. The long term benefit or impact on these drugs on the patients rehabilitation have not been assessed so far

We wish to do a service evaluation to assess the effectiveness of our policies We also wish to follow up our patients in the intermediate and longterm as they are discharged to the wards and then their journey through rehabilitation particularly looking at the impact of the early management of agitation.

The list of commonly used pharmacotherapy will be compared to national standards and to research evidence. The service evaluation would guide local policies in future with the aim to individualise care and treatment based on patients needs, future goals and outcome.

#### Methodology

For the purpose of data collection we would categorise the patients based on national standards of TBI severity.

In terms of the classification of severity, historically TBI was classified as mild, moderate or severe by using the Glasgow Coma Scale, a system used to assess coma and impaired consciousness. The Glasgow Coma Scale is divided into three components — eye opening, verbal response and motor responses. These are usually summed to produce a total score. A Glasgow Coma Scale score of 13-15 is defined as mild, 9-12 as moderate and 3-8 as severe. Post-traumatic amnesia (PTA) is another important index of the severity of traumatic brain injury. PTA is the interval from injury until the patient is orientated, and can form and later recall new memories. A PTA of 1-24 hours used to be considered to indicate a TBI within the category of moderate severity. Current classifications of moderate TBI generally refer to PTA extending beyond 24 hours, while less than that is mild. Severe TBI can PTA lasting from anywhere from a week to months especially in elderly.

For patient entering into intensive care unit we already have the threshold set at below 8 of GCS which clearly demarkcate the patient sample as severe. The patient entering on the intermediate care and wards could be both severity of Moderate i.e. GCS of 9-12 and severe as above.

For the purpose of the evaluation mild TBI are excluded. This is predominantly as this patient group have a different pathway of management and support, most of which we recognise will be in the community.

Data will be collected of all patients with moderate/severe TBI that are treated in Horsley intensive care, the neurotrauma ward (all walton wards) and rehab( Lipton and CRU) units in year 2020 (we recognise these numbers would be skewed due to Covid 19 Pandemic).
We will collect data on:-
Severity and type of injury
Age and demographics of patient
Premorbid and comorbid medical and psychiatric illness
Substance misuse history and substance withdrawal as confounders
Infection, subacute neurosurgical, pain or other causes as confounders
Other non brain poly trauma
Agitation scores or records of the same
List of drugs used for management of agitation and effects (on agitation) of them
Duration of ITU/ward/rehab stay
Aims / Objectives
Assess the effectiveness of our pharmacological management by collecting information of incidence of agitation of our with traumatic head injury patients in the immediate and intermediate care and its long term outcome.
Guideline / Standards available: Yes □ No ⊠
If yes, please attach a copy or provide web link to the most current version: Click here to enter text.
No. 10 Control of the
Name of Standard / guideline: Click here to enter text.
Source of Standard / guideline: NSF □ NICE □ Royal College □  Trust □ Other □ State other: NA
Review/assessment of guideline/standard undertaken to ensure it is appropriate & can be measured Yes $\square$ No $\boxtimes$
Is the audit / service evaluation issue:  High volume Yes □ No ☒  High risk Yes □ No ☒  High cost Yes □ No ☒  Known quality issue Yes □ No ☒  Wide variation in practice Yes □ No ☒
Sample No: Click here to enter text. Procedure codes to identify sample: Click here to enter text.
http://www.raosoft.com/samplesize.html - link to tool that may be used to calculate sample size
Are you planning to publish your audit/service evaluation findings nationally
(e.g. Medical journal)? Yes ⊠ No □
Is this a re-audit or if service evaluation, has service been reviewed previously? Yes □ No ☒

Is this project part of an agreed departmental rolling programme?	Yes □ No ☒
Rolling programme duration (number of years): Click here to enter to	ext.
<b>Rolling programme frequency:</b> Monthly □ Quarterly □ Biannu	ally 🗆 Annually 🗆
Multidisciplinary: □ Single disciplinary: □	
	No □  / per week
Patient Contact / Involvement – (If project involves patient contact that if or care please explain how in this section) Will the audit involve direct patient contact?  Yes □	s <u>not</u> part of the patients usual treatmen
How will the patient be involved?	
Patient Questionnaire $\Box$ At clinic appointment $\Box$	
Other (please give details) Click here to enter text.	
Has approval been sought from the Patient Information Panel?	Yes □ No □ N/A □
Anticipated start date: Click here to enter text.	
Anticipated project completion date: Click here to enter text.	
Anticipated Action Plan Submission date: Click here to enter text.	
<ul> <li>PLEASE ATTACH A COPY OF YOUR DATA COLLECTION TOOL / PATIENT QUE</li> <li>FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATIONS PLEASE ATTACH A EVALUATION REPORT.</li> <li>PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVISIONAL AUDIT LEAD E AUDIT TEAM.</li> </ul>	COPY OF THE PREVIOUS AUDIT OR SERVICE
Departmental Clinical Audit Lead (Signature)	Date: Click here to enter text.
Comments Click here to enter text.	
Divisional Clinical Audit Lead (Signature)	Date: Click here to enter text.
Is this topic a key clinical interest for the department / division?	Yes □ No □

## **Project Prioritisation Assessment Tool**

**Audit title:** Audit of Coagulation Tests. To identify and minimize the number of rejected samples, in order to optimize costs and improve time results

The below table provides a system for prioritising locally conceived projects and what level of clinical audit team resource should be offered / provided.

If the project is mandatory please specify what priority level:-

Level 1 – External 'must do' Level 2 'Internal 'must do'		
Criteria	Tick all that apply	Score
High cost	Υ	(x3)
High volume	Υ	(x2)
High risk		(x3)
Known quality issue	Υ	(x3)
Wide variation in practice	Υ	
NICE / NCEPOD related audit		(x3)
Defined measurable standards available	Υ	
Re-audit / repeat service evaluation		(x2)
Topic is a key clinical interest for the department / division	Υ	(x2)
Multidisciplinary project		
National / regional or multicentre project		(x2)
Total	12	Level 3 – Cat A

#### Priority levels and audit team support

Priority level	Priority score
Level 1 – External 'must do'	Category A
Level 2 – Internal 'must do'	Category A
Level 3 – High local priority	> 10
Level 4 – Medium local priority	4 – 9
Level 5 – Low local priority	< 4

Priority level	Audit team resource	
Level 1, 2 & 3	Category A – Full support	Full practical assistance offered
Level 4	Category B – Moderate support	Level of practical assistance will be
		negotiated and agreed with project lead
Level 5	Category C – Minimal support	Advice, registration and monitoring

#### **CLINICAL AUDIT / SERVICE EVALUATION PROJECT REGISTRATION FORM**

Ref No: -	Project Type: - Clinical Audit ⊠
	nation Title: Audit of Coagulation Tests. To identify and minimize the number of order to optimize costs and improve time results.
Division: Neurology	□ Neurosurgery ⊠
Project Lead: Contac	ct No: Bleep No:
Email address: Audit / service evalua	
Other professionals	involved / project team member's details
<ul> <li>patient who undergother</li> <li>Perioperative clotting anticoagulants and a second of the control of the con</li></ul>	es a significant impact on the surgical decision making and management, thus effectiveness collection, time processing and transport are crucial mainly in urgent cases. In an additional mainly in the testing process. It table samples is commonplace in laboratory practice and represents a serious problem, the sults can be e adversely compromised following analysis of these specimens and have serious
A retrospective review o	of rejected samples of clotting results will be assessed sent from the Walton Center to the March 2020 to May 2021.
• Identify the basis for	ocess failure will allow shortening awaiting periods, avoiding repeated phlebotomies patient
• Grainer Bio-met • NICE British society	
Guideline / Standard	s available: Yes 🗵 No 🗆
If yes, please attach a	copy or provide web link to the most current version:
Name of Standard / g	guideline:
Source of Standard /	guideline: Other 🗵 State other: British Society for Haematology
Review/assessment of Yes □ No □	of guideline/standard undertaken to ensure it is appropriate & can be measured

Is the audit / service evaluation issue:

High volume  Yes ⋈ No □  High risk  Yes □ No ⋈  High cost  Yes ⋈ No □  Known quality issue  Yes ⋈ No □  Wide variation in practice  Yes ⋈ No □	
	ontor toyt
Sample No: 104 Procedure codes to identify sample: Click here to e	
http://www.raosoft.com/samplesize.html - link to tool that may be used	to calculate sample size
Are you planning to publish your audit/service evaluation finding	s nationally
(e.g. Medical journal)? Yes $\square$ No $\boxtimes$	
Is this a re-audit or if service evaluation, has service been reviewe	ed previously? Yes □ No 🛛
Is this project part of an agreed departmental rolling programme?	Yes □ No ☒
Multidisciplinary: □ Single disciplinary: □	
Is Clinical Audit Team support required? Yes   If yes, please specify type of assistance required:   ♦ Population Identification □   ♦ Design of data collection tool □   (If not required please, attach a copy of the tool to be used)   ♦ Database design □   ♦ Data entry □   ♦ Analysis □   ♦ Presentation □   Collection of case notes □ Total number _	No ⊠ / per week
Will the audit involve direct patient contact? Yes □	No ⊠
Anticipated start date:/2021	
Anticipated project completion date: 08/2021 Anticipated Action Plan Submission date:06/2021	
PLEASE ATTACH A COPY OF YOUR DATA COLLECTION TOOL / PATIENT QUI	ESTIONNAIRE.
• FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATIONS PLEASE ATTACH A EVALUATION REPORT.	COPY OF THE PREVIOUS AUDIT OR SERVICE
<ul> <li>PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVISIONAL AUDIT LEAD I AUDIT TEAM.</li> </ul>	BEFORE SUBMISSION TO THE CLINICAL
Departmental Clinical Audit Lead (Signature)	Date: Click here to enter text.
Comments Click here to enter text.	
Divisional Clinical Audit Lead (Signature)	Date: Click here to enter text.
Is this topic a key clinical interest for the department / division?	Yes ⊠ No □



#### Clinical Audit / Service Evaluation Action Plan

Ref no: NS 384

Clinical Audit Title	Clinical Audit of Spinal Tumour Management and Outcomes		
Date audit complete	Feb 22	Date action plan completed	March 22
Auditor		Name of policy / guideline	Improving Outcomes for People with Brain and Other CNS
			Tumours
Division	Neurosurgery	Source of policy / guideline	NICE

#### **Audit Rationale:**

Please summarize the rationale of the audit for the members of the Clinical Audit Group (please limit to one or two sentences)

Delineate current practice at the Walton Centre in regard to 3 main objectives for spinal tumours:

Identify frequency of patient MDT discussion, Use of intra-operative neurophysiological monitoring, Post-operative complications

#### **Summary of Findings:**

Please concisely state the main conclusions of the project using bullet points

- 17.9% pts discussed in spinal MDT □ improving, especially since guidance (likely reflects change in NICE guidance issued in 2016 number post 2016 has improved dramatically although still not 100%)
- Proportion of patients discussed in MDT has increased over time
- Intra-operative neuro-monitoring is used in 12.3% of cases
- Monitoring was likely reserved for more technically challenging operations
- Surgical complication rates have remained low over the last decade for spinal tumours (16%)

#### Key success:

Please concisely state the key success identified by the project – if none identified please state N/A

- Presented at spinal MDT and agreed to discuss all primary intradural tumours
- Identified need for MDT discussion of primary intradural tumours highlighted improving nature of the data

#### **Key concerns:**

Please concisely state the key concerns identified by the project using bullet points—if none identified please state N/A

nil

#### Recommendations discussed:

Please concisely summarise the recommendations that were discussed following the completion of the project

To discuss all primary intradural tumours at MDT
Presentation / Dissemination of Project
Date findings were presented / disseminated: Neuro-ortho spinal MDT in January 2022
Department where discussed or presented:

### Actions agreed following recommendations discussed:-

\*Please ensure each action has a named lead, timescale and reportable group stated on the action plan below. Please list the evidence of the action implementation e.g SOP, protocol, standardised template, presentation or meeting minutes etc

Issue	Action required	Named lead for action	Timescale	Evidence	Reportable to (group/meeting)
Frequency of intradural tumour not at level recommended by NICE however is improving	Present findings at spinal MDT and encourage discussion of intradural tumours		Completed	MDT records	Y
2) As above	Re-audit in summer of 2022 to identify if 100% concordance in the stop-gap between audits.		Within the next 6 months.	Audit to be completed	Υ
3)					
Re-audit date2022	If no re-audit planned please give rea	asons why?			_
Will this be an on-going audit? Ye	s 🗌 No x				
Are there any potential barriers / prob	plems to prevent the implementation of the	ne above actions	? Yes 🗌 N	o x	
If yes to the above please state who the issues have been referred to:					
Name Designation Date referred					
Signature: Date:					
Have any issues been logged on the risk register? Yes No N/A Please provide details of issue(s) logged on the risk register:					



# **Project Prioritisation Assessment Tool**

## Audit title: Clinical Audit of Spinal Tumour Management and Outcomes

The below table provides a system for prioritising	g locally conceived projects and what level of clinical audit team
resource should be offered / provided.	
If the project is mandatory please specify what p	riority level:-
Level 1 – External 'must do'	Level 2 'Internal 'must do'

Criteria	Tick all that apply	Score
High cost		(x3)
High volume		(x2)
High risk		(x3)
Known quality issue		(x3)
Wide variation in practice		
NICE / NCEPOD related audit	Υ	(x3)
Defined measurable standards available	Υ	
Re-audit / repeat service evaluation		(x2)
Topic is a key clinical interest for the department / division		(x2)
Multidisciplinary project		
National / regional or multicentre project		(x2)
Total	4	Lvl 4- Cat B

#### Priority levels and audit team support

Priority level	Priority score	
Level 1 – External 'must do'	Category A	
Level 2 – Internal 'must do'	Category A	
Level 3 – High local priority	> 10	
Level 4 – Medium local priority	4 – 9	
Level 5 – Low local priority	< 4	

Priority level	Audit team resource	
Level 1, 2 & 3	Category A – Full support	Full practical assistance offered
Level 4	Category B – Moderate support	Level of practical assistance will be
		negotiated and agreed with project lead
Level 5	Category C – Minimal support	Advice, registration and monitoring

## **CLINICAL AUDIT / SERVICE EVALUATION PROJECT REGISTRATION FORM**

Ref No: - NS 384 Project Type: - Clinical Audit ⊠ Service Evaluation □
Audit / Service Evaluation Title: Clinical Audit of Spinal Tumour Management and Outcomes
<b>Division:</b> Neurology $\square$ Neurosurgery $\boxtimes$ Please specify department <b>Department of Neurosurgery</b>
Project Lead:
Contact No: Click here to enter text. Bleep No:
Email address: Audit / service evaluation supervisor:
Other professionals involved / project team members details (Please provide names and roles within the project eg data collection, analysis etc.)
Background / Rationale Spinal tumours are uncommon and typically present with focal neurological symptoms. Typically, they are caused meningiomas and schwannomas. NICE has published guidance on the appropriate management of spinal tumour The guidance stipulates that CNS tumours should be managed in the MDT setting. Additionally, they recommend that intra-operative neurophysiology recordings should be used to minimise post-operative morbidity. Complicate rates are important to continually evaluate as they provide a useful metric for optimal clinical care.
<u>Methodology</u>
To conduct this clinical audit, a retrospective review of patient clinical records will be conducted. Additionally, access to MDT records may be required. Imaging characteristics of tumours will not be required. Descriptive statistical analysis will be conducted, depending on the distribution of data for each variable. To determine if data is skewed or normally distributed, a Shapiro-Wilk test of normality will be used.
Aims / Objectives
This clinical audit has 3 main aims: 1) To determine if all patients diagnosed with spinal tumours have be presented in an MDT setting (in accordance with NICE guidance). 2) To determine if neurophysiological recording was used intra-operatively (again, in accordance with NICE guidance). 3) To evaluate post-operative complication rates following surgical resection of spinal tumours.
Standards / Criteria Details (service evaluation N/A)
The NICE guideline, "Improving outcomes for people with brain and other central nervous system tumours" will be used as a comparative metric for this clinical audit.
Guideline / Standards available: Yes ⊠ No □
If yes, please attach a copy or provide web link to the most current version: (https://www.nice.org.uk/guidance/csg10/resources/improving-outcomes-for-people-with-brain-and-other-cent nervous-system-tumours-update-27841361437
Name of Standard / guideline: Improving Outcomes for People with Brain and Other CNS Tumours
Source of Standard / guideline: NSF □ NICE ☒ Royal College □ Trust □ Other □ State other: Click here to enter text.

Yes ⊠ No □				
Is the audit / service evalu	uation issue:			
High volume	Yes □ No ⊠			
gh risk Yes □ No ⊠				
High cost	Yes □ No ⊠			
Known quality issue	Yes □ No ⊠			
Wide variation in practice	Yes □ No ⊠			
Sample No: Click here to en	ter text. Procedure codes to identify sample: Click here to enter text.			
http://www.raosoft.com/sam	nplesize.html - link to tool that may be used to calculate sample size			
Are you planning to publi	sh your audit/service evaluation findings nationally			
(e.g. Medical journal)?	Yes ⊠ No □			
Is this a re-audit or if serv	rice evaluation, has service been reviewed previously? Yes □ No ☒			
Is this project part of an a	greed departmental rolling programme? Yes □ No ☒			
Rolling programme durat	ion (number of years): n/a			
Rolling programme freque	ency: Monthly □ Quarterly □ Biannually □ Annually □			
Multidisciplinary:	Single disciplinary: □			
Is Clinical Audit Team sup If yes, please specify type of  ◆ Population Identification  ◆ Design of data collectio (If not required please, attain  ◆ Database design  ◆ Data entry  ◆ Analysis  ◆ Presentation Collection of case notes	of assistance required: □ ⊠			
Patient Contact / Involver or care please explain how in Will the audit involve dire	,			
How will the patient be in	volved?			
Patient Questionnaire	□ At clinic appointment □			
Other (please give details) Cli	ck here to enter text.			
Has approval been sough	t from the Patient Information Panel? Yes □ No □ N/A ⊠			
Anticipated start date:1/9	/21			
Anticipated project comp	letion date: 1/10/21			
<b>Anticipated Action Plan S</b>	Submission date:1/12/21			

Review/assessment of guideline/standard undertaken to ensure it is appropriate & can be measured

- PLEASE ATTACH A COPY OF YOUR DATA COLLECTION TOOL / PATIENT QUESTIONNAIRE.
- FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATIONS PLEASE ATTACH A COPY OF THE PREVIOUS AUDIT OR SERVICE EVALUATION REPORT.
- PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVISIONAL AUDIT LEAD BEFORE SUBMISSION TO THE CLINICAL AUDIT TEAM.

Departmental Clinical Audit Lead (Signature)	Date: Click	here to enter text.	
Comments Click here to enter text.			
Divisional Clinical Audit Lead (Signature)	Date: Click	here to enter text.	
Is this topic a key clinical interest for the department / division?	Yes □	No □	

## **Project Prioritisation Assessment Tool**

Audit title: Audit of quality of reporting peripheral nerve biopsies at the Walton Centre.

If the project is mandatory please specify what priority level:-

**Priority level** 

Level 1, 2 & 3

Level 4

Level 5

**Audit team resource** 

Category A – Full support

Category B – Moderate support

Category C – Minimal support

The below table provides a system for prioritising locally conceived projects and what level of clinical audit team resource should be offered / provided.

Level 1 – External 'must do' Level 2 'Internal 'must do'				
Criteria		Tick all that apply	Score	
High cost			(x3)	
High volume			(x2)	
High risk			(x3)	
Known quality issue			(x3)	
Wide variation in practice				
NICE / NCEPOD related audit			(x3)	
Defined measurable standards available		Υ		
Re-audit / repeat service evaluation			(x2)	
Topic is a key clinical interest for the department / division		Υ	(x2)	
Multidisciplinary project				
National / regional or multicentre project			(x2)	
Total		3	Level 5 – Cat C	
Priority levels and audit team support				
Priority level Priority s		core		
Level 1 – External 'must do' Category		A		
Level 2 – Internal 'must do' Category				
Level 3 – High local priority > 10				
Level 4 – Medium local priority 4 – 9				
Level 5 – Low local priority < 4				

Full practical assistance offered

Level of practical assistance will be negotiated and agreed with project lead

Advice, registration and monitoring

#### **CLINICAL AUDIT / SERVICE EVALUATION PROJECT REGISTRATION FORM**

Ref No: -	HIST/386	Project Type: - Clini	cal Audit □	Service Evaluation	on ⊠
Audit / Se Centre.	ervice Evaluati	on Title: Audit of quality	y of reportin	g peripheral nerve	biopsies at the Walton
Division:	Neurology □ N	leurosurgery ⊠ Please s	specify depar	tment <b>Neuropathol</b>	ogy
Project L	ead:				
Contact N	lo: Bleep No: I	N/A			
Email add	dress:				
Audit / se	rvice evaluation	on supervisor: N/A			
-		olved / project team me nd roles within the projec			)
Backgrou	ınd / Rationale				
acquired and methods a specimens	nd, occasionally are not leading to	nination of nerve biopsies in genetic peripheral neuropat a definitive diagnosis. The dides guidance on current ac	thies when ima 'Tissue pathwa	aging, laboratory and ays for non-neoplastic	neurophysiological neuropathology
<u>Methodol</u>	ogy				
	•	over a one-year period and ogists document and the pe		•	
Aims / Ob	<u>ojectives</u>				
	ne the percentaged report conten	ge of peripheral nerve biops ts.	sy reports that	meet the recommen	ded criteria for specimen
<u>Standard</u>	s / Criteria Det	ails (service evaluation	<u>N/A)</u>		
reports sho correlation	ould include an ir ) with a commen	each report should include sterpretation of the findings at on limitations or other re minimum requirements.	s within the av	railable clinical inform	ation (clinicopathological
Guideline	e / Standards a	vailable: Yes 🗵	No 🗆		
If yes, plea	ase attach a co	py or provide web link to	the most curr	ent version:	

Name of Standard / guideline: Section 7 of the Tissue pathways for non-neoplastic neuropathology specimens.

www.rcpath.org/resourceLibrary/g101-tissue-pathways-for-non-neoplastic-neuropathology-specimens.html

https://

Source of Standard / Trust $\Box$	_	SF $\square$ ate other: Click he	NICE  re to enter text.	Roya	al College	
Review/assessment	of quidoling/stan	dard undertake	n to ensure it	is annronriate	. & can be n	massurad
Yes ⊠ No □	oi guideiiile/stail	idald dildertake	ii to ensure it	is appropriate	c & Call De I	ileasui eu
Is the audit / service High volume High risk High cost Known quality issue Wide variation in pract	Yes □ N Yes □ N Yes □ N Yes □ N	0 ⊠ 0 ⊠ 0 ⊠				
Sample No: 6 Proce	dure codes to ide	entify sample: N	IN specimens	on TD-HC		
http://www.raosoft.com	n/samplesize.html	- link to tool that	: may be used t	o calculate sar	nple size	
Are you planning to	publish your aud	lit/service evalu	ation findings	nationally		
(e.g. Medical journal)?	Yes □	No ⊠				
Is this a re-audit or if	service evaluati	on, has service	been reviewe	d previously?	Yes □	No ⊠
Is this project part of	f an agreed depa	rtmental rolling	programme?	Yes	□ No ⊠	
Rolling programme of	duration (numbe	r of years):				
Rolling programme f	requency: Montl	nly □ Quarterl	y 🗆 Biannua	ally 🗆 Annua	ally 🗆	
Multidisciplinary:		Single discip	olinary: 🗵			
Is Clinical Audit Tear If yes, please specify t  ◆ Population Identifie  ◆ Design of data coll (If not required please)  ◆ Database design  ◆ Data entry  ◆ Analysis  ◆ Presentation Collection of case note	type of assistance cation lection tool , attach a copy of	required:  the tool to be use	□ e <i>d)</i> <sup>-</sup> otal number	No ⊠ / per week		
Patient Contact / Invo or care please explain he Will the audit involve	ow in this section)		nt contact that is Yes □	s <u>not</u> part of the <sub>l</sub>	patients usua	I treatment
How will the patient I	be involved?					
Patient Questionnaire	☐ At clinic a	appointment [	]			
Other (please give detail	ils) Click here to en	ter text.				

Has approval been sought from the Patient Information Panel?	Yes		No		N/A	$\boxtimes$
Anticipated start date:01/09/2021						
Anticipated project completion date: December 2021						
Anticipated Action Plan Submission date: December 2021						
<ul> <li>PLEASE ATTACH A COPY OF YOUR DATA COLLECTION TOOL / PATIENT QUE</li> <li>FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATIONS PLEASE ATTACH A EVALUATION REPORT. Click here to enter text.</li> <li>PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVISIONAL AUDIT LEAD E AUDIT TEAM.</li> </ul>	COPY (	OF TH	E PRE\			
Departmental Clinical Audit Lead (Signature) Date: 24/08/2021						
Comments Click here to enter text.						
Divisional Clinical Audit Lead (Signature)	D	ate:	Click h	ere t	o ente	er text.
Is this topic a key clinical interest for the department / division?	Yes	s 🗵		N	lo 🗆	



#### Clinical Audit / Service Evaluation Action Plan

Ref no: HIST/386

Clinical Audit Title	Audit of quality of reporting peripheral nerve biopsies at the Walton Centre.		
Date audit	18/11/2021	Date action plan	18/11/2021
complete		completed	
Auditor		Name of policy /	Section 7 of the Tissue pathways for
		guideline	non-neoplastic neuropathology
			specimens.
Division	Neurosurgery, Anaesthesia, Critical Care, Pain and Pathology	Source of policy /	RCPath
		guideline	

# **Summary of Findings:**

Please concisely state the main conclusions of the project using bullet points

The purpose of this audit was to review Nerve Biopsy reports produced by Neuropathology at the Walton Centre to determine the percentage that meet the recommended criteria for specimen handling and report content (see section 7 of Tissue pathways for non-neoplastic neuropathology specimens produced by the Royal college of Pathologists (RCPath)).

- 6 Nerve reports were produced during the audit period (14/07/2020 14/07/2021).
- Majority of the reports are in concordance with the RCPath Tissue Pathway guidelines.
- Three observations see Key Concerns.

Please see attached documents for full data and details:





Audit-of-quality-of-r Audit reviewing eporting-peripheral-npractice HIST386.doc

Version: 2019

# **Key success:**

Please concisely state the key success identified by the project – if none identified please state N/A

• Majority of reports in concordance with the RCPath Tissue Pathway guidelines.

This audit showed 100% compliance with the standards such as clinical information, date of biopsy, date of sample received, age at biopsy, site of biopsy, biopsy dimensions, availability of material for electron microscopy, assessment of myelinated fibre density, assessment if changes are acute or chronic (eg signs of active axonal degeneration, fibrinoid necrosis or vessel wall scarring, endoneurial fibrosis or oedema), assessment of amyloid, interpretation of the findings, clinicopathological correlation, differential diagnosis, recommendations as appropriate and SNOMED coding).

# **Key concerns:**

Please concisely state the key concerns identified by the project using bullet points—if none identified please state N/A

Although not concerns, three observations were noted:

- Material for teased fibre preparation or frozen materials are not routinely obtained in our laboratory therefore not applicable in the report.
- None of the histopathology report record size of fascicles. This is considered not clinically relevant hence information is not provided. Also majority of the reports do not have information on orientation. However all our nerve biopsy specimens are orientated both transversely and longitudinally hence never felt the requirement.
- Majority reports comment on endoneurial inflammatory cells although do not specify if those are in relation to vasculature or not. This practice is to be incorporated in the department following this audit. This was also raised as one of the UKAS findings. Perineurial cell infiltrates have not been specifically mentioned but all reports comment on epineurium.

#### Recommendations discussed:

Please concisely summarise the recommendations that were discussed following the completion of the project

Few exceptions noted whilst carrying out this audit which are as follows -

- While describing endoneurial cellular infiltrates, specific comments to be added as to their relation with the endoneurial vasculature or not.
- Nerve report template to include information on availability of material for EM.
- Changes to the existing nerve panel and follow the panel suggested in RCPath Tissue Pathway.

# **Presentation / Dissemination of Project**

<u>Date findings were presented / disseminated:</u> Will be presented at the next departmental audit meeting on 25/11/2021

Department where discussed or presented: The Neuroscience Laboratories

Version: 2019

Actions agreed following recommendations discussed:\*Please ensure each action has a named lead, timescale and reportable group stated on the action plan below. Please list the evidence of the action implementation e.g SOP, protocol, standardised template, presentation or meeting minutes etc

Issue	Action required		Timescale	Evidence	Reportable to (group/meeting)
Assessment of endoneurial inflammatory reaction, particularly in relation to vasculature.	inflammatory reaction, particularly infiltrates specific comments to be added		Immediate	Future nerve biopsy reports	N/A
<ol><li>Information of material available for electron microscopy.</li></ol>	Nerve report template to incorporate this information under macroscopy.		1month	Future nerve biopsy reports	N/A
3) Existing nerve panel	This requires changing in line with that suggested by RCPath.		1month	Future nerve biopsy reports	N/A
Will this be an on-going audit? Ye  Are there any potential barriers / pro	blems to prevent the implementation of t	he above action	s? Yes 🗌 N	lo 🛚	
If yes to the above please state who	the issues have been referred to:				
Name		Date referr	red		
Signature:	Date:				
Have any issues been logged on the	risk register? Yes No No N/A				
Please provide details of issue(s) log	ged on the risk register:				

Version: 2019



# Clinical Audit / Service Evaluation Registration Form

# **Clinical Audit definition**

Clinical Audit is a quality improvement process that seeks to improve patient care and outcomes through systematic review of care against explicit criteria and the implementation of change. Aspects of the structure, processes and outcomes of care are selected and systematically evaluated against explicit criteria. Where indicated, changes are implemented at an individual, team or service level and further monitoring is used to confirm improvement in healthcare delivery.

# **Service evaluation**

Service Evaluation is undertaken to benefit those who use a particular service and is designed and conducted to define or judge current service. Your participants will normally be those who use the service or deliver it. It involves an intervention where there is no change to the standard service being delivered (e.g. no randomization of service users into different groups). This does not require ethical approval. It is possible to use data collected from participants during a service evaluation for later research as long as:

- the data is completely anonymous;
- it is not possible to identify participants from any resulting report;
- use of the data will not cause substantial damage and distress

Please note that to complete this form your project <u>must be clinical audit or service evaluation</u>. If you are unsure whether your project is clinical audit, service review or research brief definitions are given below as a guide:

#### **Clinical Audit**

Measures existing practice against **best practice**, **evidence based clinical standards** (this may include Royal College, British Association, NICE or Local guidance etc.)

#### Research

➤ Generates new knowledge where there is no or limited research evidence available and which has the potential to be generalisable.

#### **Service Evaluation:**

> Seeks to evaluate the effectiveness or efficiency of a new or existing service to help inform local decision making (has been also referred to as service review, benchmarking or a baseline audit). This includes patient or staff satisfaction surveys.

If your project is research please contact Head of Research and Development, for advice and guidance with the project

Telephone Email

#### CLINICAL AUDIT / SERVICE EVALUATION PROJECT REGISTRATION FORM

Ref No: -	Project Type: - Clinical Audit □ Service Evaluation □
	ce Evaluation Title: Assessing the quality and quantity of maintenance fluid as for neurosurgical patients at the Walton Centre
<b>Division:</b> Neu	prology $\square$ Neurosurgery $\square$ Please specify department Click here to enter text.
Project Lead:	:
Contact No:	Bleep No:
Email addres	s:
Audit / servic	e evaluation supervisor:
Other profess	sionals involved / project team members details

# **Background / Rationale**

Patients on general surgical wards are frequently placed on Nil By Mouth (NBM) orders as part of their management. This can be for various reasons, the commonest being in preparation for surgery. Patients who are NBM require careful provision of maintenance fluids and electrolytes to replace daily losses. Without such replacement patients are prone to dehydration and electrolyte imbalances with significant consequences.

NICE guidelines provide clear quantitative guidelines on the quantity of maintenance fluids and electrolytes that ought to be prescribed according to a patient's weight. When a patient is anticipated to be placed on NBM orders, the caring team are encouraged to prescribe enough fluids to cover a 24 hour period to reduce the likelihood that a patient is NBM overnight without adequate fluids. Additionally, the choice of fluids prescribed should be carefully selected to approximate the patient's 24 hour requirements. Anecdotally, fluid volumes and electrolytes (particularly potassium) are frequently not calculated when prescribing fluids.

# **Methodology:**

- Data from 20 patients will be collected prospectively
- Inclusion criteria:
  - o Patients admitted under the care of the neurosurgical team at the Walton Centre
  - Patients with NBM orders
- Exclusion criteria:
  - Patients with sepsis
  - Patients on fluid restrictions

- o Patients on DDAVP for sodium derangements
- Data to be collected:
  - o Patient details: Walton number, age, gender, weight
  - Clinical details: reason for NBM order, electrolyte derangements on latest U+E
  - o Treatment details: volume of fluids prescribed over 24hours, choice of fluids prescribed
- From the above, a calculation of volume and electrolytes prescribed over 24hours will be made and compared to what is recommended by NICE against the patient's body weight.

# Aims / Objectives

Determine whether sufficient fluid volume and electrolytes are prescribed for NBM patients on the neurosurgical ward

# Standards / Criteria Details (service evaluation N/A)

<ul> <li>NICE Clinical Guideline (CG174), section 1.4</li> <li><a href="https://www.nice.org.uk/guidance/cg174/chapter/1-recommendations">https://www.nice.org.uk/guidance/cg174/chapter/1-recommendations</a></li> </ul>
Guideline / Standards available: Yes □ No □
If yes, please attach a copy or provide web link to the most current version:
Name of Standard / guideline: Intravenous fluid therapy in adults in hospital
Source of Standard / guideline: NSF □ NICE □ Royal College □  Trust □ Other □ State other: Click here to enter text.
Review/assessment of guideline/standard undertaken to ensure it is appropriate & can be measured $\underline{\rm Yes} \ \Box \ {\rm No} \ \Box$
Is the audit / service evaluation issue:  High volume Yes   No    High risk Yes   No    High cost Yes   No    Known quality issue Yes   No    Wide variation in practice Yes   No
Sample No: 20 Procedure codes to identify sample: Click here to enter text.
http://www.raosoft.com/samplesize.html - link to tool that may be used to calculate sample size
Are you planning to publish your audit/service evaluation findings nationally
(e.g. Medical journal)? Yes □ No □
Is this a re-audit or if service evaluation, has service been reviewed previously? Yes $\square$ No $\square$
Is this project part of an agreed departmental rolling programme? Yes □ No □
Rolling programme duration (number of years): Click here to enter text.

**Rolling programme frequency:** Monthly  $\square$  Quarterly  $\square$  Biannually  $\square$  Annually  $\square$ 

<u>Multidisciplinary</u> : ☐ Single disciplinary: ☐	
Is Clinical Audit Team support required?  If yes, please specify type of assistance required:  Population Identification  Design of data collection tool  (If not required please, attach a copy of the tool to be used)  Database design  Data entry  Analysis  Presentation  Collection of case notes  Yes  □  Assistance required: □  □  Total number	<u>No</u> □/ per week
Patient Contact / Involvement – (If project involves patient contact that or care please explain how in this section) Will the audit involve direct patient contact? Yes	t is <u>not</u> part of the patients usual treatmen
How will the patient be involved?	
Patient Questionnaire $\Box$ At clinic appointment $\Box$	
Other (please give details) Click here to enter text.	
Has approval been sought from the Patient Information Panel?	Yes □ No □ <u>N/A</u> □
Anticipated start date: As soon as possible.	
Anticipated project completion date: In 1 - 2 months.	
Anticipated Action Plan Submission date: 22/09/21	
PLEASE ATTACH A COPY OF YOUR DATA COLLECTION TOOL / PATIENT QU	JESTIONNAIRE.
• FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATIONS PLEASE ATTACH A EVALUATION REPORT.	A COPY OF THE PREVIOUS AUDIT OR SERVICE
PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVISIONAL AUDIT LEAD AUDIT TEAM.	BEFORE SUBMISSION TO THE CLINICAL
Departmental Clinical Audit Lead (Signature)	Date: Click here to enter text.
Comments Click here to enter text.	
Divisional Clinical Audit Lead (Signature)	Date: Click here to enter text.
Is this topic a key clinical interest for the department / division?	Yes □ No □



#### Clinical Audit / Service Evaluation Action Plan

Ref no: NS 386

Clinical Audit Title	Assessing the quality and quantity of maintenance fluid prescriptions for neurosurgical patients at the Walton Centre			
Date audit complete	May 2022	Date action plan	February 2022	
		completed		
Auditor		Name of policy /	NICE Clinical Guideline (CG174), section 1.4	
		guideline	o <a href="https://www.nice.org.uk/guidance/cg174/chapter/1-">https://www.nice.org.uk/guidance/cg174/chapter/1-</a>	
			<u>recommendations</u>	
Division	Neurosurgery	Source of policy /	NICE Clinical Guideline	
		guideline		

# **Summary of Findings:**

Please concisely state the main conclusions of the project using bullet points

• 100% of our patient sample did not adhere to the NICE guidelines re: fluid prescriptions in NBM situations.

# **Key success:**

Please concisely state the key success identified by the project – if none identified please state N/A

• Identifying a basic and essential missing component of patient care.

# **Key concerns:**

Please concisely state the key concerns identified by the project using bullet points—if none identified please state N/A

• Patients have not been getting adequate fluid and electrolyte replacement during their Nil By Mouth period.

# Recommendations discussed:

Please concisely summarise the recommendations that were discussed following the completion of the project

- Concise fluid prescription guideline stickers to be put at the back of doctors' ID cards for easy access during prescription
- Teaching sessions -both in person and sending out slides via email to nurses and doctors
- · Continuing to audit to make sure guidelines are being adhered to

# **Presentation / Dissemination of Project**

Date findings were presented / disseminated: to be presented at Grand Round

Version: 2019

Department where discussed or presented:	to be presented at Grand Round	

# Actions agreed following recommendations discussed:-

\*Please ensure each action has a named lead, timescale and reportable group stated on the action plan below. Please list the evidence of the action implementation e.g SOP, protocol, standardised template, presentation or meeting minutes etc

Issue	Action required	Named lead for action	Timescale	Evidence	Reportable to (group/meeting)		
Incorrect fluid prescriptions	Concise fluid prescription guideline stickers to be put at the back of doctors' ID cards for easy access during prescription		1 month	Copy of stickers & percentage uptake	Patient safety group		
2)	Teaching sessions –both in person and sending out slides via email to nurses and doctors		2 months	Copy of slides and pictures from in-person sessions	Patient safety group		
Re-audit date08/2022 If no re-audit planned please give reasons why?							
Will this be an on-going audit?	es No 🗌						
Are there any potential barriers / pro	blems to prevent the implementation of t	he above action	s?Yes 🗌 🔼	lo 🗌			
If yes to the above please state who	the issues have been referred to:						
Name Designation Date referred							
Signature:Date:							
Have any issues been logged on the risk register? Yes  N/A N/A							
Please provide details of issue(s) logged on the risk register:							

Version: 2019



# Clinical Audit / Service Evaluation Registration Form

# **Clinical Audit definition**

Clinical Audit is a quality improvement process that seeks to improve patient care and outcomes through systematic review of care against explicit criteria and the implementation of change. Aspects of the structure, processes and outcomes of care are selected and systematically evaluated against explicit criteria. Where indicated, changes are implemented at an individual, team or service level and further monitoring is used to confirm improvement in healthcare delivery.

# **Service evaluation**

Service Evaluation is undertaken to benefit those who use a particular service and is designed and conducted to define or judge current service. Your participants will normally be those who use the service or deliver it. It involves an intervention where there is no change to the standard service being delivered (e.g. no randomization of service users into different groups). This does not require ethical approval.

It is possible to use data collected from participants during a service evaluation for later research as long as:

- the data is completely anonymous;
- it is not possible to identify participants from any resulting report;
- use of the data will not cause substantial damage and distress

Please note that to complete this form your project <u>must be clinical audit or service evaluation</u>. If you are unsure whether your project is clinical audit, service review or research brief definitions are given below as a guide:

#### **Clinical Audit**

Measures existing practice against **best practice**, **evidence based clinical standards** (this may include Royal College, British Association, NICE or Local guidance etc.)

#### Research

Generates new knowledge where there is no or limited research evidence available and which has the potential to be generalisable.

#### Service Evaluation:

Seeks to evaluate the effectiveness or efficiency of a new or existing service to help inform local decision making (has been also referred to as service review, benchmarking or a baseline audit). This includes patient or staff satisfaction surveys.

If your project is research please contact Head of Research and Development, for advice and guidance with the project

Telephone Email

#### CLINICAL AUDIT / SERVICE EVALUATION PROJECT REGISTRATION FORM

Ref No: -	Project Type: - Clinical Audit ⊠	Service Evaluation □					
Audit / Service Evaluation Title: Assessing Neurosurgical Ward Round Documentation							
<b>Division:</b> Neurology □ Neurosurgery ⊠ Please specify department <b>Neurosurgery</b>							
Project Lead:							
Contact No: B	leep No: Click here to enter text.						
Email address:							
Audit / service evaluation supervisor:							
Other professionals involved / project team members details (Please provide names and roles within the project eg data collection, analysis etc.)							

# **Background / Rationale**

Ward Rounds are essential clinical activities that provide the basis of daily assessment and management of surgical inpatients. At The Walton centre, we have multidisciplinary teams looking after the neurosurgical patients, and it is important to have clear and adequate information provided during ward rounds. Guidelines by the Royal College of Surgeons (RCS) provide a structured ward round checklist to improve patient safety. The added importance of ward round notes in neurosurgery reflects the super specialised care we provide at The Walton Centre. For example, we commonly use acronyms which are rare in other specialities such as, GCS (Glasgow Coma Scale), SWI/DWI (MRI terminology) etc. There is no published data, to the best of the authors knowledge, which describes how closely neurosurgical ward round documentation adheres to published RCS guidelines.

# Methodology

Baseline/first cycle data will be collected prospectively from EP2 over consecutive 7 days. Patients included are neurosurgical patients and who are undergoing active medical care. Data point collected will be: 1. Medical professional grade, 2. Ward round documentation and 3.Consultant responsible for patient care. This data collected will be compared with a known standard of ward round documentation (please see attached RCS SHINE guidelines). If the first cycle data is below 80% compliance against the RCS SHINE guidelines, there will be a dual intervention; first, a classroom based tutorial for the senior house officers, and second, a poster which will serve as a visual reminder. A period of two weeks will elapse between intervention and second cycle. Second cycle data collection will again be a prospective 7 day period which will re-assess compliance with RCS SHINE guidelines. Data will be presented using descriptive statistics such as mode/median/range as appropriate. Graphical representation of adherence to RCS SHINE will be shown.

# **Aims / Objectives**

Aim: Increase adherence of ward documentation to RCS SHINE guidelines. Objective: To compare current ward round entries with the RCS SHINE standard. 2. To provide teaching to the junior medical team about the standard guidelines.

### Standards / Criteria Details (service evaluation N/A)

RCS SHINE guidelines, available at: https://www.rcsed.ac.uk/media/4590/tool-3-surgical-ward-round-tool.pdf

1.

Guideline / Standards available: Yes ⊠ No □
If yes, please attach a copy or provide web link to the most current version: https://www.rcsed.ac.uk/media/4590/tool-3-surgical-ward-round-tool.pdf
Name of Standard / guideline: RCS SHINE Surgical Ward Round Toolkit
Source of Standard / guideline: NSF □ NICE □ Royal College ⊠  Trust □ Other □ State other: Click here to enter text.
Review/assessment of guideline/standard undertaken to ensure it is appropriate & can be measure ${\tt Yes} \ \boxtimes \ {\tt No} \ \square$
Is the audit / service evaluation issue:  High volume Yes □ No ⊠  High risk Yes □ No ⊠  High cost Yes □ No ⊠  Known quality issue Yes □ No ⊠  Wide variation in practice Yes □ No ⊠
Sample No: 80 Procedure codes to identify sample: N/A
http://www.raosoft.com/samplesize.html - link to tool that may be used to calculate sample size
Are you planning to publish your audit/service evaluation findings nationally
(e.g. Medical journal)? Yes ⊠ No □
Is this a re-audit or if service evaluation, has service been reviewed previously? Yes □ No ☒
Is this project part of an agreed departmental rolling programme? Yes □ No ☒
Rolling programme duration (number of years): Click here to enter text.
<b>Rolling programme frequency:</b> Monthly □ Quarterly □ Biannually □ Annually □
Multidisciplinary: □ Single disciplinary: □
Is Clinical Audit Team support required? Yes □ No ☒  If yes, please specify type of assistance required:  ◆ Population Identification □  ◆ Design of data collection tool  (If not required please, attach a copy of the tool to be used)  ◆ Database design ☒  ◆ Data entry ☒  ◆ Analysis □  ◆ Presentation □  Collection of case notes □ Total number / per week
Patient Contact / Involvement – (If project involves patient contact that is <u>not</u> part of the patients usual treatment or care please explain how in this section) Will the audit involve direct patient contact?  Yes □ No ☑

How will the patient be involved?

Patient Questionnaire $\Box$ At clinic appointment $\Box$						
Other (please give details) Click here to enter text.						
Has approval been sought from the Patient Information Panel?	Yes		No		N/A	$\boxtimes$
Anticipated start date: 22/09/2021						
Anticipated project completion date: 15/11/2021						
Anticipated Action Plan Submission date:15/11/2021						
<ul> <li>PLEASE ATTACH A COPY OF YOUR DATA COLLECTION TOOL / PATIENT QUE</li> <li>FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATIONS PLEASE ATTACH A EVALUATION REPORT.</li> <li>PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVISIONAL AUDIT LEAD E AUDIT TEAM.</li> </ul>	COPY	OF TH	E PRE			
Departmental Clinical Audit Lead (Signature)	D	ate: (	Click h	nere t	o ente	er text.
Comments Click here to enter text.						
Divisional Clinical Audit Lead (Signature)	D	ate: (	Click h	nere t	o ente	er text.
Is this topic a key clinical interest for the department / division?	Yes			Ν	lo 🗆	



# **Clinical Audit / Service Evaluation Action Plan**

Ref no: NS 388

Clinical Audit Title	Audit of Consent for Posterior Lumbar Discectomy			
Date audit complete	01/03/2022	Date action plan completed	05/05/2022	
Auditor		Name of policy / guideline	2017 BASS/SBNS consensus statement	
Division	Neurosurgery	Source of policy / guideline		

# Audit Rationale:

To determine the degree of compliance with the 2017 BASS/SBNS consensus statement with regards to discussing vascular injury in the consent process.

# **Summary of Findings:**

Please concisely state the main conclusions of the project using bullet points

• Compliance with the standard was 41%

# **Key success:**

Please concisely state the key success identified by the project – if none identified please state N/A

N/A

# **Key concerns:**

Please concisely state the key concerns identified by the project using bullet points—if none identified please state N/A

- Failure to mention vascular injury during consent
- Spinal level not mentioned in 4 cases
- Consent on day of surgery in 17% of cases

# Recommendations discussed:

Please concisely summarise the recommendations that were discussed following the completion of the project

• Staff re-education regarding the need to mention vascular injury during consent

Version: 2021 Review: 2022

Presentation / Dissemination of Project
Date findings were presented / disseminated: TBC
Department where discussed or presented: TBC

# Actions agreed following recommendations discussed:-

\*Please ensure each action has a named lead, timescale and reportable group stated on the action plan below. Please list the evidence of the action implementation e.g SOP, protocol, standardised template, presentation or meeting minutes etc

		•	•		
Issue	Action required	Named lead	Timescale	Evidence	Reportable to
		for action			(group/meeting)
1) Failure to mention vascular injury	Publicise the standard		May 2022	Presentation	Neurosurgery
during consent					team
during consent					team
2)					
2)					
3)					
Re-audit date 01/09/2022	If no re-audit planned please	give reasons wh	v?		
	II IIO IO dadit plailiod piodoo	9.10 10000110 1111	y ·		
Will this he on an asing sudit?	a M Na				
Will this be an on-going audit? Ye	S 🖂 NO 📋				
Are there any potential barriers / prol	plems to prevent the implementation of t	he above actions	s? Yes ∐ No	o 🛚	
If yes to the above please state who t	the issues have been referred to:				
•					
Name	Designation	Date referred			
Cianatura	Doto: 05/05/2022				
Jigiiatui e	Signature:Date:05/05/2022				
Have any issues been logged on the risk register? Yes No No N/A					
Please provide details of issue(s) log	Please provide details of issue(s) logged on the risk register:				
• • • • • • • • • • • • • • • • • • • •	<del>-</del>				

Version: 2021 Review: 2022

# **Project Prioritisation Assessment Tool**

# Audit title: Audit of consent for posterior lumbar discectomy

Level 1, 2 & 3

Level 4

Level 5

Category A – Full support

Category B – Moderate support

Category C – Minimal support

The below table provides a system for prioritising locally conceived projects and what level of clinical audit team resource should be offered / provided.

If the project is mandatory please specify what priority level:-  Level 1 – External 'must do'   Level 2 'Internal 'must do'				
Criteria		Tick all that apply	Score	
High cost			(x3)	
High volume			(x2)	
High risk			(x3)	
Known quality issue		Υ	(x3)	
Wide variation in practice				
NICE / NCEPOD related audit			(x3)	
Defined measurable standards available		Υ		
Re-audit / repeat service evaluation			(x2)	
Topic is a key clinical interest for the department / division			(x2)	
Multidisciplinary project				
National / regional or multicentre project			(x2)	
Total		4	Level 4 – Cat B	
Priority levels and audit team support				
Priority level Priority score				
Level 1 – External 'must do' Category A				
Level 2 – Internal 'must do' Category A		A		
Level 3 – High local priority > 10				
Level 4 – Medium local priority 4 – 9				
Level 5 – Low local priority < 4				
Priority level Audit team resource				

Version 2019 Review date: 2021

Full practical assistance offered

Level of practical assistance will be

Advice, registration and monitoring

negotiated and agreed with project lead

# **CLINICAL AUDIT / SERVICE EVALUATION PROJECT REGISTRATION FORM**

Ref No: -	Project Type: - Clinical Audit ⊠ Service Evaluation □		
Audit / Service Evaluation Title: Audit of consent for posterior lumbar discectomy			
Division: Neurology	□ Neurosurgery ⊠ Please specify department		
Project Lead:			
Contact No: Bleep N	o:		
Email address:			
Audit / service evalu	ation supervisor:		
Other professionals	involved / project team members details		
morbidity and mortality risks relevant to the intumbar discectomy, it is Society of British Neuro consensus statement to	nale uring posterior lumbar discectomy is a rare (1:4000) complication, associated with significant v. The process of informed consent requires the clinician to inform the patient of all material ervention. Given the potentially life-threatening sequelae of major vascular injury during sixtle that all patients are informed of the possibility of such an occurrence. In 2017 The clogical Surgeons (SBNS) and The British Association of Spine Surgeons (BASS) issued a their members, highlighting the importance of disclosing and discussing the risk of major elective posterior lumbar discectomy.		
<u>Methodology</u>			
Retrospective caseno	te review.		
Aims / Objectives			
To compare current c	onsent practice among spinal orthopaedic and neurosurgeons against best practice.		
Standards / Criteria	Details (service evaluation N/A)		
SBNS and BASS consens	sus statement concerning major vascular injury during lumbar discectomy.		
Guideline / Standard	ls available: Yes ⊠ No □		
	a copy or provide web link to the most current version: https://www.judiciary.uk/wp-/09/2017-0193-Response-by-Royal-College-of-Surgeons.pdf		
Name of Standard /	guideline: major vascular damage during lumbar discectomy; consensus statement		
Source of Standard Trust □	/ guideline: NSF □ NICE □ Royal College ⊠ Other □ State other: Click here to enter text.		
<b>Review/assessment</b> Yes ⊠ No □	of guideline/standard undertaken to ensure it is appropriate & can be measured		
Is the audit / service	evaluation issue:		

High volume	Yes □ No ⊠			
High risk High cost	Yes □ No ⊠ Yes □ No ⊠			
Known quality issue	Yes ⊠ No □			
Wide variation in practice	Yes □ No ⊠			
Sample No: 50 Procedure	codes to identify sa	mple: Click here to ente	er text.	
http://www.raosoft.com/sam	nplesize.html - link to to	ool that may be used to	calculate sa	mple size
Are you planning to publi	sh your audit/service	evaluation findings r	nationally	
(e.g. Medical journal)?	Yes □ No ▷	⊴		
Is this a re-audit or if serv	ice evaluation, has s	ervice been reviewed	previously?	? Yes □ No ☒
Is this project part of an a	•		Yes	s □ No ⊠
Rolling programme durat	on (number of years)	): Click here to enter text		
Rolling programme freque	ency: Monthly  Q	uarterly   Biannual	ly 🗆 Annu	ıally □
Multidisciplinary:	Single	e disciplinary:		
Is Clinical Audit Team sup If yes, please specify type of  ◆ Population Identification  ◆ Design of data collection (If not required please, attack  ◆ Database design  ◆ Data entry  ◆ Analysis  ◆ Presentation Collection of case notes	nf assistance required: n n tool		No □ / per week	<b>S</b>
Patient Contact / Involver or care please explain how in Will the audit involve dire	this section)	es patient contact that is $\underline{p}$	<u>not</u> part of the No ⊠	patients usual treatmen
How will the patient be in	volved?			
Patient Questionnaire	☐ At clinic appointme	ent 🗆		
Other (please give details) Cli	ck here to enter text.			
Has approval been sough	t from the Patient Inf	ormation Panel? Ye	s 🗆 No	□ N/A ⊠
Anticipated start date:25/	10/2021			
Anticipated project comp	letion date: 25/11/202	21		
Anticipated Action Plan S	ubmission date:06/12	2/2021		

- PLEASE ATTACH A COPY OF YOUR DATA COLLECTION TOOL / PATIENT QUESTIONNAIRE.
- FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATIONS PLEASE ATTACH A COPY OF THE PREVIOUS AUDIT OR SERVICE EVALUATION REPORT.
- PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVISIONAL AUDIT LEAD BEFORE SUBMISSION TO THE CLINICAL AUDIT TEAM.

Departmental Clinical Audit Lead (Signature)	Date: Click	here to enter text.
Comments Click here to enter text.		
Divisional Clinical Audit Lead (Signature)	Date: Click	here to enter text.
Is this topic a key clinical interest for the department / division?	Yes □	No □

# **Project Prioritisation Assessment Tool**

Audit title: Global Neurotrauma Outcomes Study: Spine

If the project is mandatory please specify what priority level:-

Level 3 – High local priority

Level 5 – Low local priority

Level 4 – Medium local priority

The below table provides a system for prioritising locally conceived projects and what level of clinical audit team resource should be offered / provided.

Level 1 – External 'must do' Level 2 'Internal 'must do'				
Criteria	Tick all tha	at apply Score		
High cost		(x3)		
High volume		(x2)		
High risk		(x3)		
		(1.0)		
Known quality issue	Υ	(x3)		
Wide variation in practice	Y			
NICE / NCEPOD related audit		(x3)		
Defined measurable standards available				
Re-audit / repeat service evaluation		(x2)		
Topic is a key clinical interest for the department /	division	(x2)		
Multidisciplinary project				
National / regional or multicentre project	Υ	(x2)		
Total	6	Level 4- Cat B		
Priority levels and audit team support				
Priority level	Priority score			
Level 1 – External 'must do'	Category A	ry A		
Level 2 – Internal 'must do'	Category A	у А		

Priority level	Audit team resource	
Level 1, 2 & 3	Category A – Full support	Full practical assistance offered
Level 4	Category B – Moderate support	Level of practical assistance will be
		negotiated and agreed with project lead
Level 5	Category C – Minimal support	Advice, registration and monitoring

> 10

4 - 9

< 4

#### CLINICAL AUDIT / SERVICE EVALUATION PROJECT REGISTRATION FORM

Ref No: -	Project Type: - Clinical Audit □	Service Evaluation ⊠
Audit / Service Eval	uation Title: Global Neurotraun	na Outcomes Study: Spine
Division: Neurology	☐ Neurosurgery ⊠ Please specify	/ department <b>Spine</b>
Project Lead:		
Contact No: Bleep N	lo:	
Email address:		
Audit / service evalu	ation supervisor:	

Other professionals involved / project team members details

# **Background**

Traumatic spinal injury (TSI) accounts for a significant proportion of disability and death worldwide, with the majority of this burden affecting individuals in low- to middle- income countries. Crucially, to date, the current disease profile of TSI has not been characterised globally. In addition, the global approach to the care of patients following TSI is inconsistent with considerable geographical differences in process of care reported, and limited data available on the impact of these variations on outcomes following TSI. A better understanding of case-mix and processes of care is urgently needed to underpin efforts to identify ways of improving outcome relevant to different socioeconomic settings globally.

#### <u>Methods</u>

A multi-centre, international, prospective, observational study. Any unit assessing patients with TSI worldwide will be eligible to participate. Each participating unit will form a study team responsible for gaining local approval, identifying patients for inclusion and conducting data collection. Data will be collected via a secure online platform in an anonymised form. Processes of care will be characterised by a detailed provider profiling exercise. A registry describing the case-mix and care of all adults presenting with radiologically confirmed TSI will be collected, in a given consecutive 30-day period during the study period starting in 2021.

# **Results**

The dataset, developed through an iterative feedback process involving clinicians from low and high Human Development Index (HDI) countries, includes patient demographics, details of injury mechanism, local injury management and, if applicable, timing and nature of surgery, post-operative care and immediate postoperative complications. Outcome measures include Frankel grade at 6 weeks post-admission (or at discharge or death, whichever event occurs first), early mortality, peri-operative complications, adverse events of special interest, functional status and mobility. Descriptive analyses of case-mix and the variations 3 in processes of care will be conducted. Available resources, use of guidelines and variations in processes of care will be characterised using both provider profiling responses and patient-level data collected. Areas where known best practice is deficient or unavailable will be identified as potential targets for future implementation studies.

### **Objectives**

- 1.1 Primary Objective Characterise case-mix, processes of care and variations in nonoperative and operative management strategies, including emergency, ward, surgical and ICU care, in patients presenting with traumatic spinal injury (TSI) between centres across low and high Human Development Index (HDI) countries
- 1.2 Secondary Objectives
- Summarise the current resources and management pathways for patients presenting with suspected traumatic spinal injury worldwide, through validation of provider profiling data
- Describe differences in current (i) indications for conservative management vs surgery, and (ii) short term outcomes (early mortality, functional, neurological, adverse events) following TSI worldwide.
- Identify gaps in implementation of current evidence-based best practice and explore possible reasons in specific settings.
- Identify targets for future global health, process of care or clinical interventions to improve outcomes across different settings.
- Obtain point-estimates of, and gain insights into local variations in the epidemiology of TSI.
- Define patient profiles which predict efficacy of specific interventions and pathways of care. Identify possible performance indicators to characterise TSI care across settings in preparation for a future consensus study.

Standards / Criteria Detai	ls (servi	ce eva	<u>luation</u>	N/A)				
N/A								
Guideline / Standards ava	ailable:	Yes		No	$\boxtimes$			
If yes, please attach a copy	or provi	de web	link to	the mo	st current	version:	Click here to enter text.	
Name of Standard / guide	eline: Not	t applica	ble					
Source of Standard / guid Trust		NSF State	□ other:		NICE		Royal College	
Review/assessment of gu	ıideline/	standa	rd unde	e <b>rtake</b> r	ı to ensu	re it is ap	ppropriate & can be r	measurec
Is the audit / service eval	uation is	ssue:						
High volume	Yes [	□ No	$\boxtimes$					
High risk		□ No						
High cost	Yes [							
Known quality issue Wide variation in practice	Yes [	⊠ No ⊠ No						
Sample No: Unknown Pr	ocedure	codes	to ide	ntify sa	mple: No	ot necess	sary	
http://www.raosoft.com/san	nplesize.	<u>html</u> - li	ink to to	ol that	may be u	sed to ca	lculate sample size	
Are you planning to publi	ish your	audit/s	service	evalua	tion find	ings nati	onally	
(e.g. Medical journal)?	Yes ⊠		No 🗆	]				
Is this a re-audit or if serv	ice eva	luation	, has se	ervice l	oeen revi	iewed pre	eviously? Yes	No ⊠

Is this project part of an agreed departmental rolling programme?	Yes □ No 🛛
Rolling programme duration (number of years): Click here to enter text	
Rolling programme frequency: Monthly □ Quarterly □ Biannuall	y □ Annually □
Multidisciplinary: □ Single disciplinary: ⊠	
Is Clinical Audit Team support required?  If yes, please specify type of assistance required:  ◆ Population Identification  ◆ Design of data collection tool  (If not required please, attach a copy of the tool to be used)  ◆ Database design  ◆ Data entry  ◆ Analysis  ◆ Presentation  Collection of case notes	No ⊠ _/ per week
Patient Contact / Involvement – (If project involves patient contact that is represented by the contact or care please explain how in this section)  Will the audit involve direct patient contact?  Yes	not part of the patients usual treatment  No ⊠
How will the patient be involved?	
Patient Questionnaire $\Box$ At clinic appointment $\Box$	
Other (please give details) Click here to enter text.	
Has approval been sought from the Patient Information Panel? Yes	s □ No □ N/A ⊠
Anticipated start date: November 2021	
Anticipated project completion date: Data – December 2021, write-u	p undetermined
Anticipated Action Plan Submission date:2 years post-start	
PLEASE ATTACH A COPY OF YOUR DATA COLLECTION TOOL / PATIENT QUEST	IONNAIRE – within protocol.
• FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATIONS PLEASE ATTACH A CO EVALUATION REPORT.	
<ul> <li>PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVISIONAL AUDIT LEAD BEF AUDIT TEAM.</li> </ul>	ORE SUBMISSION TO THE CLINICAL
Departmental Clinical Audit Lead (Signature)	Date: 29/09/2021
Comments Click here to enter text.	
Divisional Clinical Audit Lead (Signature)	Date: Click here to enter text.
Is this topic a key clinical interest for the department / division?	∕es □ No □



#### Clinical Audit / Service Evaluation Action Plan

Ref no: NS 390

Clinical Audit Title	Central line insertion documentation audit / Re-audit of CVC LocSIPPs' documentation adherence					
Date audit complete	March 2021	Date action plan completed	N/A			
Auditor		Name of policy / guideline	N/A			
Division	Critical care	Source of policy / guideline	N/A			

# **Summary of Findings:**

Please concisely state the main conclusions of the project using bullet points

- The 'Before procedure', 'Time Out' and 'Sign Out' subsections of the LocSIPPs had a completion rate of 100%
- The 'During procedure' section however only had a completion rate of 43%

# **Key success:**

Please concisely state the key success identified by the project – if none identified please state N/A

• Clinicians have been adhering to the CVC LOCSSIP forms, especially the 3 main sections (i.e. Before procedure, Time out and sign out) whilst performing CVC insertion on Horsley ITU

# **Key concerns:**

Please concisely state the key concerns identified by the project using bullet points—if none identified please state N/A

• The completion rate of the 'during procedure' section on the LocSIPP

# Recommendations discussed:

Please concisely summarise the recommendations that were discussed following the completion of the project

- Continue to adhere to the CVC LOCCSSIP forms when performing CVC insertion, reminders to all appropriate staff to fill in the during procedure section, presentation and discussion has been made during the audit meeting
- CVC LOCCSSIP also available in theatre for any CVC that are inserted in theatres
- To re-audit to check for improvement

# **Presentation / Dissemination of Project**

Date findings were presented / disseminated: 11.03.21

Version: 2019

Department where discussed or presented:	Horsley ITU	

Actions agreed following recommendations discussed:\*Please ensure each action has a named lead, timescale and reportable group stated on the action plan below. Please list the evidence of the action implementation e.g SOP, protocol, standardised template, presentation or meeting minutes etc

Issue	Action required	Named lead	Timescale	Evidence	Reportable to		
Ongoing adherence to CVC     LOCSIPPS documentation	Staff to be reminded of form adherence	for action	March 2021 - Complete		(group/meeting) Anaesthetic and critical care ops group		
2)	Re-audit compliance rates		1 year – reg form submitted		Anaesthetic and critical care ops group		
3)	Discuss outcomes with Anaesthetic and ITU ops group meetings		1 year		Anaesthetic and critical care ops group		
4)							
Re-audit dateMarch 2022	If no re-audit planned please give re	asons why?			_		
Will this be an on-going audit?	es 🗆 X No 🗀						
Are there any potential barriers / pro	blems to prevent the implementation of t	he above actions	? Yes 🗌 N	o			
If yes to the above please state who	the issues have been referred to:NA						
Name Designation Date referred							
Signature: Date:11.04.21							
Have any issues been logged on the risk register? Yes  No NA X							

Version: 2019

Please provide details of issue(s) logged on the risk register:	

Version: 2019

# **Project Prioritisation Assessment Tool**

# Audit title: Re-audit of CVC LocSIPPs' documentation adherence

If the project is mandatory please specify what priority level:-

Level 1 – External 'must do'

Criteria

The below table provides a system for prioritising locally conceived projects and what level of clinical audit team resource should be offered / provided.

Level 2 'Internal 'must do'

Tick all that apply

Score

High cost				(x3)		
High volume					(x2)	
High risk					(x3)	
Known quality iss	ue				(x3)	
Wide variation in	practice					
NICE / NCEPOD re	elated audit				(x3)	
Defined measural	ole standards available					
Re-audit / repeat service evaluation					(x2)	
Topic is a key clinical interest for the department / division			า		(x2)	
Multidisciplinary project						
National / regional or multicentre project					(x2)	
Total			0		Level 5- Cat C	
Priority levels a	nd audit team support					
Priority level		Prior	ity score			
Level 1 – Extern	al 'must do'	Cate	Category A			
Level 2 – Intern	al 'must do'	Cate	gory A			
Level 3 – High local priority > 10						
Level 4 – Medium local priority 4 – 9						
Level 5 – Low local priority < 4						
Priority level	Audit team resource					
Level 1, 2 & 3			Full practical a	assistance offer	ed	
Level 4			Level of practical assistance will be			
			negotiated and agreed with project lead			
Level 5	Category C – Minimal support		Advice, regist	ration and mon	itoring	
-						

# **CLINICAL AUDIT / SERVICE EVALUATION PROJECT REGISTRATION FORM**

Ref No: - P	Project Type: - Clinical Audit ⊠ Service Evaluation □
Audit / Service Evalua	tion Title: Re-audit of CVC LocSIPPs' documentation adherence
<b>Division:</b> Neurology $\square$	Neurosurgery   Please specify department Anaesthetics and Critical Care
Project Lead:	
Contact No: Click here t	to enter text. Bleep No: Click here to enter text.
Email address:	
Audit / service evaluat	tion supervisor:
-	and roles within the project eg data collection, analysis etc.)
intensive care communi	le for Invasive Procedures (LocSSIPs) have been introduced in the daily practice of the ity to improve patient safety and prevent never event. However, in order for the ourpose of preventing never event, they should be filled in correctly at the time of
<u>Methodology</u>	
between the 1st Dec 20	pective study on the documentation of LocSIPPS for CVC performed on Horsley ITU 020 and 31st Dec 2020. We looked at whether the 'before procedure', 'time out', rocedure' sections of the LocSIPPs were completed. The data were collected and spreadsheet.
Aims / Objectives	
	es to check if the health care professionals trained in performing central lines are e central venous catheter (CVC) LocSIPPs at the time of carrying out the procedure.
Standards / Criteria De	etails (service evaluation N/A)
Data was retrospectively f	from CVC LocSIPPs that were completed between 1st Dec 2020 to 31st Dec 2020.
Guideline / Standards	available: Yes □ No ⊠
If yes, please attach a c	copy or provide web link to the most current version: Click here to enter text.
Name of Standard / gu	uideline: Click here to enter text.
Source of Standard / g Trust □ C	guideline: NSF   NICE   Royal College   Other   State other: Click here to enter text.
Review/assessment of	f guideline/standard undertaken to ensure it is appropriate & can be measured

Yes □ No □

Is the audit / service evalu	ation issue:			
High volume	Yes □ No ⊠			
High risk	Yes □ No ⊠			
High cost	Yes □ No ⊠			
Known quality issue	Yes □ No ⊠			
Wide variation in practice	Yes □ No ⊠			
Sample No: Click here to en	ter text. <b>Procedure co</b>	des to identify sample	e: Click here to er	nter text.
http://www.raosoft.com/sam	plesize.html - link to to	ol that may be used to	calculate sample	size
Are you planning to public	sh your audit/service	evaluation findings n	ationally	
(e.g. Medical journal)?	Yes □ No ⊠			
Is this a re-audit or if serv	ice evaluation, has se	rvice been reviewed	previously? \	Yes ⊠ No □
Is this project part of an a	greed departmental ro	olling programme?	Yes □	No ⊠
Rolling programme durati	on (number of years):	: Click here to enter text.		
Rolling programme freque	ency: Monthly □ Qu	uarterly □ Biannually	y □ Annually	
Multidisciplinary:	Single	disciplinary:		
Is Clinical Audit Team sup If yes, please specify type of  ◆ Population Identification  ◆ Design of data collection (If not required please, attack  ◆ Database design  ◆ Data entry  ◆ Analysis  ◆ Presentation Collection of case notes	f assistance required:	Yes   D D D D D D D D D D D D D D D D D D	No ⊠ _/ per week	
Patient Contact / Involven or care please explain how in t Will the audit involve dire	this section)	s patient contact that is $\underline{n}$	ot part of the pation	ents usual treatment
How will the patient be inv	olved?			
Patient Questionnaire	At clinic appointmer	nt 🗆		
Other (please give details) Cli	ck here to enter text.			
Has approval been sough	t from the Patient Info	ormation Panel? Yes	s 🗆 No 🗆	N/A ⊠
Anticipated start date:04/0	)2/21			
Anticipated project compl	etion date: 15/02/21			
Anticipated Action Plan S	ubmission date:12/03	/21		

- PLEASE ATTACH A COPY OF YOUR DATA COLLECTION TOOL / PATIENT QUESTIONNAIRE.
- FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATIONS PLEASE ATTACH A COPY OF THE PREVIOUS AUDIT OR SERVICE EVALUATION REPORT.
- PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVISIONAL AUDIT LEAD BEFORE SUBMISSION TO THE CLINICAL AUDIT TEAM.

Departmental Clinical Audit Lead (Signature)	Date: Click	here to enter text.
Comments Click here to enter text.		
Divisional Clinical Audit Lead (Signature)	Date: Click	here to enter text.
Is this topic a key clinical interest for the department / division?	Yes □	No □



# Clinical Audit / Service Evaluation Registration Form

# **Clinical Audit definition**

Clinical Audit is a quality improvement process that seeks to improve patient care and outcomes through systematic review of care against explicit criteria and the implementation of change. Aspects of the structure, processes and outcomes of care are selected and systematically evaluated against explicit criteria. Where indicated, changes are implemented at an individual, team or service level and further monitoring is used to confirm improvement in healthcare delivery.

# **Service evaluation**

Service Evaluation is undertaken to benefit those who use a particular service and is designed and conducted to define or judge current service. Your participants will normally be those who use the service or deliver it. It involves an intervention where there is no change to the standard service being delivered (e.g. no randomization of service users into different groups). This does not require ethical approval.

It is possible to use data collected from participants during a service evaluation for later research as long as:

- the data is completely anonymous;
- it is not possible to identify participants from any resulting report;
- · use of the data will not cause substantial damage and distress

Please note that to complete this form your project <u>must be clinical audit or service evaluation</u>. If you are unsure whether your project is clinical audit, service review or research brief definitions are given below as a guide:

#### **Clinical Audit**

Measures existing practice against **best practice**, **evidence based clinical standards** (this may include Royal College, British Association, NICE or Local guidance etc.)

# Research

Generates new knowledge where there is no or limited research evidence available and which has the potential to be generalisable.

#### Service Evaluation:

Seeks to evaluate the effectiveness or efficiency of a new or existing service to help inform local decision making (has been also referred to as service review, benchmarking or a baseline audit). This includes patient or staff satisfaction surveys.

If your project is research please contact Head of Research and Development, for advice and guidance with the project

Telephone Email

#### CLINICAL AUDIT / SERVICE EVALUATION PROJECT REGISTRATION FORM

Ref No: -	Project Type: - Clinical Audit ☐ Service Evaluation ☒
	uation Title: Prevalence of airway complications and association with aerosol precautions - re, service evaluation (AeroComp)
Division: Neurology	□ Neurosurgery ⊠ Please specify department <b>Anaesthesia</b>
Project Lead:	
Contact No: Bleep N	O: Click here to enter text.
Email address:	
Audit / service evalu	nation supervisor:
	involved / project team members details es and roles within the project eg data collection, analysis etc.)

# **Background / Rationale**

Although most airway management is uncomplicated, when complications occur they can becatastrophic resulting in significant morbidity and mortality [1]. The severe acute respiratorysyndrome coronavirus-2 (SARS-CoV-2) pandemic has resulted in significant changes to airwaymanagement [2] due to concern over transmission of aerosolised virus particles to healthcareprofessionals [3]. Initial reports suggest that patients infected with SARS-CoV-2 may be more at risk ofairway complications including hypoxaemia [4], airway trauma [5], and airway oedema [6]. While it ispossible SARS-CoV-2 itself may be a risk factor for airway complications, aerosol precautions, designed to reduce the transmission of virus particles to healthcare workers, may also contribute

#### Methodology

Prospective study, - Site (automatically populated dependent upon the login credentials of the local investigator)-Day of the study- Age of patient (grouped into 18-39, 40-59, 60-79 and ≥ 80 years)- Sex of patient- American Society of Anesthesiologists (ASA) physical status- Patient body mass index (BMI), grouped into underweight (< 18.5 kg/m²), normal (18.5 –24.9 kg/m²), overweight (25.0 – 29.9 kg/m²), class 1 obesity (30.0 – 34.9 kg/m²), class 2 obesity (35.0 – 39.9 kg/m²), class 3 obesity (>= 40.0 kg/m²)- Surgical urgency (elective; expedited; urgent; emergency)- Start time of procedure (first set of observations entered into the anaesthetic record),grouped into daytime (07:30–17:59); evening (18:00–23:59); and overnight (00:00–07:29)- Surgical specialty- Surgical severity (minor; intermediate; major)- Location of procedure: within or outside the main operating theatre complex (includingstand-alone day surgery units), used to identify "remote-site anaesthesia".- Grade of anaesthetist managing airway (initial airway manager and second airway managerif required)- PPE worn by anaesthetist managing airway: - Eye protection: visor; goggles; other - Respiratory protection: surgical mask; disposable FFP2/3 mask; re-usable FFP2/3 mask; powered airpurifying respirator; other - Body protection: plastic apron; long-sleeved gown; hazmat suit; other - Gloves: single pair; double pair; other

# Aims / Objectives

1. To determine the incidence of airway complications in patients undergoing generalanaesthesia, and any association with components of the aerosol precaution bundle.

### Standards / Criteria Details (service evaluation N/A)

Patient inclusion criteria: ● Adult patients (≥ 18 years of age) ● Undergoing a surgical, radiological or cardiological procedure (interventional or diagnostic) with the primary method of anaesthesia planned to be general anaesthesia7.2 Patient exclusion criteria ● Paediatric patients (< 18 years of age) ● Patients where the induction of

arrest at the time of airway intervention● Patients having obstetric procedures (pregnant patients undergoing nonobstetric surgery willbe included) 

Procedures planned to be performed under regional anaesthesia, local anaesthesia orsedation ● First set of observations outside the 96-hour study period ● Patients already with an airway device in place (e.g. ventilated patients transferred from ITU, tracheostomy) Guideline / Standards available: Yes  $\boxtimes$ No If yes, please attach a copy or provide web link to the most current version: Name of Standard / guideline: Aerocomp study protocol **NSF** NICE **Source of Standard / guideline:** Royal College Trust □ Other State other: Aerocomp national service evaluation Review/assessment of guideline/standard undertaken to ensure it is appropriate & can be measured Yes ⊠ No □ Is the audit / service evaluation issue: Yes ⊠ No □ High volume Yes □ No ⊠ High risk High cost Yes □ No ⊠ Known quality issue Yes □ No ⊠ Yes ⊠ No □ Wide variation in practice Sample No: 60 Procedure codes to identify sample: NA http://www.raosoft.com/samplesize.html - link to tool that may be used to calculate sample size Are you planning to publish your audit/service evaluation findings nationally (e.g. Medical journal)? Yes ⊠ No □ Is this a re-audit or if service evaluation, has service been reviewed previously? Yes □ No ☒ Is this project part of an agreed departmental rolling programme? Yes □ No 🛛 Rolling programme duration (number of years): Click here to enter text. **Rolling programme frequency:** Monthly \( \square \) Quarterly \( \square \) Biannually \( \square \) Annually \( \square \) Multidisciplinary: Single disciplinary:  $\boxtimes$ Is Clinical Audit Team support required?  $\boxtimes$ Yes No If yes, please specify type of assistance required: Population Identification Design of data collection tool (If not required please, attach a copy of the tool to be used) Database design Data entry Analysis Presentation Collection of case notes ☐ Total number / per week

general anaesthesia occurs in the emergency department(ED), critical care unit or general ward● Patients in cardiac

Patient Contact / Involvement – (If project involves patient or care please explain how in this section)		t that is		
Will the audit involve direct patient contact?	Yes		No	
How will the patient be involved?				
Patient Questionnaire				
Other (please give details) Click here to enter text.				
Has approval been sought from the Patient Information	n Pane	1? Ye	es 🗆	No □ N/A □
Anticipated start date:November 2021				
Anticipated project completion date: November 2021				
Anticipated Action Plan Submission date:January 202	2			
PLEASE ATTACH A COPY OF YOUR DATA COLLECTION TOOL /	/ PATIEN	IT QUES	ΓΙΟΝΝΑΙ	RE.
<ul> <li>FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATIONS PLEAEVALUATION REPORT.</li> </ul>	ASE ATT	ACH A CO	OPY OF T	HE PREVIOUS AUDIT OR SERVICE
<ul> <li>PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVISIONAL AUDIT TEAM.</li> </ul>	. AUDIT	LEAD BE	FORE SUI	BMISSION TO THE CLINICAL
Departmental Clinical Audit Lead (Signature)	Date:	5/1021		
Comments I am unable to comment since I am personally	involv	ed in th	e proje	ot.
Divisional Clinical Audit Lead (Signature)			Date:	Click here to enter text.
Is this topic a key clinical interest for the department /	divisio	on?	Yes ⊠	No 🗆

# **Project Prioritisation Assessment Tool**

# Audit title: CSF cell count comparison 2021

If the project is mandatory please specify what priority level:-

The below table provides a system for prioritising locally conceived projects and what level of clinical audit team resource should be offered / provided.

Level 1 – External 'must do' Level 2 'Inte	iternal 'must do'					
Criteria	Tick all that apply	Score				
High cost	N	(x3)				
High volume	N	(x2)				
High risk	N	(x3)				
Known quality issue	N	(x3)				
Wide variation in practice	N					
NICE / NCEPOD related audit	N	(x3)				
Defined measurable standards available	N					
Re-audit / repeat service evaluation	Υ	(x2)				
Topic is a key clinical interest for the department / division	N	(x2)				
Multidisciplinary project	N					
National / regional or multicentre project	N	(x2)				
Total	2	Level 5 – Cat C				
Priority levels and audit team support						

Priority level	Priority score
Level 1 – External 'must do'	Category A
Level 2 – Internal 'must do'	Category A
Level 3 – High local priority	> 10
Level 4 – Medium local priority	4 – 9
Level 5 – Low local priority	< 4

Priority level	Audit team resource	
Level 1, 2 & 3	Category A – Full support	Full practical assistance offered
Level 4	Category B – Moderate support	Level of practical assistance will be
		negotiated and agreed with project lead
Level 5	Category C – Minimal support	Advice, registration and monitoring

# **CLINICAL AUDIT / SERVICE EVALUATION PROJECT REGISTRATION FORM**

Ref No: - BIOC/182	Project Type: - Clinical Audit □ Service Evaluation ⊠
Audit / Service Eval	uation Title: CSF cell count comparison 2021
Division: Neurology	☐ Neurosurgery ☐ Please specify department <b>The Neuroscience Laboratories</b>
Project Lead:	
Contact No: BI	eep No:
Email address:	
Audit / service eval	uation supervisor:
-	s involved / project team members details es and roles within the project eg data collection, analysis etc.)

# **Background / Rationale**

The Neurobiochemistry department in The Neuroscience Labs at The Walton Centre (WCFT) perform CSF cell counts during working hours (Monday to Friday, 9 am to 5 pm). This enables rapid generation of results for most WCFT patients (target turnaround time is <2 hours), and minimises the risks associated with transport of precious CSF samples. However, the workload of the Neurobiochemistry department is such that it is not feasible to fund this service on a 24/7 basis. Therefore, for samples received outside working hours, a service is provided by the Microbiology department at Liverpool Clinical Laboratories (LCL) based at The Royal Liverpool University Hospital. CSF cell counts are also performed at LCL for WCFT patients if only a single specimen collection bottle is received, to prevent sample contamination before it can be cultured in Microbiology. Both laboratories are UKAS accredited for CSF cell counts (accreditation numbers are 8642 for WCFT, 9756 for LCL Microbiology), indicating that both sites perform work to a high standard. This audit is intended to provide additional reassurance that the CSF cell count results from both sites are comparable. Ideally, both sites would analyse the same sample and results would be compared directly; however, this is not feasible due to the instability of the cells in CSF (Reference 1). Therefore, the approach adopted for this audit is to review CSF cell count results from individual patients where multiple samples have been taken and analysed at both sites, and assess whether these correlate clinically. References: (1) Public Health England. UK Standards for Microbiology Investigations. Investigation of Cerebrospinal Fluid 2017

### <u>Methodology</u>

Every CSF cell count from a patient on intensive care (ITU), high dependency (HDU) or a surgical ward that was analysed at the Neuroscience Labs over a 12-month period will be identified. Patients from these locations are most likely to have increased numbers of cells present in CSF, and are most likely to have had repeat samples taken. To assess whether repeat samples were sent to Microbiology for CSF cell count, the relevant patient records in TD-Web (electronic results viewer) will then be reviewed. The results of any cell counts performed within 7 days of those done at the Neuroscience Labs will be compared, to ensure that all of the results fit the same clinical picture.

#### Aims / Objectives

All CSF cell counts should yield clinically comparable results, whether analysed at the Neuroscience Labs or at LCL.

Standards / Criteria Details (service evaluation N/A)

Guideline / Standards available: Yes □ No ⊠
If yes, please attach a copy or provide web link to the most current version: Click here to enter text.
Name of Standard / guideline: N/A
Source of Standard / guideline: NSF □ NICE □ Royal College □ Trust □ Other □ State other: Click here to enter text.
Review/assessment of guideline/standard undertaken to ensure it is appropriate & can be measured the second secon
Is the audit / service evaluation issue:  High volume Yes □ No ⊠  High risk Yes □ No ⊠  High cost Yes □ No ⊠  Known quality issue Yes □ No ⊠  Wide variation in practice Yes □ No ⊠
Sample No: One year's worth of CSF cell count results from patients in ITU, HDU and the surgical wards  Procedure codes to identify sample: Patients in ITU, HDU and the surgical wards as identified in the laborato information management system (LIMS), TD-NexLabs <a href="http://www.raosoft.com/samplesize.html">http://www.raosoft.com/samplesize.html</a> - link to tool that may be used to calculate sample size
· · · · · · · · · · · · · · · · · · ·
Are you planning to publish your audit/service evaluation findings nationally  (e.g. Medical journal)? Yes □ No ⊠
Is this a re-audit or if service evaluation, has service been reviewed previously? Yes ⊠ No □
Is this project part of an agreed departmental rolling programme?  Yes ⋈ No □
Rolling programme duration (number of years): Ongoing, performed every 2 years
<b>Rolling programme frequency:</b> Monthly □ Quarterly □ Biannually □ Annually □
Multidisciplinary: □ Single disciplinary: ⊠
Is Clinical Audit Team support required? Yes □ No ☑  If yes, please specify type of assistance required:  ◆ Population Identification □  ◆ Design of data collection tool □  (If not required please, attach a copy of the tool to be used)  ◆ Database design □  ◆ Analysis □  ◆ Presentation □
Collection of case notes   Total number / per week

Patient Contact / Involvement – (If project involves patient	contac	t that is	<u>not</u> part	of the pa	atients usua	al treatment
or care please explain how in this section) Will the audit involve direct patient contact?	Yes		No	$\boxtimes$		
How will the patient be involved?						
Patient Questionnaire						
Other (please give details) Click here to enter text.						
Has approval been sought from the Patient Informatio	n Pane	el? Ye	es 🗆	No [	□ N/A	
Anticipated start date:01/12/2021						
Anticipated project completion date: 31/01/2022						
Anticipated Action Plan Submission date:31/01/2022						
<ul> <li>PLEASE ATTACH A COPY OF YOUR DATA COLLECTION TOOL              BIOC182 data             collection proforma.di         </li> <li>FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATIONS PLEATEVALUATION REPORT.</li> <li>PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVISIONAL AUDIT TEAM.</li> </ul>	ASE ATT	ACH A CO	DPY OF T	HE PREVI		
Departmental Clinical Audit Lead (Signature) _ Date:	04/11/2	2021				
Comments Click here to enter text.						
Divisional Clinical Audit Lead (Signature)			Date:	Click he	re to enter	text.
Is this topic a key clinical interest for the department /	divisio	on?	Yes □		No □	



#### Clinical Audit / Service Evaluation Action Plan

Ref no: BIOC/182 NS393

Clinical Audit Title	CSF cell count comparison audit 2021				
Date audit complete	10/02/2022	Date action plan completed	21/02/2022		
Auditor		Name of policy / guideline	N/A		
Division	Neurosurgery (Neuroscience	Source of policy / guideline	N/A		
	Laboratories)				

# **Summary of Findings:**

Please concisely state the main conclusions of the project using bullet points

- Between 01/11/2020 and 31/10/2021, 62 patients from ITU, HDU or a surgical ward had a CSF cell count performed in the Neuroscience Laboratories at WCFT. Of these 62 patients, 25 also had a CSF cell count performed in the Microbiology department at LCL within 7 days of the cell count performed at WCFT. These 25 patients were included in the audit. A total of 68 CSF cell count results from these patients were included in the audit.
- In 21 of the 25 cases (84%), the CSF cell count results from both sites were consistent with each other and the overall clinical picture.
- In three cases where one or more cell counts appeared to be out of consensus, a number of possible factors other than the location of the analysis were identified that could explain the discrepant results. These factors included possible CNS infection (stated in clinical details), which would cause increased numbers of white blood cells in the CSF. Treatment of the infection would then cause a reduction in white blood cell count.
- In the fourth case there was insufficient data to assess fully whether the discrepancy could be explained, and indeed whether it was a true discrepancy.
- The full data set is included below:



# Key success:

Please concisely state the key success identified by the project – if none identified please state N/A

• In the majority of cases (84%), the CSF cell count results were consistent with each other and the clinical picture, independent of the site on which the sample was analysed.

Version: 2019

# **Key concerns:**

Please concisely state the key concerns identified by the project using bullet points—if none identified please state N/A

- There were four cases with a cell count result that was out of consensus with other samples from the same patient. In three of these cases, the discrepancies could be explained by other factors, whereas in the fourth there was insufficient data to be able to say whether the result was actually discrepant or part of an emerging trend.
- For 17 out of the 68 samples included in the audit (25%), the results from Microbiology at LCL appeared in TD-Web as an "interim report", containing the cell count result but no culture results.

#### Recommendations discussed:

Please concisely summarise the recommendations that were discussed following the completion of the project

• Raise the interim report issue with LCL to establish whether this is due to electronic reporting problems or other factors

#### **Presentation / Dissemination of Project**

<u>Date findings were presented / disseminated:</u> Neurobiochemistry lab meeting 02/03/2022; Neuroscience Laboratories departmental audit meeting 24/03/2022; Neuroscience Laboratories departmental audit meeting 26/05/2022

<u>Department where discussed or presented</u>: Neuroscience Laboratories

# Actions agreed following recommendations discussed:-

\*Please ensure each action has a named lead, timescale and reportable group stated on the action plan below. Please list the evidence of the action implementation e.g SOP, protocol, standardised template, presentation or meeting minutes etc

Issue	Action required	Named lead for action	Timescale	Evidence	Reportable to (group/meeting)
Some Microbiology reports on TD- Web remain as interim, with no culture results	Contact LCL IT to investigate the absence of culture results. If required this will be taken to the LCL SLA meeting for discussion.		September 2022	Investigation of possible reasons for	Department audit meeting
2)					
3)					

Version: 2019

4)					
Re-audit date _Dec 2023_ Will this be an on-going audit? Ye		ease give reasons why?	,		_
Are there any potential barriers / prob	•		tions? Yes	No 🛚	
If yes to the above please state who t	he issues have been referred	l to:			
Name	Designation	Date re	eferred		
Signature:	Date:				
Have any issues been logged on the	risk register? Yes 🗌 No	□ N/A □			
Please provide details of issue(s) log	ged on the risk register:				

Version: 2019



# Clinical Audit / Service Evaluation Registration Form

### **Clinical Audit definition**

Clinical Audit is a quality improvement process that seeks to improve patient care and outcomes through systematic review of care against explicit criteria and the implementation of change. Aspects of the structure, processes and outcomes of care are selected and systematically evaluated against explicit criteria. Where indicated, changes are implemented at an individual, team or service level and further monitoring is used to confirm improvement in healthcare delivery.

# **Service evaluation**

Service Evaluation is undertaken to benefit those who use a particular service and is designed and conducted to define or judge current service. Your participants will normally be those who use the service or deliver it. It involves an intervention where there is no change to the standard service being delivered (e.g. no randomization of service users into different groups). This does not require ethical approval.

It is possible to use data collected from participants during a service evaluation for later research as long as:

- the data is completely anonymous;
- it is not possible to identify participants from any resulting report;
- use of the data will not cause substantial damage and distress

Please note that to complete this form your project <u>must be clinical audit or service evaluation</u>. If you are unsure whether your project is clinical audit, service review or research brief definitions are given below as a guide:

#### **Clinical Audit**

Measures existing practice against **best practice**, **evidence based clinical standards** (this may include Royal College, British Association, NICE or Local guidance etc.)

#### Research

Generates new knowledge where there is no or limited research evidence available and which has the potential to be generalisable.

#### Service Evaluation:

Seeks to evaluate the effectiveness or efficiency of a new or existing service to help inform local decision making (has been also referred to as service review, benchmarking or a baseline audit). This includes patient or staff satisfaction surveys.

If your project is research please contact Head of Research and Development, for advice and guidance with the project

Telephone Email

#### CLINICAL AUDIT / SERVICE EVALUATION PROJECT REGISTRATION FORM

Ref No: -	Project Type: - Clinical Audit ⊠	Service Evaluation □
	uation Title: Comparison of Clini Compared To Previous Face to Fa	cal Outcomes For The Online Pain Management ace Outcomes
Division: Neurology	☐ Neurosurgery ☒ Please specify	department Click here to enter text.
Project Lead:		
Contact No: Bleep N	No: Click here to enter text.	
Email address:		
<u>•</u>	uation supervisor: s involved / project team member es and roles within the project eg d	

# **Background / Rationale**

The Pain Management Programme (PMP) Department supports people from all over the UK with disabling chronic pain conditions to improve quality of life and reduce reliance on other health care providers. Our service provides a general pain management programme but also several specialist programmes including Young Adult, Facial and Pelvic with new developments on the horizon. Since the pandemic required face to face clinical activity to cease, our service capitalised on available technology to continue to provide a service to our patients. Our online activity with patients has been running since August 2020 and continues whilst we offer hybrid models from September 2021. We aim to conduct this audit to review, present and learn from our service activity and outcomes since we became online activity from September 2021 till August 2021 as well as pre-pandemic data for comparison. It is important to interpret these results in the context of our patient population and in pandemic circumstances which will be expanded on in the discussion. Furthermore, questionnaire outcomes can only demonstrate some of the benefits we observe in our patients following intervention therefore we will also include physical measures and patient feedback. We will provide contextual information to aid interpretation throughout.

### Methodology

Patient Group: In order to present the group with the largest number of outcomes for statistical power, we will only present those that attended the 'General PMP' and not include specialist programmes such as facial, pelvic or young adult. This will comprise patients with conditions such as chronic widespread pain, Fibromyalgia, low back pain, Complex Regional Pain Syndrome (CRPS). They will be of varied ages from 18 year old onwards. The majority of our patient will be relatively local although some will be based in areas external to Liverpool as we are the main specialist centre for pain in The North West UK. Design: This audit will comprise three components: 1) Pre and post outcomes comparison of the Online PMP, 2) Comparison between Online PMP and Face to Face 16 Day PMP prepandemic and 3) A matched sample comparison of Online PMP and Face to Face 16 Day PMP between patients of similar ages, gender, diagnosis and mental health status. Outcomes collected pre and post-treatment: we collect a range of subjective validated measures to assess multiple domains with the pain experience including pain intensity, distress, pain-related anxiety, self-efficacy and level of depression. We also collect physical performance measures including goal performance and use the 'sit to stand' test. We also administer a satisfaction questionnaire at the end of our programme. Our outcomes measures are stored securely in accordance with Clinical Effectiveness guidelines and we will extract the data anonymously for analysis using Excel and SPSS ® Statistical Package. All outcomes will be presented where appropriate as frequency, mean scores with standard error or percentage for some proportion data. Where statistical analyses criteria allows, we will test for statistical difference using within and between sample t-tests for normal data distribution (or non-parametric equivalent). PMPs are now recommended to utilise Reliable Change Index (RCI) and Clinically Significant Change (CSC) to determine individual reliable and meaningful improvements using the reliability of measures used and the population in question (Morley, 2013). Fenton &

Morley (2013) also provide data which we can use to benchmark our outcomes to that expected in a randomised control trial of a PMP (Fenton & Morley, 2013). We will therefore use RCI, CSC and effect size calculations to determine improvement.

# Aims / Objectives

The aim of this audit is to determine if our change to Online PMP offers a 'good enough' service compared to our previous standard face to face programme. We also aim to determine from our satisfaction data if patients agree that this service is good enough for their needs.

# Standards / Criteria Details (service evaluation N/A)

<ol> <li>Does the online programme ma online PMP programme perforn their care since the online service and Morley (2013).</li> </ol>	n as good as our prev	ious face to face? 3) Are	patients overall satis	fied with
Guideline / Standards available:	Yes ⊠ No			
If yes, please attach a copy or provid	le web link to the m	ost current version:		
Name of Standard / guideline: Both Randomized Controlled Trials to benchn 2013;154: 2108-2119. Morley, S. (2013) analysis of individual patient data and b	nark Routine Clinic (p ) A rough guide to ev	sychological) Treatments aluating your Pain Manag	for chronic pain. Pai gement Programme:	n The
Source of Standard / guideline:  Trust □ Other ⊠	NSF □ State other: Publis	NICE □ hed data from RTCs	Royal College	
Review/assessment of guideline/s $oxed{Yes}\ oxtimes\ oxtimes\ oxtimes\ oxtimes$	tandard undertak	en to ensure it is appr	opriate & can be r	neasured
Is the audit / service evaluation is				
S	〗 No □ 〗 No ⊠			
High cost Yes □				
, ,	No ⊠			
Wide variation in practice Yes □	] No ⊠			
Sample No: Click here to enter text.	Procedure codes t	o identify sample: Clid	ck here to enter text.	
http://www.raosoft.com/samplesize.h	ntml - link to tool tha	t may be used to calcu	late sample size	
Are you planning to publish your a	audit/service eval	uation findings nation	ally	
(e.g. Medical journal)? Yes ⊠	No □			
Is this a re-audit or if service evalu	uation, has service	been reviewed previ	ously? Yes ⊠	No □
Is this project part of an agreed de	epartmental rollinç	programme?	Yes □ No 🛚	
Rolling programme duration (num	ber of years): Click	here to enter text.		
Rolling programme frequency: Mo	onthly 🗆 Quarte	lv □ Biannuallv □	Annually □	

Multidisciplinary: 🗵 Single	e disciplin	ary:	]			
Is Clinical Audit Team support required?  If yes, please specify type of assistance required:  ◆ Population Identification  ◆ Design of data collection tool  (If not required please, attach a copy of the tool to  ◆ Database design  ◆ Data entry  ◆ Analysis  ◆ Presentation  Collection of case notes	□ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □		No r / per	⊠ week		
Patient Contact / Involvement – (If project involve	es patient o	contact the	at is <u>not</u> part	of the patie	ents usual tr	 eatmen
or care please explain how in this section) Will the audit involve direct patient contact?		Yes ∑	☑ No	$\boxtimes$		
How will the patient be involved?						
Patient Questionnaire 🗵 At clinic appointme	ent 🗆					
Other (please give details) Click here to enter text.						
Has approval been sought from the Patient Info	ormation	Panel?	Yes □	No ⊠	N/A ⊠	
Anticipated start date:05/11/2021						
Anticipated project completion date: 15/12/202	21					
Anticipated Action Plan Submission date:15/12	2/2021					
PLEASE ATTACH A COPY OF YOUR DATA COLLECTION	ON TOOL /	PATIENT C	UESTIONNAI	RE.		
FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUAT EVALUATION REPORT.	IONS PLEA	SE ATTACH	A COPY OF T	HE PREVIOL	JS AUDIT OR S	SERVICE
<ul> <li>PLEASE ENSURE THIS FORM IS SIGNED BY YOUR D AUDIT TEAM.</li> </ul>	IVISIONAL	AUDIT LEA	D BEFORE SU	BMISSION T	O THE CLINIC	AL
Departmental Clinical Audit Lead (Signature Da	ate: 15 No	vember :	2021			
Comments Click here to enter text.						
Divisional Clinical Audit Lead (Signature)			Date:	Click here	to enter tex	t.
Is this topic a key clinical interest for the depar	rtment / c	division?	Yes □	I	No □	



#### Clinical Audit / Service Evaluation Action Plan

Ref no: 394

Clinical Audit Title	Comparison of Clinical Ou Face Outcomes	tcomes For The Online Pain Man	agement Programme (PMP) Compared To Previous Face to
Date audit complete		Date action plan completed	
Auditor		Name of policy / guideline	A tale of two RCTs: Using Randomized Controlled Trials to benchmark Routine Clinic (psychological) Treatments for chronic pain.
Division	Neurosurgery	Source of policy / guideline	Fenton G, Morley S. A tale of two RCTs: using randomized controlled trials to benchmark routine clinical (psychological) treatments for chronic pain. Pain. 2013 Oct;154(10):2108-2119. doi: 10.1016/j.pain.2013.06.033. Epub 2013 Jun 24. PMID: 23806654

#### Audit Rationale:

Please summarize the rationale of the audit for the members of the Clinical Audit Group (please limit to one or two sentences)

We aimed to audit our patient outcomes of our pain management programme as delivered online from September 2021 till August 2021 and compare it with pre-pandemic face to face outcomes. To the best of our knowledge, there is limited published data on pain management programme (PMP) outcomes during the pandemic.

# **Summary of Findings:**

Please concisely state the main conclusions of the project using bullet points

- Conversion rates from assessment to online PMP were lower than pre-pandemic suggesting fewer patients were suitable or wished to attend an online programme.
- The online group were 10 years younger, more patients were in full time work and it did not comprise our usual cohort of retired patients. Although our face to face PMP typically includes more female patients, even fewer men attended online PMP compared to the face to face PMP. This suggests that our online clinical work is being accessed by a different population compared to the face to face group.
- The outcomes for the online PMP surpassed accepted benchmarked PMP outcome measures in the UK (Fenton & Morley, 2013) which is also seen with the face to face PMP. This suggests online PMP treatment delivery performed as good as expected for a face to face PMP in our subgroup of suitable patients.
- Patient satisfaction data suggests that although the online programme had practical benefits, they felt greater clinical gains could be made in face to face.

Version: 2021 Review: 2022

# **Key success:**

Please concisely state the key success identified by the project – if none identified please state N/A

• Delivery of our online PMP is efficacious for a select group of patients deemed suitable following MDT assessment.

# **Key concerns:**

Please concisely state the key concerns identified by the project using bullet points—if none identified please state N/A

• The differences in the demographics of the online group compared to face to face suggest we are targeting a different population with our online service and possibly discriminating against other cohorts of patients. Some patients were unsuitable for the online PMP, including those without a computer and those patients complex needs, who the PMP Team considered were required to wait for face-to-face.

#### Recommendations discussed:

Please concisely summarise the recommendations that were discussed following the completion of the project

- Our team are assured that quality of treatment is not affected for those who attend online PMP and that patients are making significant improvements.
- It is important to be aware that online is not a replacement for face to face PMP work because we can only effectively treat a smaller number of patients in the absence of face to face groups.
- We will create an MDT assessment guidance document to support clinicians assessing patients to identify relevant factors that suggest a patients will be best suited to either online or face to face.

# **Presentation / Dissemination of Project**

Date findings were presented / disseminated: Presentation to PMP team and Pain Clinic (Planned for 11<sup>th</sup> Feb 2022)

Department where discussed or presented: PMP team and Pain Clinic.

# Actions agreed following recommendations discussed:-

\*Please ensure each action has a named lead, timescale and reportable group stated on the action plan below. Please list the evidence of the action implementation e.g SOP, protocol, standardised template, presentation or meeting minutes etc

Issue	Action required	Named lead for action	Timescale	Evidence	Reportable to (group/meeting)
1)Lack of existing published data on online pain management programmes	Write up this audit for publication		6 months	Submission to a journal	PMP Research Committee)

Version: 2021 Review: 2022

2) Lack of 6 month follow up data	Examine outcomes of follow up data and compare with face to face	12 months	Written up report	Service Lead
3) Guidance document	Written internal guidance for department	Service Lead		
Re-audit date Dec 2024 If no re	-audit planned please give reasons why?			
Will this be an on-going audit?	Yes □ No ⊠			
Are there any potential barriers / p	roblems to prevent the implementation of the al	bove actions? Yes 🗌	No 🛚	
If yes to the above please state wh	o the issues have been referred to:			
Name	Designation	Date referred		
Signature:	Date:			
Have any issues been logged on the	<u> </u>			

Version: 2021 Review: 2022



#### Clinical Audit / Service Evaluation Action Plan

Ref no: BIOC/213 NS 396

Clinical Audit	CSF Index and Oligoclonal band (OCB) results 2021		
Title			
Date audit	25/03/2020	Date action plan	07/04/2022
complete		completed	
Auditor		Name of policy /	
		guideline	
Division	The Neuroscience Laboratories, Neurosurgery Division	Source of policy /	
		guideline	

# **Summary of Findings:**

Please concisely state the main conclusions of the project using bullet points

- 1101 OCB results were identified between 1<sup>st</sup> November 2018 -26<sup>th</sup> November 2021. Results were excluded based on exclusion criteria (refer to the attached report). Of the 935 results remaining, 386 results (41.3%) had a T1 OCB status i.e. no bands present in the CSF or serum 61.4% were female with a median IgG Index of 0.51 compared to 0.50 for males. The calculated reference range was 0.37-0.68.
- Of the 935 patients included in the study 935 had a final diagnosis of MS (24.2%). Of these 212 (93.81%) were OCB positive i.e. T2/T3 pattern. Ratio of females to males was 2.21:1. Median IgG index for both sexes were raised, 0.99 for females and 0.74 for males.
- The diagnostic utility of an elevated IgG index (>0.7) for the diagnosis of MS: sensitivity 73 %, specificity 90%, PPV 71%, NPV 91%
- The diagnostic utility of a positive OCB status for the diagnosis of MS: sensitivity 94%, specificity 87%, PPV 70%, NPV 98%
- Comparison of our calculated diagnostic utility of IgG Index to that calculated by Simonsen et al is shown below:

	Our study	Simonsen et al
Sensitivity	73 %	82%
Specificity	90 %	92%
PPV	71 %	99%
NPV	91 %	27%

- The calculated reference range for IgG index confirms that the current in use cut off value of 0.7 is appropriate for The Walton Centres patient population.
- The diagnosis of MS in our patient population was inline with those reported in the literature, the observed prevalence of MS was higher for females than males, at a ratio of 2:1.
- The sensitivity of OCB for the diagnosis of MS was 93.8%, similar to the sensitivity of 95% reported within the literature.
- The diagnostic sensitivity of positive OCB was significantly higher than that of an elevated IgG Index. Replacement of OCB analysis with IgG

Version: 2019

Index would miss approximately 20% of diagnoses.

- The diagnostic specificity of an elevated IgG Index was marginally higher than a positive OCB status, both showed acceptable specificities >80%. OCB status or an elevated IgG Index must be interpreted with other investigations for a diagnosis of MS.
- In conclusion, the current cut off value of 0.7 to define an elevated IgG Index is appropriate for the patient population served by the Walton Centre.
- An elevated IgG Index does not have an acceptable diagnostic sensitivity to replace OCB analysis for the diagnosis of MS.

# **Key success:**

Please concisely state the key success identified by the project – if none identified please state N/A

- Verified our reference range for CSF IgG index based on our patient population with a cut off of 0.7 as a raised CSF IgG index result.
- We can confirm that the CSF IgG index does correlate with OCB status, however we have determined that the CSF IgG index alone does not have acceptable diagnostic sensitivity to replace OCB analysis to aid in the diagnosis of MS.

#### **Key concerns:**

Please concisely state the key concerns identified by the project using bullet points— if none identified please state N/A N/A

#### Recommendations discussed:

Please concisely summarise the recommendations that were discussed following the completion of the project

•

# **Presentation / Dissemination of Project**

Date findings were presented / disseminated: Report emailed to all relevant members of Neurobiochemistry staff 07/04/22

Department where discussed or presented: Neurobiochemistry, The Neuroscience Laboratories

# Actions agreed following recommendations discussed:-

\*Please ensure each action has a named lead, timescale and reportable group stated on the action plan below. Please list the evidence of the action implementation e.g SOP, protocol, standardised template, presentation or meeting minutes etc

Issue	Action required	Named lead for action	Timescale	Evidence	Reportable to (group/meeting)
1)		N/A	N/A	N/A	N/A

Version: 2019

2)						
3)						
4)						
Re-audit date If r	no re-audit planned please give reasons v	<b>vhy?</b> No further u	seful informati	on to be gained	in the short term	
Will this be an on-going audit? Ye	s □ No ⊠					
Are there any potential barriers / prob	plems to prevent the implementation of th	ne above actions	? Yes 🗌 No	o ⊠		
If yes to the above please state who t	he issues have been referred to:					
Name	Designation	_ Date referre	d			
Signature:	Date:					
Have any issues been logged on the	risk register? Yes   No   N/A					
Please provide details of issue(s) logged on the risk register:						

Version: 2019



# Clinical Audit / Service Evaluation Registration Form

### **Clinical Audit definition**

Clinical Audit is a quality improvement process that seeks to improve patient care and outcomes through systematic review of care against explicit criteria and the implementation of change. Aspects of the structure, processes and outcomes of care are selected and systematically evaluated against explicit criteria. Where indicated, changes are implemented at an individual, team or service level and further monitoring is used to confirm improvement in healthcare delivery.

# Service evaluation

Service Evaluation is undertaken to benefit those who use a particular service and is designed and conducted to define or judge current service. Your participants will normally be those who use the service or deliver it. It involves an intervention where there is no change to the standard service being delivered (e.g. no randomization of service users into different groups). This does not require ethical approval.

It is possible to use data collected from participants during a service evaluation for later research as long as:

- the data is completely anonymous;
- it is not possible to identify participants from any resulting report;
- use of the data will not cause substantial damage and distress

Please note that to complete this form your project <u>must be clinical audit or service evaluation</u>. If you are unsure whether your project is clinical audit, service review or research brief definitions are given below as a guide:

#### **Clinical Audit**

Measures existing practice against best practice, evidence based clinical standards (this may include Royal College, British Association, NICE or Local guidance etc.)

#### Research

Generates new knowledge where there is no or limited research evidence available and which has the potential to be generalisable.

#### **Service Evaluation:**

Seeks to evaluate the effectiveness or efficiency of a new or existing service to help inform local decision making (has been also referred to as service review, benchmarking or a baseline audit). This includes patient or staff satisfaction surveys.

If your project is research please contact Head of Research and Development, for advice and guidance with the project

Telephone Email

#### CLINICAL AUDIT / SERVICE EVALUATION PROJECT REGISTRATION FORM

Ref No: - BIOC/213 NS396 Project Type: - Clinical Audit ⊠ Service Evaluation □
Audit / Service Evaluation Title: Clinical audit of CSF index and oligoclonal band (OCB) results
<b>Division:</b> Neurology □ Neurosurgery ⊠ Please specify department <b>The Neuroscience Laboratories</b>
Project Lead:
Contact No: Bleep No: N/A
Email address:
Audit / service evaluation supervisor:
Other professionals involved / project team members details (Please provide names and roles within the project eg data collection, analysis etc.)

# **Background / Rationale**

The Neurobiochemistry department in The Neuroscience Labs at The Walton Centre (WCFT) perform CSF IgG Index and oligoclonal band (OCB) analysis during working hours (Monday to Friday, 9 am to 5 pm). OCB status is currently included in the 2017 revised McDonald criteria for the diagnosis of Multiple Sclerosis, as demonstration of dissemination in time (DIT) (reference 1). It has recently been reported in the literature that CSF IgG index can be used to predict OCB status in patients with Multiple Sclerosis, thus removing the need for OCB analysis to be performed (reference 2). There are conflicting reports in the literature regarding the diagnostic utility of CSF IgG Index with some laboratories moving towards reporting IgG index only, (reference 2, 3) and some deciding to not report it at all. We want to establish the diagnostic utility of CSF IgG Index in our patient population to determine if there is a correlation with OCB status and to review our IgG index reference values. Reference 1: Thompson et al. (2017) Diagnosis of Multiple Sclerosis: 2017 revisions of the McDonald Criteria. Reference 2: Simonsen et al (2020) 'The diagnostic value of IgG index versus oligoclonal bands in cerebrospinal fluid of patients with multiple sclerosis. Reference 3: Zheng et al (2020) 'IgG Index Revisited: Diagnostic Utility and Prognostic Value in Multiple Sclerosis'.

# **Methodology**

Retrospective study of all patients from The Walton Centre who had OCB and CSF Index measured from November 2018 – November 2021. Patient results and demographics for this time period will be accessed via the laboratory information management system (LIMS), TD-NexLab. Final diagnosis for these patients and details of their medication history will be identified using ePortal. Statistical analysis will then be performed to assess correlation between CSF IgG Index and OCB status according to different patient cohorts and to assess the current IgG index reference range.

#### Aims / Objectives

To determine if CSF IgG index correlates with OCB status. To verify our reference range for CSF IgG Index based on our patient population.

### Standards / Criteria Details (service evaluation N/A)

N/A

Guideline / Standard	ls available:	Yes [	□ No	$\boxtimes$			
If yes, please attach a	a copy or provi	de web lin	k to the mo	st current	version: Clic	k here to enter tex	t.
Name of Standard /	guideline: N/A						
Source of Standard Trust □	/ guideline: Other □	NSF D	] <b>ner</b> : Click her	NICE e to enter t	□ text.	Royal College	
Review/assessment Yes □ No □	of guideline/s	standard	undertaker	n to ensur	e it is appr	opriate & can be	measure
Is the audit / service High volume High risk High cost Known quality issue Wide variation in prac	Yes [ Yes [ Yes [ Yes [	sue:   No       No       No       No       No       No					
Sample No: 1101 pati	ent results iden	tified from	the 3 year p	eriod for h	aving OCB an	alysis.	
Procedure codes to identified in the LIMS, 1		<b>le:</b> Patient	ts from The V	Valton Cen	tre trust who	have had OCB ana	lysis as
http://www.raosoft.com	<u>m/samplesize.l</u>	<u>ntml</u> - link	to tool that	may be us	sed to calcul	ate sample size	
Are you planning to	publish your	audit/ser	vice evalua	ition findi	ngs nation	ally	
(e.g. Medical journal)	? Yes ⊠	Ν	lo 🗆				
Is this a re-audit or i	f service eval	uation, h	as service l	been revi	ewed previ	ously? Yes	□ No 🖾
Is this project part o	f an agreed d	epartmen	ıtal rolling ı	programm	ne?	Yes □ No 🛭	3
Rolling programme	duration (num	ber of ye	ears):				
Rolling programme	frequency: M	onthly $\square$	Quarterly	<sup>,</sup> □ Biaı	nnually 🗆	Annually $\square$	
Multidisciplinary:		S	Single discip	linary: [	$\boxtimes$		
Is Clinical Audit Tea  If yes, please specify  ◆ Population Identifi  ◆ Design of data col (If not required please  ◆ Database design  ◆ Data entry  ◆ Analysis  ◆ Presentation  Collection of case not	type of assistal cation llection tool e, attach a copy	nce requi	□ ol to be use □ □ □		No er / pe	⊠ r week	
Collection of case Hot	.03			Jai Hullibe	- , he	. MCCV	

Patient Contact / Involvement — (If project involves patient or care please explain how in this section) Will the audit involve direct patient contact?	contact Yes	that is	<u>not</u> part No	of the patients usual treatment
How will the patient be involved?				
Patient Questionnaire				
Other (please give details) Click here to enter text.				
Has approval been sought from the Patient Information	n Pane	<b>!?</b> Ye	es 🗆	No □ N/A □
Anticipated start date:01/12/2021				
Anticipated project completion date: 01/04/2022				
Anticipated Action Plan Submission date:01/04/2022				
<ul> <li>PLEASE ATTACH A COPY OF YOUR DATA COLLECTION TOOL A</li> <li>FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATIONS PLEAEVALUATION REPORT.</li> <li>PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVISIONAL AUDIT TEAM.</li> </ul>	SE ATTA	ACH A CO	DPY OF TI	HE PREVIOUS AUDIT OR SERVICE
Departmental Clinical Audit Lead (Signature) _ Date: 0	)1/12/2	021		-
Comments Click here to enter text.				
Divisional Clinical Audit Lead (Signature)			Date:	Click here to enter text.
Is this topic a key clinical interest for the department /	divisio	n?	Yes □	No □



# Clinical Audit / Service Evaluation Registration Form

### **Clinical Audit definition**

Clinical Audit is a quality improvement process that seeks to improve patient care and outcomes through systematic review of care against explicit criteria and the implementation of change. Aspects of the structure, processes and outcomes of care are selected and systematically evaluated against explicit criteria. Where indicated, changes are implemented at an individual, team or service level and further monitoring is used to confirm improvement in healthcare delivery.

# **Service evaluation**

Service Evaluation is undertaken to benefit those who use a particular service and is designed and conducted to define or judge current service. Your participants will normally be those who use the service or deliver it. It involves an intervention where there is no change to the standard service being delivered (e.g. no randomization of service users into different groups). This does not require ethical approval.

It is possible to use data collected from participants during a service evaluation for later research as long as:

- the data is completely anonymous;
- it is not possible to identify participants from any resulting report;
- · use of the data will not cause substantial damage and distress

Please note that to complete this form your project <u>must be clinical audit or service evaluation</u>. If you are unsure whether your project is clinical audit, service review or research brief definitions are given below as a guide:

#### **Clinical Audit**

Measures existing practice against **best practice**, **evidence based clinical standards** (this may include Royal College, British Association, NICE or Local guidance etc.)

#### Research

Generates new knowledge where there is no or limited research evidence available and which has the potential to be generalisable.

#### Service Evaluation:

Seeks to evaluate the effectiveness or efficiency of a new or existing service to help inform local decision making (has been also referred to as service review, benchmarking or a baseline audit). This includes patient or staff satisfaction surveys.

If your project is research please contact Head of Research and Development, for advice and guidance with the project

**Email** 

# **CLINICAL AUDIT / SERVICE EVALUATION PROJECT REGISTRATION FORM**

Ref No: - NS397	Project Type: - Clinical Audit ☐ Service Evaluation ⊠
Audit / Service Evaluati (DREZ lesion).	on Title: Evaluation of the ablative service for brachial plexus avulsion
<b>Division:</b> Neurology □ N	leurosurgery ⊠ Please specify department Click here to enter text.
Project Lead:	
Contact No: Bleep No:	Click here to enter text.
Email address:	
Audit / service evaluation	on supervisor:
	olved / project team members details and roles within the project eg data collection, analysis etc.)
<b>Background / Rationale</b> Evaluation of the ablative so	ervice for brachial plexus avulsion (DREZ lesion).
<u>Methodology</u>	
Retrospective review of collected prospectively.	linical notes, MRI and neurophysiology protocol including outcome measure
Aims / Objectives	
	in a cohort of 40-50 pts over 12 yrs. Review of procedural changes over last 12 ology,surgical approach, lesion etc).
Standards / Criteria Det	ails (service evaluation N/A)
Primary outcome measure in the notes/database)	(VAS) other secondary outcome measures (QOL etc collected prospectively and present
Guideline / Standards a	vailable: Yes □ No ⊠
lf yes, please attach a co	py or provide web link to the most current version: Click here to enter text.
Name of Standard / guid	deline: Click here to enter text.
Source of Standard / gu Trust □ Oth	· · · · · · · · · · · · · · · · · · ·
Review/assessment of g	guideline/standard undertaken to ensure it is appropriate & can be measured
Is the audit / service ev	aluation issue:

High volume	Yes □ No ⊠
High risk High cost	Yes □ No ⊠ Yes □ No ⊠
Known quality issue	Yes □ No ⊠
Wide variation in practice	Yes □ No ⊠
Sample No: 40-55 Proced	lure codes to identify sample: Drez lesion for brachial plexus avulsion
http://www.raosoft.com/sam	nplesize.html - link to tool that may be used to calculate sample size
Are you planning to publi	sh your audit/service evaluation findings nationally
(e.g. Medical journal)?	Yes ⊠ No □
Is this a re-audit or if serv	rice evaluation, has service been reviewed previously? Yes $\square$ No $\boxtimes$
Is this project part of an a	greed departmental rolling programme? Yes □ No ☒
Rolling programme durati	ion (number of years): Click here to enter text.
Rolling programme freque	ency: Monthly □ Quarterly □ Biannually □ Annually □
Multidisciplinary:	Single disciplinary: ⊠
Is Clinical Audit Team sup If yes, please specify type of  ◆ Population Identification  ◆ Design of data collection (If not required please, attack  ◆ Database design  ◆ Data entry  ◆ Analysis  ◆ Presentation Collection of case notes	of assistance required:
Patient Contact / Involven or care please explain how in a Will the audit involve dire	·
How will the patient be in	volved?
Patient Questionnaire	□ At clinic appointment □
Other (please give details) Cli	ck here to enter text.
Has approval been sough	t from the Patient Information Panel? Yes □ No □ N/A ⊠
Anticipated start date:Dec	2021
Anticipated project comp	letion date: Feb 2022
Anticipated Action Plan S	ubmission date:N/A

- PLEASE ATTACH A COPY OF YOUR DATA COLLECTION TOOL / PATIENT QUESTIONNAIRE.
- FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATIONS PLEASE ATTACH A COPY OF THE PREVIOUS AUDIT OR SERVICE EVALUATION REPORT.
- PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVISIONAL AUDIT LEAD BEFORE SUBMISSION TO THE CLINICAL AUDIT TEAM.

Departmental Clinical Audit Lead (Signature)	Date: Click	here to enter text.
Comments Click here to enter text.		
Divisional Clinical Audit Lead (Signature)	Date: Click here to enter text.	
Is this topic a key clinical interest for the department / division?	Yes □	No □